CD44 Intracellular Domain: Unraveling Cytoskeletal Interactions, Signaling Mechanisms, and Therapeutic Potential

Abstract

This article provides a comprehensive analysis of the CD44 intracellular domain (CD44-ICD) and its critical interactions with cytoskeletal proteins. Aimed at researchers and drug development professionals, it explores the foundational structure of CD44-ICD, detailing its conserved binding motifs for ERM proteins and ankyrin that facilitate connections to the actin and spectrin networks. The content covers established and emerging methodologies for studying these interactions, addresses common experimental challenges, and validates findings through comparative analysis of different cellular models. By synthesizing current research, this review highlights how CD44-cytoskeletal crosstalk influences fundamental cellular processes in health and disease, offering valuable insights for developing novel therapeutic strategies targeting this key signaling hub.

The Structural Blueprint of CD44-ICD and Its Cytoskeletal Interface

Conserved Architecture of the CD44 Intracellular Domain

The CD44 intracellular domain (ICD) is a 72-amino-acid segment that exhibits remarkable evolutionary conservation, underscoring its critical role in cellular function [1]. Despite lacking intrinsic enzymatic activity, this short cytoplasmic tail serves as a central hub for organizing the structural and signaling machinery of the cell [1]. Its interactions with cytoskeletal proteins and cytoplasmic effectors regulate vital processes including cell adhesion, migration, trafficking, and metabolic programming—functions that are co-opted in pathological states such as cancer metastasis [1] [2]. This application note details the conserved architectural features of the CD44 ICD and provides standardized protocols for investigating its interactions, framed within the context of cytoskeletal protein binding research.

Structural Features of the CD44 Intracellular Domain

The functional versatility of the CD44 ICD arises from specific, conserved structural motifs that facilitate interactions with cytoskeletal adaptors and signaling molecules.

Table 1: Conserved Structural Motifs within the CD44 Intracellular Domain

Motif Name	Amino Acid Position	Sequence	Binding Partner	Primary Function
FERM-binding Domain [1]	292-300	RRRCGQKKK	ERM proteins (Ezrin, Radixin, Moesin)	Links CD44 to actin cytoskeleton [3]
Ankyrin-binding Domain [1]	304-318	NSGNGAVEDRKPSGL	Ankyrin	Connects CD44 to spectrin network [3]
Basolateral Targeting Motif [1]	331-332	LV	Unknown	Cellular trafficking and polarization
PDZ-binding Domain [1]	358-361	KIGV	PDZ-domain proteins	Signal complex assembly

Phosphorylation Regulation

The CD44 ICD undergoes dynamic post-translational modification, primarily phosphorylation, which regulates its activity. Key phosphorylation sites include Ser325, which is constitutively phosphorylated by Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) and is crucial for HA-mediated cell migration [1]. Ser291 and Ser316 are additional phospho-sites regulated by protein kinase C (PKC) and other kinases, revealing a complex layer of control over CD44 function [1].

Quantitative Data on CD44-Cytoskeleton Interactions

Experimental data from cross-linking, fluorescence resonance energy transfer (FRET), and fluorescence recovery after photobleaching (FRAP) studies quantify the functional consequences of CD44-cytoskeleton binding.

Table 2: Impact of Cytoskeletal Interactions on CD44 Organization and Function

Experimental Manipulation	Effect on CD44 Clustering	Effect on CD44 Mobility	Functional Outcome
Actin depolymerization (Latrunculin B) [3]	Reduced/abolished	Increased	Impaired neutrophil rolling on E-selectin [3]
Deletion of Ankyrin-binding site (ΔANK) [3]	Larger, looser clusters	Modestly increased	Impaired rolling and Src kinase activation [3]
Deletion of ERM-binding site (ΔERM) [3]	Minimal impact on clustering	Data not available	Data not available
Double deletion (ΔANKΔERM) [3]	Clustering abolished	Modestly increased	Data not available
Overexpression of CD44-ICD [4]	Disrupted cytoskeletal anchoring	Data not available	Loss of HA binding & pericellular matrix assembly [4]

Detailed Experimental Protocols

Protocol 1: Proximity Ligation Assay (PLA) for Visualizing CD44 Clustering-Induced Interactions

This protocol visualizes dynamic, condition-dependent interactions between the CD44 ICD and its cytoplasmic binding partners, such as those induced by ligand binding or antibody-mediated clustering [5].

Key Resources:

• Antibodies: Rat monoclonal anti-CD44 (e.g., clone IM7) targeting the extracellular domain; antibody against the cytoplasmic partner (e.g., rabbit anti-MARK2/PAR1b).
• Cells: Adherent cells (e.g., mammary epithelial cells) cultured on collagen-coated coverslips.
• Reagents: Duolink PLA kit, cross-linking secondary antibodies, fixation solution (e.g., 4% PFA), permeabilization buffer (e.g., 0.1% Triton X-100).

Procedure:

• Cell Preparation and Cross-linking: Plate cells on collagen-coated coverslips and grow to ~70% confluence. Stimulate cells by adding anti-CD44 primary antibody (e.g., 10 µg/mL in serum-free medium) and incubate (e.g., 60 minutes, 37°C). Remove primary antibody and add cross-linking secondary antibody (e.g., 1 µg/mL, 30 minutes, 37°C). Include controls with non-specific IgG.
• Fixation and Permeabilization: Wash cells with PBS and fix with 4% PFA for 15 minutes at room temperature. Permeabilize cells with 0.1% Triton X-100 in PBS for 10 minutes.
• Proximity Ligation Assay: Follow the manufacturer's instructions for the Duolink PLA kit:
  • Block cells with provided blocking solution.
  • Incubate with primary antibodies against CD44 and the intracellular target protein, raised in different species.
  • Incubate with species-specific PLA probes (minus and plus).
  • Perform ligation and amplification steps to generate fluorescent signals at sites of protein proximity (<40 nm).
• Imaging and Analysis: Mount coverslips with Duolink mounting medium containing DAPI. Image using a fluorescence microscope. Quantify PLA signals (puncta) per cell using image analysis software (e.g., ImageJ) [5].

Protocol 2: Co-immunoprecipitation to Assess CD44-Ankyrin Interaction

This biochemical method validates stable interactions between full-length CD44 and cytoskeletal adaptor proteins like ankyrin.

Key Resources:

• Antibodies: Antibody for immunoprecipitation (e.g., anti-CD44 cytoplasmic tail), antibody for detection (e.g., anti-ankyrin-3).
• Cells: Relevant cell type (e.g., chondrocytes).
• Reagents: Lysis buffer (e.g., RIPA buffer with protease and phosphatase inhibitors), Protein A/G beads, wash buffer, SDS-PAGE and Western blotting equipment.

Procedure:

• Cell Lysis: Wash cells with ice-cold PBS and lyse in a suitable non-denaturing lysis buffer.
• Immunoprecipitation: Pre-clear the cell lysate. Incubate the lysate with an antibody against the CD44 cytoplasmic domain overnight at 4°C. Add Protein A/G beads and incubate for 2-4 hours.
• Washing and Elution: Pellet beads and wash extensively with lysis buffer. Elute bound proteins by boiling in SDS-PAGE sample buffer.
• Analysis: Resolve eluted proteins and inputs by SDS-PAGE. Perform Western blotting using an antibody against ankyrin to confirm interaction [4].

CD44 Downstream Signaling Pathways

Upon ligand binding and clustering, the CD44 ICD nucleates the formation of signaling complexes that activate multiple downstream pathways.

CD44 Signal Transduction Network: This diagram illustrates how the clustered CD44 receptor, upon binding extracellular ligands, integrates signals through cytoskeletal adaptors to activate key downstream pathways governing cell behavior.

The Scientist's Toolkit: Key Research Reagents

Table 3: Essential Reagents for CD44 Intracellular Domain Interaction Research

Reagent Category	Specific Example	Function/Application in Research
Antibodies for Clustering	Rat anti-CD44 (Clone IM7) [3] [5]	Induces functional clustering of CD44 extracellular domain to mimic ligand-induced activation.
CD44 Mutants	ΔANK (Ankyrin-binding deficient) [3]	Disrupts CD44-ankyrin interaction to study its role in clustering, signaling, and cell migration.
	ΔERM (ERM-binding deficient) [3]	Disrupts CD44-actin linkage via ERM proteins to investigate cytoskeletal anchoring.
Cytoskeletal Inhibitors	Latrunculin B [3]	Depolymerizes actin filaments to assess the role of the actin cytoskeleton in CD44 organization.
Small Molecule Inhibitors	LCC-12 (Supformin) [6]	Targets mitochondrial Cu²⁺ signaling downstream of CD44, used to study metabolic reprogramming.
Assay Kits	Duolink Proximity Ligation Assay (PLA) [5]	Visualizes and quantifies condition-specific protein-protein interactions in situ.

The CD44 intracellular domain (ICD), though short and devoid of enzymatic activity, is a critical hub for coordinating cellular structure and signaling. Its function is governed by interactions with specific cytoskeletal adaptor proteins via three key binding motifs: FERM, Ankyrin, and PDZ. This application note details the structural basis of these interactions, provides quantitative binding data, and outlines validated experimental protocols for studying them. The document is framed within broader research on CD44-cytoskeleton interactions, offering life science researchers and drug development professionals a practical toolkit for investigating this multifunctional receptor.

The CD44 receptor is a single-pass transmembrane glycoprotein that functions as a primary receptor for hyaluronan (HA) and other extracellular matrix components [1] [7]. Its intracellular domain (ICD) is a 72-amino-acid segment that is highly conserved across species, underscoring its fundamental biological importance [1] [8]. Despite lacking intrinsic enzymatic activity, the CD44 ICD serves as a crucial platform for assembling signaling complexes and linking the actin cytoskeleton to the plasma membrane [1]. This coordination is facilitated by short, linear binding motifs within the ICD that interact with specific classes of cytoskeletal adaptor proteins, namely FERM domain proteins, Ankyrin, and PDZ domain proteins [1] [8]. These interactions are essential for CD44's role in cell adhesion, migration, signal transduction, and its established function as a cancer stem cell marker [1]. The following sections dissect each interaction, providing structural details, quantitative binding parameters, and robust methodological approaches for their experimental investigation.

Structural Features of the CD44 Intracellular Domain

The CD44 ICD contains several defined structural motifs that mediate specific protein-protein interactions, as illustrated in the diagram below.

The functional integrity of the CD44 ICD is regulated by post-translational modifications. Phosphorylation is restricted to serine residues, with Ser325 identified as the primary site of constitutive phosphorylation by Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) [1] [8]. Phosphorylation at Ser325 is critical for HA-mediated cell migration [1]. Furthermore, the juxtamembrane cysteine residue (Cys295) within the FERM-binding motif is a putative site for palmitoylation, which can regulate CD44's partitioning into lipid rafts and its subsequent associations [1] [9].

The FERM Domain Interaction

Structural Basis and Biological Role

The FERM (4.1, Ezrin, Radixin, Moesin) domain is a three-lobed (F1, F2, F3) structural module found in ERM family proteins. The interaction occurs between the F3 lobe of the FERM domain and a membrane-proximal, positively charged cluster (²⁹²RRRCGQKKK³⁰⁰) on the CD44 ICD [1] [10] [11]. Structural studies of moesin and radixin in complex with the CD44 peptide reveal that the CD44 peptide forms an additional beta-strand that integrates into the anti-parallel beta-sheet of the F3 subdomain [10] [11]. This binding event is allosterically regulated by phosphatidylinositol 4,5-bisphosphate (PIP₂) and phosphorylation of the ERM protein's C-terminal tail, which releases autoinhibition and exposes the FERM domain for CD44 binding [10]. This interaction is fundamental for bridging CD44 to the actin cytoskeleton, thereby regulating cell adhesion, morphology, and migration [12] [1].

Quantitative Binding Data

Table 1: Quantitative Data for FERM Domain Interactions with CD44

FERM Protein	Ligand Sequence	Binding Affinity / Key Data	Structural Details (PDB Code)	Reference
Moesin	KKKLVIN	TR-FRET assay established; key residues: R246, D252, H288 (MSN)	Buried surface area: 1392 Ų (6TXS)	[10]
Radixin	KKKLVIN	Co-crystallization with radixin FERM domain	Structure determined (2ZPY)	[11]
Ezrin	Not Specified	Co-immunoprecipitation demonstrated in chondrocytes	Interaction modest compared to ankyrin	[12]

Experimental Protocol: TR-FRET Binding Assay for Moesin-CD44

This protocol outlines a robust method for quantifying the interaction between the moesin FERM domain and the CD44 cytoplasmic tail peptide using a Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) assay [10].

Materials & Reagents

• Purified 6xHis-tagged Moesin FERM domain
• FITC-conjugated CD44 peptide (sequence: KKKLVIN)
• Terbium (Tb³⁺)-chelated anti-6xHis antibody
• Assay buffer (e.g., PBS, pH 7.4, with 0.01% Tween-20 and 1 mg/mL BSA)
• Black, low-volume, 384-well microplate
• TR-FRET compatible plate reader

Procedure

• Sample Preparation: In a low-volume 384-well plate, add 10 µL of assay buffer containing the 6xHis-Moesin FERM domain at a final concentration of 10-50 nM.
• Labeling: Add 5 µL of a solution containing the Tb³⁺-anti-6xHis antibody to each well. Incubate for 30-60 minutes at room temperature to allow the antibody to bind the His-tagged protein.
• Peptide Addition: Add 5 µL of the FITC-conjugated CD44 peptide at a series of concentrations (e.g., 0.1 nM to 1 µM) to generate a binding curve. For competition assays, add unlabelled CD44 peptide or mutant controls as competitors.
• Incubation: Allow the plate to incubate in the dark for 2-4 hours at room temperature to reach binding equilibrium.
• TR-FRET Measurement: Read the plate on a TR-FRET-compatible reader. Excite at ~340 nm and simultaneously measure emission at 490 nm (Tb³⁺ donor) and 520 nm (FITC acceptor).
• Data Analysis: Calculate the TR-FRET ratio as (Acceptor Emission / Donor Emission) * 10,000. Plot the TR-FRET ratio against the peptide concentration and fit the data to a sigmoidal dose-response curve to determine the EC₅₀ or IC₅₀.

The Ankyrin Interaction

Structural Basis and Biological Role

CD44 binds directly to the Ankyrin Repeat Domain (ARD) of ankyrin proteins via a conserved motif (³⁰⁴NSGNGAVEDRKPSGL³¹⁸) in its cytoplasmic tail [12] [13]. Detailed mapping has identified the S2 subdomain (amino acids 218-381) of the ankyrin ARD as the primary binding region for CD44 [13]. This interaction is functionally critical, as it promotes the association of CD44 with the spectrin-actin cytoskeleton and facilitates signal transduction. In endothelial cells, the CD44-ankyrin complex recruits the inositol 1,4,5-triphosphate (IP₃) receptor within lipid rafts, promoting HA-mediated Ca²⁺ signaling, which leads to nitric oxide production, cell adhesion, and proliferation [9]. In chondrocytes and ovarian tumor cells, this interaction is essential for retaining the HA-binding capacity of CD44 and supporting HA-mediated cell migration [12] [13].

Quantitative Binding Data

Table 2: Quantitative Data for Ankyrin Domain Interactions with CD44

Ankyrin Construct	Functional Role / Finding	Assay Type	Reference
Full-length Ankyrin	Co-immunoprecipitates with CD44 in chondrocytes; interaction diminished by CD44-ICD overexpression	Co-immunoprecipitation	[12]
ARD (Ankyrin Repeat Domain)	Primary binding site for CD44; transfection upregulates HA-mediated tumor cell migration	In vitro binding, microinjection, functional assays	[13]
S2 Subdomain (aa 218-381)	Direct binding region for CD44 within the ARD	In vitro binding assay with recombinant fragments	[13]
ARD Fragment	Overexpression disrupts endogenous ankyrin binding, blocks HA-mediated Ca²⁺ signaling	Functional interference / Dominant-negative	[9]

Experimental Protocol: Co-immunoprecipitation of CD44-Ankyrin Complexes

This protocol describes a method to validate the interaction between endogenous or exogenously expressed CD44 and ankyrin in mammalian cells [12] [9].

Materials & Reagents

• Cell line of interest (e.g., chondrocytes, endothelial cells, ovarian tumor SKOV3 cells)
• Lysis Buffer: 1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), supplemented with protease and phosphatase inhibitors
• Primary Antibodies: Anti-CD44 antibody, Anti-ankyrin antibody (e.g., for ankyrin-3)
• Control Isotype IgG
• Protein A/G or Anti-Species Magnetic Beads
• Wash Buffer: 0.1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl (pH 7.5)
• Elution Buffer: 1X SDS-PAGE Loading Buffer

Procedure

• Cell Lysis: Culture and treat cells as required. Wash cells with ice-cold PBS and lyse them in Lysis Buffer for 30 minutes on ice. Clarify the lysates by centrifugation at 14,000 x g for 15 minutes at 4°C.
• Pre-clearing: Incubate the supernatant with control IgG and beads for 30-60 minutes to reduce non-specific binding. Collect the supernatant after a brief centrifugation.
• Immunoprecipitation: Aliquot the pre-cleared lysate into two tubes. To one tube, add the specific anti-CD44 antibody. To the control tube, add an equivalent amount of control IgG. Incubate with end-over-end mixing for 2-4 hours at 4°C.
• Bead Capture: Add Protein A/G or magnetic beads to each tube and incubate for an additional 1-2 hours with mixing.
• Washing: Pellet the beads and wash them 3-5 times with 1 mL of Wash Buffer.
• Elution: After the final wash, completely remove the wash buffer and resuspend the beads in 40-60 µL of 1X SDS-PAGE Loading Buffer. Boil the samples for 5-10 minutes to elute the immunoprecipitated complexes.
• Analysis: Analyze the eluates by SDS-PAGE and Western blotting. Probe the blot with anti-ankyrin antibody to detect co-precipitated ankyrin and with anti-CD44 antibody to confirm successful immunoprecipitation.

The PDZ Domain Interaction

Structural Basis and Biological Role

The extreme C-terminus of the CD44 ICD contains a class I PDZ-binding motif (³⁵⁸KIGV³⁶¹) [1]. This motif can interact with PDZ domains found in scaffolding proteins, such as NHERF1 (EBP50) [14]. NHERF1 contains two PDZ domains (PDZ1 and PDZ2) and a C-terminal ERM-binding domain, allowing it to act as a multi-functional scaffold that links transmembrane receptors like CD44 to the actin cytoskeleton via ERM proteins [14]. The PDZ1 domain of NHERF1 is highly malleable and exhibits higher affinity and promiscuity for various targets compared to the more rigid PDZ2 domain. These interactions are crucial for organizing macromolecular signaling complexes that regulate receptor trafficking, stability, and downstream signaling events.

Experimental Protocol: Pull-Down Assay with Recombinant PDZ Domains

This protocol uses recombinant GST-tagged PDZ domains to confirm a direct interaction with the CD44 cytoplasmic tail and assess binding specificity [14].

Materials & Reagents

• Recombinant GST-tagged PDZ domains (e.g., NHERF1 PDZ1 and PDZ2)
• GST protein (negative control)
• Cell lysate from cells expressing CD44 or a synthesized CD44 cytoplasmic tail peptide
• Glutathione (GSH)-Sepharose resin
• Lysis/Wash Buffer: PBS (pH 7.4) with 1% Triton X-100 and protease inhibitors
• Elution Buffer: 10-50 mM reduced Glutathione in 50 mM Tris-HCl, pH 8.0

Procedure

• Protein Immobilization: Express and purify the recombinant GST-PDZ domains and GST control. Incubate equal molar amounts of each protein with pre-washed GSH-Sepharose resin for 1 hour at 4°C with gentle mixing.
• Equilibration: Wash the resin twice with Lysis/Wash Buffer to remove unbound protein.
• Binding Reaction: Incubate the immobilized GST-fusion proteins with the cell lysate or the CD44 peptide for 2-4 hours at 4°C with end-over-end mixing.
• Washing: Pellet the resin and wash extensively (3-5 times) with Lysis/Wash Buffer to remove non-specifically bound proteins.
• Elution: Elute the bound proteins by incubating the resin with Elution Buffer for 10-15 minutes at room temperature. Repeat the elution step and pool the eluates.
• Analysis: Analyze the input, unbound, wash, and eluted fractions by SDS-PAGE and Western blotting. Probe for the presence of CD44 to confirm a specific interaction with the PDZ domain.

Integrated Signaling and Cross-Talk

The coordinated actions of FERM, ankyrin, and PDZ domain interactions enable CD44 to regulate complex cellular behaviors. The following diagram illustrates the integrated signaling pathways stemming from these key interactions.

A significant level of cross-talk and regulation exists between these interactions. For example, the release of the CD44 intracellular domain (CD44-ICD) via sequential proteolytic cleavage exerts a dominant-negative effect on full-length CD44 function by competing for cytoskeletal adaptor proteins like ankyrin-3 [12]. Furthermore, the activation state of ERM proteins and the phosphorylation status of the CD44 ICD can modulate these interactions, adding another layer of regulatory complexity [1] [10].

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for CD44 Cytoskeletal Interaction Research

Reagent / Tool	Description / Example	Primary Function in Research
CD44-ICD Constructs	C-terminal tags (Myc, GFP); overexpression vectors [12]	Study dominant-negative effects, subcellular localization, and protein interactions.
Mutant Constructs	Ankyrin-binding site mutants (e.g., within 304-318), ERM-binding mutants [12]	Determine the functional specificity of individual binding motifs.
Recombinant FERM/PDZ	Purified FERM domains (Moesin, Radixin), GST-tagged PDZ domains [10] [14]	Conduct in vitro binding assays (TR-FRET, pull-down) and structural studies.
Ankyrin Fragments	Recombinant ARD and S2 subdomain (aa 218-381) [13]	Map precise interaction sites and perform functional interference studies.
Lipid Raft Disruptors	Methyl-β-cyclodextrin (cholesterol depletion) [9]	Investigate the role of membrane microdomains in CD44 signaling complexes.
Specific Antibodies	Anti-CD44 (clone 020), anti-ankyrin-3, anti-moesin [12] [9]	Detect proteins in immunoassays, Western blotting, and co-immunoprecipitation.

The CD44 intracellular domain (ICD), a segment of just 72 amino acids, is a critical hub for cellular signaling despite lacking intrinsic enzymatic activity [8]. Its function is profoundly regulated by post-translational modifications (PTMs), with phosphorylation acting as a master molecular switch [15] [8]. This reversible modification at specific serine residues dictates the conformational state of the CD44 ICD, thereby controlling its high-affinity interaction with cytoskeletal adaptor proteins and orchestrating downstream signaling cascades [15] [16]. These phosphorylation-regulated interactions are fundamental to processes such as cell migration, proliferation, and tumor progression [7] [15]. This Application Note provides a detailed experimental framework for investigating these phosphorylation-driven regulatory switches, enabling researchers to decipher the molecular logic of CD44 signal transduction.

The Molecular Basis of Phosphorylation Regulation

Key Phosphorylation Sites and Their Functional Impact

The CD44 ICD contains several serine residues, but phosphorylation is primarily restricted to S291, S316, and S325 [8]. These sites are not modified simultaneously but are subject to a dynamic and reciprocal regulatory mechanism.

• S325 Phosphorylation: This is the primary site of constitutive phosphorylation, mediated by Ca2+/calmodulin-dependent protein kinase II (CaMKII) [8]. The activation of CaMKII is itself regulated by CD44-mediated mobilization of intracellular Ca2+, creating a potential positive feedback loop [8]. Phosphorylation at S325 is generally associated with an "open" conformation that promotes the recruitment and binding of the N-terminal FERM domain of Ezrin/Radixin/Moesin (ERM) proteins [15].
• S291 and S316 Phosphorylation: These sites are phosphorylated by Protein Kinase C (PKC) [8]. The phosphorylation of S291, in particular, induces a "closed" conformation of the CD44 ICD and inhibits its association with FERM proteins [15]. The overall phosphorylation state of the CD44 ICD represents a balance between the activities of CaMKII and PKC.

Table 1: Key Phosphorylation Sites on the CD44 Intracellular Domain

Residue	Kinase	Effect on Conformation	Effect on FERM Binding	Functional Outcome
Serine 325	CaMKII	Promotes "open" state [15]	Promotes [15]	Enhances HA-mediated cell migration [16]
Serine 291	PKC	Promotes "closed" state [15]	Inhibits [15]	Inhibits cell migration on HA substratum [16]
Serine 316	PKC (indirectly)	Not fully elucidated	Contributes to S291-mediated inhibition [8]	Implicated in dynamic signaling regulation [8]

Interdependence with the Membrane Lipid Environment

The phosphorylation-dependent regulation of CD44 is not an isolated event but is tightly coupled to the membrane lipid composition. The phosphoinositide PIP2 (Phosphatidylinositol 4,5-bisphosphate) is a critical co-regulator [15].

• PIP2 Dependence: The conformational changes induced by phosphorylation at S291 and S325, and their subsequent effect on FERM binding, are strictly dependent on the presence of PIP2 in the inner leaflet of the plasma membrane [15]. Molecular dynamics simulations show that PIP2 effects the relative stability of the closed and open conformations of the CD44 ICD.
• Charge Neutralization: The multiple negative charges of the PIP2 headgroups are thought to help neutralize the positive charges in the juxtamembrane region of the CD44 ICD, as well as the additional negative charge introduced by phosphorylation, facilitating the membrane liberation and conformational changes necessary for FERM binding [15]. Replacing PIP2 with other anionic lipids like POPS greatly abrogates this effect [15].

The following diagram illustrates the interdependent regulatory mechanism governed by phosphorylation and PIP2.

Experimental Protocols

Protocol 1: Analyzing CD44-FERM Binding Using Coarse-Grained Molecular Dynamics (CG-MD) Simulations

This protocol is adapted from studies that used Martini force field simulations to unravel the molecular details of CD44-FERM complexation [15].

1. Research Reagent Solutions Table 2: Essential Reagents for CG-MD Simulations of CD44-FERM Interaction

Reagent / Tool	Function / Description	Source / Example
Martini 2.2 Force Field	Coarse-grained molecular dynamics force field for efficient sampling of microsecond timescales.	http://www.cgmartini.nl [15]
GROMACS-5.1.2 Software	Molecular dynamics simulation package used to perform all CG-MD calculations.	www.gromacs.org [15]
PIP2 Lipid Parameters	Parameters for phosphatidylinositol 4,5-bisphosphate (charge -4e).	Martini lipidome [15]
Phosphorylated Serine Parameters	CG parameters for doubly negatively charged phospho-serine.	Martini amino acid database [15]
CD44 & FERM CG Models	Coarse-grained models of CD44-CTD (TMD + 36aa) and Radixin-FERM (PDB: 2ZPY).	martinize.py script; PDB [15]

2. Methodology

• System Setup:

  • Model Construction: Generate three CD44 models: Wild-Type (WT), S291-phosphorylated (S291p), and S325-phosphorylated (S325p). The CD44 construct should include the transmembrane domain and a truncated cytoplasmic domain (36 residues) covering the FERM-binding and phosphorylation sites [15]. Model the TMD as an α-helix and the CTD as a flexible coil.
  • Membrane Building: Construct an asymmetric lipid bilayer using a tool like insane.py. The outer leaflet should be 100% POPC. The inner (cytoplasmic) leaflet should be 95% POPC / 5% PIP2 to study the PIP2-dependent mechanism [15]. A control system with 80% POPC / 20% POPS can be used to abrogate the PIP2 effect.
  • System Assembly: Insert the CD44 model into the bilayer, oriented parallel to the membrane normal. For binding simulations, place the FERM domain in the cytoplasmic solution, ~3.0 nm from the membrane surface. The initial distance between the centroids of CD44 and FERM should be ~6.2 nm to avoid biased initial interactions [15]. Solvate the system with CG water and neutralize with counterions.

• Simulation Execution:

  • Run simulations using GROMACS. For each system (e.g., WT-CD44/FERM, S291p-CD44/FERM, S325p-CD44/FERM in PIP2-containing membrane), perform 10 independent replicates, each for 3 microseconds (total 30 μs per system) to ensure adequate sampling of the binding events [15].
  • Use a standard simulation temperature (e.g., 310 K) and pressure (1 bar) coupling.

• Data Analysis:

  • Binding Efficiency: Calculate the fraction of simulation time during which the CD44-FERM complex is formed. A complex is typically defined when any bead of the FERM domain is within a certain cut-off distance (e.g., 0.55 nm) of any bead in the CD44-CTD [15].
  • Conformational Analysis: Analyze the root-mean-square deviation (RMSD) of the CD44-CTD and the distance between the phosphorylation sites and the membrane surface to characterize "open" vs. "closed" states.
  • Membrane Interaction: Monitor the interaction between basic residues in the CD44 juxtamembrane region and the PIP2 lipids throughout the simulation trajectory.

Protocol 2: Functional Validation of Phosphorylation Mutants in Cell Migration

This protocol is based on classic and modern studies that characterize CD44 phosphorylation mutant phenotypes using cell-based functional assays [16].

1. Research Reagent Solutions Table 3: Key Reagents for Cell-Based Validation of CD44 Phosphorylation

Reagent / Tool	Function / Description	Source / Example
CD44-Negative Cell Line	Provides a null background for transfection (e.g., certain human melanoma or murine fibroblast lines).	ATCC [16]
CD44 Phosphorylation Mutants	Plasmid constructs encoding CD44 with Ser→Ala (non-phosphorylatable) or Ser→Asp/Glu (phosphomimetic) mutations at S291, S325.	Custom generation via site-directed mutagenesis [16]
Hyaluronan-Coated Substrata	Surface functionalized with high molecular weight HA to assay CD44-specific adhesion and migration.	Sigma-Aldrich [17]
PKC & CaMKII Modulators	Pharmacological activators (e.g., PMA for PKC) and inhibitors to manipulate the cellular phosphorylation state.	Tocris Bioscience [8]

2. Methodology

• Cell Transfection and Culture:

  • Transfert a CD44-negative cell line (e.g., a human melanoma line) or a line expressing low endogenous CD44 with plasmids encoding: a) WT-CD44, b) S325A (non-phosphorylatable), c) S325D/E (phosphomimetic), d) S291A, and e) S291D/E [16].
  • Culture transfected cells under appropriate conditions and select stable clones using a suitable antibiotic (e.g., G418).

• Adhesion and Migration Assays:

  • HA Adhesion Assay: Plate stable transfectants onto culture dishes coated with high molecular weight HA (~30-100 kDa). After a set time (e.g., 1-2 hours), wash off non-adherent cells and quantify the remaining adhered cells using colorimetric or fluorescent methods [16] [17].
  • HA Migration Assay: Use a haptotaxis or wound-healing ("scratch") assay on an HA-coated substratum. For haptotaxis, use a Boyden chamber with an HA-coated membrane. Seed serum-starved cells in the upper chamber and quantify migration towards a serum-containing medium in the lower chamber after 6-24 hours [16].

• Expected Results:

  • Adhesion: All CD44-expressing constructs (WT and mutants) should support similar levels of HA binding and cell adhesion, confirming that phosphorylation does not significantly affect ligand binding affinity [16].
  • Migration: Cells expressing WT-CD44 will show enhanced migration on HA. S325A mutants (non-phosphorylatable) and S291D/E mutants (phosphomimetic for the inhibitory site) will show significantly impaired migration, despite normal adhesion. Conversely, S325D/E mutants may exhibit constitutive, high migration [16]. This dissociates the role of CD44 in adhesion from its role in migration, pinpointing phosphorylation as the specific switch for motility.

The workflow for the integrated experimental approach, from molecular simulation to cellular validation, is summarized below.

CD44 Proteolytic Processing and ICD Generation

CD44 proteolytic processing is a critical regulatory mechanism that transforms this transmembrane adhesion molecule into a potent intracellular signaling molecule. The generation of the CD44 Intracellular Domain (CD44-ICD) via sequential proteolytic cleavage represents a key pathway linking extracellular stimuli to changes in nuclear gene expression [18] [8]. This process is of significant interest in cancer research and drug development, as it influences tumor cell survival, migration, and metastasis [19] [20]. This Application Note details the molecular mechanism of CD44-ICD generation, provides validated experimental protocols for its study, and outlines essential reagent solutions for researchers investigating CD44-ICD interactions with cytoskeletal proteins and transcriptional regulators.

Molecular Mechanism of CD44 Proteolytic Processing

CD44 undergoes sequential proteolytic cleavage at the cell surface, resulting in the release of its intracellular domain. This process involves two sequential cleavage events mediated by distinct protease families [18] [21]:

Table 1: Proteases Involved in CD44 Cleavage

Protease Category	Specific Proteases	Cleavage Site	Resulting Fragment
Ectodomain Sheddases	MMP14 (MT1-MMP), ADAM10, ADAM17, Meprin β	Membrane-proximal extracellular region	Soluble CD44 ectodomain + Membrane-bound C-terminal fragment (CTF)
Intramembrane Cleavage	γ-Secretase complex	Within transmembrane domain	CD44 Intracellular Domain (CD44-ICD) release

The CD44-ICD fragment, comprising approximately 72 amino acids in its standard form, subsequently translocates to the nucleus [18] [8]. There it functions as a co-transcriptional regulator, potentially influencing the expression of genes involved in cell survival, migration, and metastasis, including CD44 itself and matrix metalloproteinases (MMPs) like MMP-9 [18] [20]. This proteolytic cascade can be triggered by various physiological stimuli, including activation of Protein Kinase C (PKC) by phorbol esters (e.g., TPA), increased intracellular calcium concentrations, and mechanical stress such as cell wounding [18].

CD44 Intracellular Domain Generation Pathway

Experimental Protocols

Induction and Detection of CD44-ICD

This protocol outlines the induction of CD44 proteolytic processing in glioma cells and subsequent detection of CD44-ICD by immunoblotting [18].

Materials:

• Cell Line: Human glioma U251MG cells (or PC3 prostate cancer cells [20])
• Inducers: Phorbol 12-myristate 13-acetate (TPA) (e.g., 100 nM)
• Inhibitors:
  • Metalloprotease Inhibitor: BB2516 (e.g., 10 μM)
  • γ-Secretase Inhibitor: DAPT (e.g., 10 μM) or MG132 (e.g., 25 μM) [18] [20]
• Antibodies: Anti-CD44cyto antibody (recognizes C-terminal region) [18]

Procedure:

• Cell Culture: Maintain U251MG cells in appropriate medium (e.g., RPMI-1640 with 10% FBS) until ~80% confluent.
• Induction (3-6 hours): Treat cells with 100 nM TPA in fresh serum-free medium to stimulate CD44 ectodomain shedding [18].
• Inhibitor Control (Pre-treatment): Pre-incubate separate cell cultures with BB2516 (10 μM) for 1 hour before TPA addition to block metalloprotease activity, or with DAPT (10 μM) to inhibit γ-secretase [18] [20].
• Chase Period: After induction, wash cells and incubate in fresh medium for up to 3 hours to allow for CD44-ICD generation [18].
• Cell Lysis and Fractionation: Lyse cells using RIPA buffer. For subcellular localization, separate lysates into membrane/cytosol and nuclear fractions using commercial kits or differential centrifugation [18].
• Immunoblotting:
  • Separate proteins by SDS-PAGE (10-15% gradient gel recommended).
  • Transfer to PVDF membrane.
  • Probe with anti-CD44cyto antibody.
  • Expected Results: CD44-ICD appears as a ~12-16 kDa fragment in nuclear fractions [18] [20]. Full-length CD44 and ectodomain cleavage products (~25 kDa) are detected in membrane/cytosol fractions.

Co-Immunoprecipitation for CD44-ICD Interaction Studies

This protocol validates the interaction between CD44-ICD and its binding partners, such as the transcription factor RUNX2 [20].

Materials:

• Cell Line: PC3 human prostate cancer cells (naturally express CD44 and RUNX2) [20]
• Lysis Buffer: Non-denaturing lysis buffer (e.g., containing 1% Triton X-100, protease inhibitors)
• Antibodies: Anti-CD44 antibody (e.g., 156-3C11), Anti-RUNX2 antibody (e.g., D1L7F) [20]
• Other Reagents: Protein A/G agarose beads

Procedure:

• Cell Preparation: Culture PC3 cells to 70-80% confluence. Treat with TPA or vehicle control as in Protocol 3.1 to enhance CD44-ICD generation.
• Cell Lysis: Lyse cells in non-denaturing lysis buffer on ice for 30 minutes. Centrifuge to clear insoluble debris.
• Pre-clearing: Incubate lysate with Protein A/G beads for 1 hour to reduce non-specific binding.
• Immunoprecipitation (4°C, overnight):
  • Incubate pre-cleared lysate with anti-CD44 antibody or species-matched control IgG.
  • Add Protein A/G beads and incubate for an additional 2-3 hours.
• Washing and Elution: Wash beads extensively with lysis buffer. Elute bound proteins with 2X Laemmli sample buffer by boiling for 5 minutes.
• Analysis:
  • Analyze eluates by immunoblotting with anti-RUNX2 and anti-CD44 antibodies.
  • Expected Result: Co-precipitation of RUNX2 with CD44-ICD confirms their interaction, particularly in nuclear fractions or in cells overexpressing RUNX2 [20].

Table 2: Key Reagents for CD44-ICD Interaction Studies

Reagent Category	Specific Examples	Function/Application	Key Research Findings
Chemical Inducers	TPA (PMA) [18]Ionomycin [18]	Activates PKC, induces ectodomain sheddingInduces calcium influx, promotes cleavage	Rapidly induces CD44 ectodomain cleavage followed by ICD generation [18]
Protease Inhibitors	BB2516 [18]GM6001 [4]DAPT [20]	Metalloprotease inhibitorBroad-spectrum MMP inhibitorγ-Secretase inhibitor	Blocks initial ectodomain cleavage [18]Prevents CD44-ICD release and nuclear translocation [20]
Cell Lines	U251MG Glioma [18]PC3 Prostate Cancer [20]	Model for CD44 signaling studiesModel for CD44-ICD/RUNX2 interactions	Endogenously produces CD44-ICD upon stimulation [18]CD44-ICD interacts with RUNX2 in nucleus [20]
Antibodies	Anti-CD44cyto [18]Anti-CD44-ICD [20]	Detects C-terminal fragments, ICDSpecifically detects CD44-ICD	Identifies ~12-16 kDa CD44-ICD fragment in immunoblots [18]

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Tools for CD44 Proteolytic Processing Studies

Research Tool	Specific Product/Example	Research Application	Functional Role
CD44-ICD Expression Constructs	Plasmid encoding CD44ICD tagged with HA/Myc/GFP [18]	Nuclear translocation studiesTranscriptional activation assays	CD44ICD localizes to nucleus and activates transcription [18]
CD44 Functional Inhibitors	Macrocyclic Peptides (L4-3, D4-3) [22]	Inhibit CD44-HA interactionModulate downstream signaling	Reduces cell adhesion; impacts AKT and EGFR signaling in glioma [22]
γ-Secretase Inhibitors	DAPT [20]	Blocks intramembrane cleavagePrevents CD44-ICD generation	Inhibits CD44-ICD formation, leading to accumulation of CTF fragments [20]
CD44 Interaction Assay Tools	Recombinant RUNX2 protein [20]	Study CD44-ICD transcription factor complexes	CD44-ICD acts as co-transcriptional factor with RUNX2 for MMP-9 regulation [20]

Technical Notes and Applications

Functional Consequences of CD44-ICD Generation

The release of CD44-ICD has significant functional implications for cell behavior, particularly in cancer:

• Transcriptional Activation: CD44-ICD translocates to the nucleus and activates transcription through TPA-Responsive Elements (TRE), potentially acting as a co-transcriptional factor with proteins like RUNX2 to regulate genes such as MMP-9 [18] [20].
• Dominant-Negative Effects: Overexpression of CD44-ICD can disrupt the function of full-length CD44 by competing for cytoskeletal adaptor proteins like ankyrin, thereby impairing hyaluronan binding and pericellular matrix assembly [4].
• Role in Cell Signaling: CD44-ICD generation links extracellular stimulation to changes in gene expression, potentially influencing cell migration, invasion, and tumor progression [18] [20].

Troubleshooting CD44-ICD Detection

• Low ICD Signal: Ensure proper induction with TPA and sufficient chase period. Verify nuclear fractionation efficiency.
• Non-specific Bands: Include inhibitor controls (BB2516, DAPT) to confirm fragment identity.
• Weak Co-IP Results: Use crosslinkers if interactions are transient. Ensure fresh protease inhibitors are present in lysis buffers.

CD44-ICD Functional Consequences

The cluster of differentiation 44 (CD44) is a single-chain transmembrane glycoprotein that functions as a primary receptor for hyaluronic acid (HA) and other extracellular matrix (ECM) components [7] [1]. While its extracellular domain mediates ligand binding, the short, highly conserved 72-amino-acid intracellular domain (ICD) serves as a critical platform for cytoskeletal organization and signal transduction, despite lacking intrinsic enzymatic activity [1] [23]. This domain orchestrates complex cellular behaviors—including adhesion, migration, proliferation, and stemness—by interacting with key cytoskeletal partners: ERM (Ezrin, Radixin, Moesin) proteins, ankyrin, and actin networks [1] [23] [24]. These interactions facilitate the mechanical integration of extracellular cues with intracellular responses, a process vital in both physiological contexts and disease states such as cancer progression and therapeutic resistance [7] [25]. This Application Note details the structural basis, functional consequences, and experimental approaches for investigating CD44-cytoskeleton interactions, providing a structured resource for researchers in cell biology and drug discovery.

Molecular Anatomy of the CD44 Intracellular Domain

The CD44-ICD is structured into specific motifs that facilitate discrete protein-protein interactions, enabling the receptor to bridge the plasma membrane with the cytoskeletal machinery [1].

Table 1: Key Structural Motifs within the CD44 Intracellular Domain

Motif Name	Amino Acid Sequence (Human)	Position	Primary Binding Partner(s)	Functional Consequence of Interaction
FERM-binding Domain	²⁹²RRRCGQKKK³⁰⁰	Juxtamembrane	ERM proteins (Ezrin, Radixin, Moesin) [1] [24]	Linkage to the actin cytoskeleton; regulates receptor clustering and adhesion [1] [24].
Ankyrin-binding Domain	³⁰⁴NSGNGAVEDRKPSGL³¹⁸	Central	Ankyrin (various isoforms) [1] [12]	Connects to the spectrin cytoskeleton; facilitates HA-mediated calcium signaling and matrix retention [23] [12].
Basolateral Targeting Motif	³³¹LV³³²	C-terminal	Dihydrophobic motif-recognizing proteins [1]	Involved in subcellular trafficking and polarized localization.
PDZ-binding Motif	³⁵⁸KIGV³⁶¹	C-terminal	PDZ-domain containing proteins [1]	Potential role in scaffolding signaling complexes.

The functionality of the CD44-ICD is further regulated by post-translational modifications, most notably phosphorylation. Serine 325 (Ser325) is a primary phosphorylation site targeted by Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) [1]. This modification is constitutively present on approximately one-third of CD44 molecules and is crucial for HA-mediated cell migration [1]. Dynamic interplay exists between phosphorylation states; for instance, dephosphorylation of Ser325 can occur alongside phosphorylation of Ser291 and Ser316 by Protein Kinase C (PKC) pathways, indicating complex regulatory crosstalk [1].

Functional Roles of Cytoskeletal Partnerships

The interactions between CD44 and its cytoskeletal partners underpin a wide array of cellular functions, from basic mechanics to sophisticated signaling.

ERM Proteins: Masters of Actin Cross-linking

The binding of CD44 to ERM proteins is a cornerstone of its ability to connect to the actin cortex. This interaction is critical for:

• Receptor Clustering: Fluorescence Resonance Energy Transfer (FRET) and cross-linking studies on neutrophils and transfected cells demonstrate that CD44 forms nanometer-scale clusters on the cell membrane. Disruption of actin polymerization with latrunculin B or deletion of the ERM-binding domain abrogates this clustering, underscoring the role of an intact actin-ERM-CD44 axis [24].
• Cell Adhesion and Rolling: In neutrophils, the ERM- and ankyrin-dependent clustering of CD44 is essential for its function as a ligand for E-selectin during the rolling phase of extravasation, a prerequisite for transmigration into tissues [24].
• Protrusion Formation in 3D Environments: Glioblastoma cells invading HA-rich, nanoporous matrices form CD44-coated microtentacles (McTNs). These dynamic protrusions, containing both actin and microtubules, require CD44 and its cytoskeletal linkages for adhesion and migration, representing a mechanism distinct from classical integrin-based migration [26].

Ankyrin: The Spectrin Cytoskeleton Integrator

The interaction between CD44 and ankyrin provides an alternative or complementary link to the cytoskeleton, primarily the spectrin network [1] [12]. This partnership is vital for:

• Pericellular Matrix Assembly: In chondrocytes, the interaction between CD44 and ankyrin-3 (also known as ankyrin-G) is necessary for the stable anchorage of CD44 to the cytoskeleton, enabling cells to bind HA and retain a robust pericellular matrix. Overexpression of the isolated CD44-ICD acts in a dominant-negative manner, competing with full-length CD44 for ankyrin binding and disrupting matrix retention [12].
• Calcium Mobilization: In endothelial cells, the CD44-ankyrin complex promotes the interaction between inositol 1,4,5-trisphosphate (IP3) receptors and the cytoskeleton, regulating IP3 receptor localization and affinity, thereby facilitating HA-mediated Ca²⁺ signaling [23].
• Uncoupling Motility from Proliferation: Studies on primary dermal fibroblasts reveal a novel, hierarchical role for CD44. Deletion of CD44 impairs stiffness-dependent cell motility without affecting other mechanosensitive responses like cell spreading, stress fiber formation, focal adhesion maturation, or—notably—cell proliferation. This indicates CD44 acts downstream of initial mechanosensing to specifically execute motility programs [27].

Coordination with Downstream Signaling Pathways

The CD44-cytoskeleton complex is not merely a structural unit but a signaling hub. Upon HA binding, the CD44-ICD nucleates a signaling platform that activates multiple pathways:

• Rho GTPase Signaling: CD44 engagement activates Rho family GTPases (RhoA, Rac1, Cdc42) through Rho-specific guanine nucleotide exchange factors (GEFs) [23]. This leads to cytoskeletal reorganization, actin polymerization, and myosin contractility, driving cell migration and invasion [7] [23].
• MAPK and PI3K/Akt Pathways: The CD44-ICD, via interactions with ERM proteins and other adapters, can promote activation of the MAPK/ERK and PI3K/Akt pathways, influencing cell growth and survival [7].
• IQGAP1 as a Signaling Integrator: IQGAP1 binds to both CD44 and the microtubule-associated protein CLIP170, cross-linking actin and microtubule networks within structures like microtentacles. This interplay is crucial for the protrusion and stabilization required for migration in HA-rich environments [26].

The following diagram synthesizes these interactions into a coherent signaling network:

Diagram Title: CD44-Cytoskeleton Interaction and Signaling Network

Application Notes & Experimental Protocols

This section provides detailed methodologies for key experiments characterizing CD44-cytoskeleton interactions.

Protocol: Co-immunoprecipitation of CD44 Complexes with Ankyrin and ERM

Objective: To validate direct protein-protein interactions between CD44 and its cytoskeletal partners (ankyrin-3, ERM) in a cellular context [12].

Reagents & Materials:

• Lysis Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, supplemented with protease and phosphatase inhibitor cocktails.
• Antibodies: Anti-CD44 antibody (e.g., clone OX49 for rat systems; EMD-Millipore for human), anti-ankyrin-3 antibody (Santa Cruz Biotechnology), anti-ERM antibody (Cell Signaling Technologies).
• Other: Protein A/G magnetic beads, NuPAGE gels, Western blotting apparatus.

Procedure:

• Cell Lysis: Culture relevant cells (e.g., chondrocytes, endothelial cells). Wash with ice-cold PBS and lyse using the lysis buffer (500 µL per 10⁷ cells) for 30 minutes on ice. Clarify the lysate by centrifugation at 16,000 × g for 15 minutes at 4°C.
• Pre-clearing: Incubate the supernatant with protein A/G beads for 1 hour at 4°C to reduce non-specific binding. Discard the beads.
• Immunoprecipitation: Incubate the pre-cleared lysate with 2–5 µg of anti-CD44 antibody or an isotype control antibody overnight at 4°C with gentle rotation.
• Bead Capture: Add protein A/G magnetic beads and incubate for an additional 2 hours.
• Washing: Pellet the beads and wash extensively (3-5 times) with ice-cold lysis buffer.
• Elution: Elute the bound proteins by boiling the beads in 2X Laemmli sample buffer for 5 minutes.
• Analysis: Resolve the eluates by SDS-PAGE (NuPAGE gels) and perform Western blotting. Probe the membrane with anti-ankyrin-3 or anti-ERM antibodies to detect co-precipitated proteins.

Key Consideration: The interaction between CD44 and ankyrin-3 is prominent in chondrocytes, whereas in other cell types, ERM interactions may dominate. Cell type-specific optimization is critical [12].

Protocol: Functional Analysis of CD44 Clustering via FRET/FRAP

Objective: To quantify CD44 membrane organization and dynamics and its dependence on the actin cytoskeleton [24].

Reagents & Materials:

• Plasmids: CD44 fused to Yellow Fluorescent Protein (CD44-YFP) and CD44 fused to Cyan Fluorescent Protein (CD44-CFP).
• Inhibitors: Latrunculin B (actin depolymerization agent).
• Equipment: Confocal microscope equipped with FRET and FRAP capabilities.

Procedure (FRET for Clustering):

• Transfection: Transfect K562 cells or other relevant cell lines with CD44-YFP and CD44-CFP constructs.
• Treatment: Treat a subset of cells with Latrunculin B (e.g., 1 µM for 30 minutes) to disrupt actin filaments.
• Image Acquisition: Collect images using a confocal microscope. For FRET, excite CFP (donor) and measure emission in the YFP (acceptor) channel.
• Analysis: Calculate FRET efficiency. A decrease in FRET efficiency upon Latrunculin B treatment indicates that actin integrity is required for tight CD44 co-clustering.

Procedure (FRAP for Mobility):

• Preparation: Transfert cells with CD44-YFP.
• Photobleaching: Use a high-intensity laser to bleach YFP fluorescence in a small region of the cell membrane.
• Recovery Monitoring: Track the fluorescence recovery into the bleached area over time.
• Analysis: Generate a recovery curve and calculate the mobile fraction and half-time of recovery. Increased mobility (faster recovery) is expected after Latrunculin B treatment or deletion of the CD44 cytoplasmic domain, indicating reduced cytoskeletal restraint [24].

Protocol: Dominant-Negative Interference with CD44-ICD Overexpression

Objective: To dissect the functional contribution of specific CD44-cytoskeleton interactions by expressing the isolated intracellular domain [12].

Reagents & Materials:

• Constructs: Plasmids encoding the CD44 Intracellular Domain (CD44-ICD) fused to GFP or a Myc tag. Generate mutants with point mutations in the ankyrin-binding site (e.g., within NSGNGAVEDRKPSGL) or the FERM-binding domain (e.g., within RRRCGQKKK).
• Assay Reagents: Fluorescently-labeled HA, calcein-AM for cell viability.

Procedure:

• Cell Transfection: Transiently or stably transfect cells (e.g., chondrocytes, fibroblasts) with the CD44-ICD constructs or an empty vector control.
• Functional Assay - Pericellular Matrix Retention:
  • Allow cells to assemble a pericellular matrix.
  • Treat with a brief exposure to hyaluronidase to remove existing matrix, then allow recovery in the presence of fluorescent HA.
  • Quantify the reassembly of the HA-rich pericellular coat by fluorescence microscopy. Cells overexpressing CD44-ICD will show impaired matrix retention compared to controls.
• Functional Assay - Cell Rolling/Motility:
  • For neutrophils, express wild-type CD44 or CD44-ΔANK (lacking the ankyrin-binding site) in CD44-deficient cells.
  • Perform rolling assays on E-selectin-coated surfaces under flow. Impaired rolling is expected for the ΔANK mutant [24].
• Validation: Use co-immunoprecipitation to confirm that CD44-ICD overexpression reduces the interaction between full-length endogenous CD44 and ankyrin-3 [12].

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for Studying CD44-Cytoskeleton Interactions

Reagent / Tool	Specific Example / Catalog Number	Primary Function in Research
Anti-CD44 Antibodies	Clone OX49 (BD Biosciences); EMD-Millipore (human)	Immunoprecipitation; blocking CD44-ligand interactions; immunofluorescence.
Anti-Ankyrin-3 Antibody	Santa Cruz Biotechnology	Detection and co-immunoprecipitation of ankyrin-3 (ankyrin-G).
Anti-ERM / pERM Antibodies	Cell Signaling Technologies	Detecting total and activated (phosphorylated) ERM proteins.
Actin Polymerization Inhibitor	Latrunculin B (Sigma-Aldrich)	Disrupts actin filaments to probe actin-dependence of CD44 clustering and function.
CD44-ICD Expression Constructs	GFP- or Myc-tagged CD44-ICD (cloned into pcDNA3.1, pEGFP-N2)	Dominant-negative disruption of endogenous CD44-cytoskeleton interactions.
CD44 Cytoplasmic Mutants	ΔANK (ankyrin-binding site deletion); ΔERM (FERM-binding site mutation)	Structure-function analysis of specific cytoskeletal linkages.
FRET/FRAP Systems	CD44-YFP / CD44-CFP plasmids	Quantifying CD44 membrane clustering and dynamics in live cells.

Data Presentation & Analysis

Table 3: Quantitative Summary of CD44-Cytoskeleton Functional Interactions

Experimental Readout	Wild-Type (Control) Phenotype	Perturbed CD44-ICD/Cytoskeleton Phenotype	Key Supporting Evidence
CD44 Membrane Clustering	High FRET efficiency, indicating tight co-clustering [24].	Reduced FRET efficiency after Latrunculin B or in ΔANKΔERM mutants [24].	FRET/Cross-linking studies in K562 cells/neutrophils.
Cell Migration / Motility	Stiffness-dependent increase in net displacement and directionality [27].	Impaired motility response on stiff substrates in CD44KO fibroblasts [27].	Nuclear tracking on tunable hydrogels.
Pericellular Matrix Assembly	Robust HA-rich matrix retained around cells [12].	Disrupted matrix retention upon CD44-ICD overexpression [12].	Microscopic analysis in chondrocytes.
Neutrophil Rolling on E-selectin	Efficient rolling adhesion under flow [24].	Impaired rolling in cells expressing CD44-ΔANK mutant [24].	Flow chamber adhesion assays.
HA Internalization & Metabolism	Efficient endocytic uptake of HA [28].	Disrupted upon cytoskeletal disruption or CD44 tail deletion.	Tracking of fluorescent HA.
Intracellular Ca²⁺ Signaling	HA binding triggers Ca²⁺ mobilization [23].	Blocked by competitors of CD44/ankyrin interaction [23].	Fluorescent calcium indicator dyes (e.g., Fura-2).

The CD44 intracellular domain serves as a vital mechanistic link, translating extracellular adhesion events into intracellular cytoskeletal reorganization and signaling. Its structured interactions with ERM proteins and ankyrin allow it to engage both the actin and spectrin cytoskeletons, respectively, enabling diverse cellular outputs from matrix assembly to directed migration. The experimental frameworks outlined here—ranging from biochemical co-precipitation to live-cell imaging and dominant-negative strategies—provide a robust toolkit for deconstructing these complex relationships. A deep understanding of these CD44-driven mechanobiological pathways is paramount for developing novel therapeutic strategies aimed at diseases such as cancer, fibrosis, and chronic inflammation, where CD44 and cytoskeletal dynamics are critically implicated.

Experimental Approaches for Probing CD44-Cytoskeleton Interactions

Cross-linking and FRET-Based Analysis of CD44 Clustering

The CD44 receptor, a transmembrane glycoprotein, is the principal cell surface receptor for hyaluronic acid (HA) and is implicated in a vast array of cellular processes including cell adhesion, migration, proliferation, and survival [7] [8]. Its role in cancer is particularly significant, where it serves as a well-established cancer stem cell (CSC) marker and is a key player in tumor progression and metastasis [29] [30] [8]. The functional capacity of CD44 is intimately linked to its oligomerization state. Receptor clustering is a critical event for effective signal transduction, influencing cytoskeletal rearrangements and downstream signaling pathways [31] [8]. This document provides detailed application notes and protocols for analyzing CD44 clustering, a methodology central to advancing a broader thesis on CD44 intracellular domain (ICD) interaction assays with cytoskeletal proteins.

The CD44 intracellular domain, though short and devoid of intrinsic enzymatic activity, is a crucial hub for protein interactions [8] [32]. It contains specific structural motifs that facilitate binding to cytoskeletal adaptor proteins such as ezrin, radixin, and moesin (ERM), as well as ankyrin [8] [4]. These interactions anchor CD44 to the actin cytoskeleton, a connection that is vital for its role in cell adhesion and migration. Furthermore, the CD44-ICD can be released into the cytoplasm via proteolytic cleavage, where it may exert dominant-negative effects on full-length CD44 function or even translocate to the nucleus to influence transcription [4] [20]. Therefore, investigating the clustering of the full-length receptor and its regulation is a fundamental prerequisite for understanding the complex functional outcomes of CD44-ICD interactions.

Background and Significance

The CD44-HA Axis and Molecular Weight Dependence

The interaction between CD44 and its primary ligand, hyaluronic acid, is a cornerstone of its function. This interaction is not static; CD44 can exist in inactive, inducible active, or constitutively active states, with its activation status influenced by post-translational modifications, receptor clustering, and associations with the cytoskeleton [7]. A critical factor governing this interaction is the molecular weight of HA. High Molecular Weight (HMW) HA has been demonstrated to promote CD44 clustering on endothelial cells, leading to increased cell viability and tube formation, processes indicative of angiogenic potential [31]. In contrast, Low Molecular Weight (LMW) HA does not elicit the same response. This finding is of paramount importance for experimental design, as the choice of HA is a key determinant in successfully recapitulating physiologically and pathologically relevant CD44 clustering in vitro.

Key Functional Regions of the CD44 Intracellular Domain

The short 72-amino-acid cytoplasmic tail of CD44 is a master regulator of its function. Its sequence contains several conserved motifs that serve as binding sites for critical cytoplasmic effectors [8] [32]. The FERM-binding domain (amino acids 292-300) mediates interaction with ERM proteins, providing a direct link to the actin cytoskeleton [8]. Adjacent to this is the ankyrin-binding domain (amino acids 304-318), which allows CD44 to interact with ankyrin proteins, another bridge to the cytoskeleton [8] [4]. Research in chondrocytes has shown that the interaction with ankyrin-3 is particularly important for the retention of the hyaluronan-based pericellular matrix, and disruption of this interaction impairs CD44 function [4]. The integrity of these domains is essential, as mutation or deletion of the CD44-ICD results in aberrant cellular localization and a loss of HA-binding capacity [8].

Table 1: Key Structural and Functional Motifs within the CD44 Intracellular Domain

Motif Name	Amino Acid Sequence (Human)	Interacting Partner(s)	Primary Functional Consequence
FERM-Binding Domain	²⁹²RRRCGQKKK³⁰⁰	Ezrin, Radixin, Moesin (ERM)	Linkage to actin cytoskeleton; regulation of adhesion and migration
Ankyrin-Binding Domain	³⁰⁴NSGNGAVEDRKPSGL³¹⁸	Ankyrin-3 (Ank3)	Cytoskeletal anchoring; critical for pericellular matrix assembly
Basolateral Targeting Motif	³³¹LV³³²	Undefined	Targeting of CD44 to the basolateral membrane in polarized cells
PDZ-Binding Motif	³⁵⁸KIGV³⁶¹	PDZ-domain containing proteins	Potential regulation of signal complex assembly
Primary Phosphorylation Site	Ser³²⁵	Ca²⁺/Calmodulin-dependent Kinase II (CaMKII)	Regulation of HA-mediated cell migration

The following diagram illustrates the key structural motifs of the CD44 receptor and its interaction with the cytoskeleton, which are fundamental to the clustering analysis.

Materials and Reagents

Research Reagent Solutions

A successful cross-linking and FRET analysis requires careful selection and preparation of reagents. The table below catalogues the essential materials, their functions, and critical considerations for their use, drawing from recent methodological applications.

Table 2: Essential Reagents for CD44 Clustering Studies

Reagent / Material	Function / Application	Key Considerations & Examples
High Molecular Weight (HMW) Hyaluronic Acid (HA)	Primary ligand to induce native CD44 clustering.	Use MW > 500 kDa. HMW-HA, but not LMW-HA, induces CD44 clustering and downstream signaling [31].
Anti-CD44 Monoclonal Antibody	Tool for receptor cross-linking and detection.	Choose antibodies targeting the extracellular domain. Clone 156-3C11 is commonly used for immunoprecipitation [20].
BS³ (Bis(sulfosuccinimidyl)suberate)	Homobifunctional, amine-reactive cross-linker.	Membrane-impermeable; stabilizes protein-protein interactions at the cell surface before lysis.
FRET-Compatible Anti-CD44 Antibodies	Donor and acceptor fluorophores for FRET.	Conjugates must have overlapping emission/absorption spectra (e.g., Cy3/Cy5 pair).
Cell Lines with High CD44 Expression	Model systems for in vitro studies.	PC3 prostate cancer cells, various breast cancer cells (e.g., EMT-positive lines). CD44v isoforms are often cancer-restricted [29] [20].
γ-Secretase Inhibitor (e.g., DAPT)	Inhibits proteolytic cleavage of CD44.	Prevents generation of CD44-ICD, allowing focus on full-length receptor clustering [20].
Lysis Buffer (with Protease Inhibitors)	Cell lysis and protein extraction.	Must be compatible with subsequent cross-link reversal and analysis (e.g., RIPA buffer) [30] [20].
Antibodies for CD44-ICD & Cytoskeletal Proteins	Analysis of interactions (Western Blot, IP).	CD44-ICD (KAL-KO601); Ezrin (3145S); Ankyrin-3 specific antibodies [4] [20].

Experimental Protocols

Protocol 1: Chemical Cross-Linking of CD44 for Oligomerization Analysis

This protocol details the steps to stabilize and detect CD44 oligomers on the surface of live cells using a chemical cross-linker.

1. Cell Preparation and Stimulation

• Culture CD44-expressing cells (e.g., PC3, or EMT-positive breast cancer cells) to 70-80% confluence.
• Optional Stimulation: To induce clustering, serum-starve cells for 4-6 hours, then stimulate with 100 µg/mL of HMW-HA (≥ 500 kDa) in serum-free medium for 30-60 minutes at 37°C [31]. For a negative control, use serum-free medium alone or medium containing LMW-HA.

2. Cross-Linking Reaction

• Gently wash the cells twice with ice-cold PBS, pH 8.0 (amine-free buffer is critical for efficient cross-linking).
• Prepare a fresh solution of the membrane-impermeable cross-linker BS³ (e.g., 1-2 mM) in ice-cold PBS, pH 8.0.
• Add the BS³ solution to the cells and incubate for 30 minutes at 4°C with gentle rocking. This low-temperature incubation minimizes internalization.
• Quench the cross-linking reaction by adding Tris-HCl, pH 7.5, to a final concentration of 20 mM and incubate for 15 minutes at 4°C.

3. Sample Lysis and Analysis

• Wash the cells twice with ice-cold PBS to remove the quencher.
• Lyse the cells using a suitable RIPA buffer supplemented with protease and phosphatase inhibitors. Incubate on ice for 20-30 minutes, then clarify the lysate by centrifugation at 14,000 x g for 15 minutes at 4°C.
• Cross-link Reversal: To accurately determine molecular weights via Western Blot, reverse the cross-links by heating the lysate in Laemmli sample buffer containing 100 mM DTT at 95°C for 10 minutes.
• Analyze the samples by SDS-PAGE and Western Blotting under non-reducing or reducing conditions (post-reversal). Probe with an anti-CD44 antibody. Cross-linked oligomers will appear as high-molecular-weight smears or discrete bands above the ~85 kDa monomeric CD44s.

Protocol 2: FRET-Based Analysis of CD44 Clustering

This protocol utilizes Fluorescence Resonance Energy Transfer (FRET) to detect and quantify the proximity of CD44 molecules in real-time in live cells, providing direct evidence of clustering.

1. Cell Staining with FRET Pair

• Culture cells on glass-bottom dishes or coverslips suitable for high-resolution microscopy.
• For live-cell staining, wash the cells with a suitable buffer (e.g., HBSS with Ca²⁺/Mg²⁺).
• Label cell-surface CD44 by incubating with a primary anti-CD44 antibody (e.g., F10-44-2) for 20 minutes at 4°C to prevent internalization.
• Wash away unbound antibody.
• Subsequently, stain the cells with a mixture of secondary antibodies conjugated to a FRET donor (e.g., Alexa Fluor 488, AF488) and acceptor (e.g., Alexa Fluor 555, AF555) at a defined ratio (e.g., 1:1). Use Fab fragments to minimize non-specific cross-linking via the antibody Fc region. Incubate for 20 minutes at 4°C, then wash.

2. Image Acquisition and FRET Calculation

• Acquire images on a confocal microscope or an epifluorescence system equipped with FRET filters.
• Acquire three sets of images for each field of view:
  • Donor channel: Excite with donor wavelength (e.g., 488 nm), collect donor emission (e.g., 500-550 nm).
  • Acceptor channel: Excite with acceptor wavelength (e.g., 555 nm), collect acceptor emission (e.g., 560-620 nm).
  • FRET channel: Excite with donor wavelength (e.g., 488 nm), collect acceptor emission (e.g., 560-620 nm).
• FRET Efficiency Calculation: Calculate the FRET efficiency using the acceptor photobleaching method. After acquiring the initial three images, photobleach the acceptor fluorophore in a defined region of interest (ROI) using high-intensity laser light at the acceptor excitation wavelength. Re-acquire the donor channel image. The increase in donor fluorescence intensity post-bleaching is directly related to FRET efficiency, calculated as: FRET Efficiency (%) = [(Donorpost - Donorpre) / Donor_post] × 100. A higher FRET efficiency indicates closer proximity (<10 nm) of CD44 molecules, confirming clustering.

The following diagram outlines the core workflow and principle of the acceptor photobleaching FRET method described in the protocol.

Protocol 3: Co-Immunoprecipitation to Assess Cytoskeletal Tethering

This protocol is used to investigate the interaction between clustered CD44 and cytoskeletal adaptor proteins, a key downstream consequence of clustering.

1. Cell Lysis and Pre-Clearance

• Prepare cell lysates from cross-linked or HMW-HA-stimulated cells using a mild, non-denaturing lysis buffer (e.g., 1% Triton X-100, 25 mM Tris pH 7.4, 150 mM NaCl) with protease and phosphatase inhibitors. This preserves protein-protein interactions.
• Pre-clear the lysate by incubating with Protein A/G Agarose beads for 30-60 minutes at 4°C to reduce non-specific binding. Pellet the beads and collect the supernatant.

2. Immunoprecipitation

• Incubate the pre-cleared lysate with an anti-CD44 antibody (e.g., 156-3C11) or an isotype control antibody for 2 hours to overnight at 4°C with constant agitation.
• Add Protein A/G Agarose beads and incubate for an additional 1-2 hours to capture the antibody-antigen complex.
• Pellet the beads by gentle centrifugation and wash thoroughly 3-4 times with ice-cold lysis buffer.

3. Elution and Analysis

• Elute the bound proteins by boiling the beads in 2X Laemmli sample buffer for 5-10 minutes.
• Analyze the eluates by SDS-PAGE and Western Blotting.
• Probe the membrane not only for CD44 to confirm the pull-down but also for cytoskeletal partners such as ezrin (using antibody 3145S) or ankyrin-3 [4] [20]. An increased co-precipitation of these adaptors upon HMW-HA stimulation is a strong biochemical indicator of successful, functional CD44 clustering and cytoskeletal anchoring.

Data Analysis and Interpretation

Expected Outcomes and Data Presentation

The application of the described protocols will generate quantitative data on CD44 oligomerization and its functional interactions. The table below summarizes key metrics and their interpretations.

Table 3: Key Analytical Metrics for CD44 Clustering Experiments

Method	Primary Readout	Interpretation of Positive Clustering	Correlation with Cytoskeletal Tethering
Chemical Cross-Linking + WB	Appearance of high MW bands/smear on blot (e.g., dimers ~170 kDa, trimers ~255 kDa).	Increased density of high MW oligomers relative to monomeric CD44.	Co-IP showing strengthened interaction with Ezrin/Ankyrin in cross-linked samples.
FRET (Acceptor Photobleaching)	FRET Efficiency (%).	A significant increase in FRET efficiency (%) in stimulated vs. unstimulated cells.	Spatial correlation of high FRET efficiency zones with areas of actin cytoskeleton remodeling.
Co-Immunoprecipitation (Co-IP)	Band intensity for Ezrin/Ankyrin in CD44 IP.	Increased abundance of cytoskeletal proteins in the CD44 immunoprecipitate.	Direct biochemical evidence of complex formation.

Troubleshooting Notes

• Low FRET Efficiency: Ensure the donor and acceptor fluorophores are a matched pair. Verify that the antibody labeling does not itself induce clustering (use Fabs). Check for excessive acceptor bleaching during image acquisition.
• High Background in Cross-Linking: Optimize the concentration of the cross-linker BS³; too high a concentration can lead to non-specific cross-linking. Ensure the quenching step is complete and that the lysis buffer is compatible.
• Weak Co-IP Signal: Use a fresh, non-denaturing lysis buffer and ensure protease inhibitors are present. Increase the amount of input protein or extend the incubation time with the antibody. Validate the specificity of the interaction by including relevant controls (e.g., cells lacking CD44, isotype control antibody).

Mutagenesis Strategies for Binding Site Characterization

The CD44 intracellular domain (CD44-ICD), a remarkably conserved 72-73 amino acid segment, serves as a critical signaling hub that integrates extracellular cues with intracellular responses, despite lacking intrinsic enzymatic activity [1] [8]. Its function is governed by specific structural motifs that facilitate interactions with cytoskeletal proteins and signaling effectors, including ezrin/radixin/moesin (ERM) proteins, ankyrin, and components of the cell-trafficking machinery [1] [8] [24]. Mutagenesis represents a foundational approach for deconvoluting the contribution of individual residues and motifs to these complex interactions. This protocol details targeted mutagenesis strategies to characterize binding sites within the CD44-ICD, with direct application to research focused on cytoskeletal association, signal transduction, and therapeutic development.

Table 1: Key Functional Motifs in the Human CD44 Intracellular Domain

Functional Motif	Amino Acid Position	Key Interacting Partner(s)	Biological Function
FERM-Binding Domain	292-RRRCGQKKK-300	ERM proteins (Ezrin, Radixin, Moesin)	Cytoskeletal anchoring; membrane organization and clustering [1] [8]
Ankyrin-Binding Domain	304-NSGNGAVEDRKPSGL-318	Ankyrin (esp. 65/130 kDa Ankyrin-3 isoforms)	Cytoskeletal association; signal transduction; matrix retention [1] [4] [8]
Phosphorylation Site (Primary)	Ser325	Ca²⁺/Calmodulin-dependent Kinase II (CaMKII)	Regulates HA-mediated cell migration [1] [8]
Phosphorylation Sites (Secondary)	Ser291, Ser316	Protein Kinase C (PKC), Protein Kinase A (PKA)	Dynamic regulation of CD44 function [1] [8]
Basolateral Targeting Motif	331-LV-332	Cell trafficking machinery	Regulation of intracellular trafficking [1] [8]
PDZ-Binding Domain	358-KIGV-361	PDZ-domain containing proteins	Signal complex assembly [1] [8]

Mutagenesis Strategy and Experimental Design

A systematic mutagenesis strategy is essential for mapping functional relationships within the CD44-ICD. The approach should progress from broad domain deletion to precise point mutations.

Design of Mutagenesis Constructs

The following constructs are fundamental for characterizing CD44-ICD binding sites:

• Full-Length CD44 (CD44FL) with C-terminal Epitope Tags: The backbone for all mutagenesis. A C-terminal tag (e.g., myc, V5, or fluorescent protein) enables tracking of mutant expression and localization without interfering with extracellular ligand binding [4] [33].
• Deletion Mutants: Generate constructs lacking specific motifs to assess their necessity for protein interactions and phenotypic outcomes.
  • ΔERM: Deletion of the FERM-binding domain (aa 292-300).
  • ΔANK: Deletion of the ankyrin-binding domain (aa 304-318).
  • ΔICD: Complete deletion of the intracellular domain (after the transmembrane domain) [24].
• Point Mutants: Create alanine substitution mutants to disrupt specific interactions without large-scale structural perturbations.
  • Phospho-null Mutants: Serine to Alanine (S325A, S291A, S316A) to prevent phosphorylation [8] [34].
  • Phospho-mimetic Mutants: Serine to Aspartic Acid (S325D) to mimic constitutive phosphorylation [34].
  • Motif Disruption: Alanine substitutions of critical charged or hydrophobic residues within binding motifs (e.g., within the ankyrin-binding domain) [4].
• CD44-Intracellular Domain (CD44-ICD) Fragment: A construct expressing only the liberated cytoplasmic tail (aa ~290-361). This is used to study its function as a dominant-negative or a transcriptional co-regulator [4] [33] [20].

Experimental Workflow for Functional Characterization

A typical workflow for characterizing CD44-ICD mutants is as follows:

• Construct Generation & Expression: Generate mutant constructs via site-directed mutagenesis and express them in relevant cell lines (e.g., PC3 prostate cancer cells, chondrocytes, or CD44-negative cells like LNCaP) [4] [20].
• Interaction Validation: Perform co-immunoprecipitation (Co-IP) and immunoblotting to quantify interactions with partners like ankyrin and ERM proteins [4] [20] [24].
• Phosphorylation Status Analysis: Use phospho-specific antibodies to assess the phosphorylation state of residues like Ser325 in different mutants [8] [34].
• Functional & Phenotypic Assays:
  • Cytoskeletal Organization: Evaluate F-actin arrangement and CD44 clustering via immunofluorescence and FRET/FRAP [24].
  • Cell Migration: Conduct HA-mediated migration assays (e.g., wound healing) [1] [8].
  • Gene Transcription: Measure transcript levels of CD44-ICD/RUNX2 target genes (e.g., MMP-9, OPN) using qRT-PCR [20].
  • Pericellular Matrix Assembly: Assess the ability of cells to bind hyaluronan and form a pericellular coat [4].

Table 2: Key Assays for Characterizing CD44-ICD Mutants

Assay Category	Specific Method	Readout / Key Measurement	Application Example
Protein-Protein Interaction	Co-immunoprecipitation (Co-IP)	Pull-down of ankyrin or ERM proteins with CD44 mutants [4] [20]	Determine if ΔANK mutation disrupts ankyrin-3 binding [4]
Post-Translational Modification	Immunoblotting with phospho-specific antibodies	Phosphorylation level at Ser325 [8] [34]	Confirm loss of phosphorylation in S325A mutant [34]
Cellular Phenotype	HA-mediated cell migration assay	Rate of cell migration towards an HA gradient [1] [8]	Assess impaired migration in phosphorylation-deficient mutants [8]
Gene Regulation	Quantitative RT-PCR (qRT-PCR)	mRNA expression of MMP-9, OPN [20]	Measure effect of CD44-ICD fragment on transcription [20]
Subcellular Localization	Immunofluorescence / Confocal microscopy	Co-localization of CD44-ICD and RUNX2 in the nucleus [20]	Validate nuclear translocation of CD44-ICD fragment [33] [20]
Receptor Clustering & Dynamics	Fluorescence Recovery After Photobleaching (FRAP)	Mobility and clustering of CD44 at the plasma membrane [24]	Demonstrate increased mobility in ΔICD mutant [24]

Detailed Experimental Protocols

Protocol 1: Co-immunoprecipitation to Assess Ankyrin-3 Binding

This protocol is adapted from methodologies used to demonstrate that the CD44-ICD exerts a dominant-negative effect by competing with full-length CD44 for ankyrin binding [4].

Materials:

• Cells: PC3 cells (or relevant cell line) transfected with CD44FL-wt, CD44FL-ΔANK, or CD44-ICD constructs.
• Lysis Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, supplemented with protease and phosphatase inhibitors.
• Antibodies: Anti-CD44 antibody (e.g., against the extracellular domain or an epitope tag) and normal IgG as a control; antibody against ankyrin-3.
• Beads: Protein A/G agarose or magnetic beads.

Procedure:

• Cell Lysis: 48 hours post-transfection, lyse cells in ice-cold lysis buffer for 30 minutes. Centrifuge at 14,000 × g for 15 minutes at 4°C to clear insoluble debris.
• Pre-clearing: Incubate the supernatant with protein A/G beads for 1 hour at 4°C to reduce non-specific binding. Collect the supernatant.
• Immunoprecipitation: Incubate equal amounts of total protein (500-1000 µg) with anti-CD44 antibody or control IgG overnight at 4°C with gentle rotation.
• Bead Capture: Add protein A/G beads and incubate for 2-4 hours at 4°C.
• Washing: Pellet beads and wash 3-5 times with lysis buffer.
• Elution and Analysis: Elute bound proteins by boiling in 2X Laemmli sample buffer. Separate proteins by SDS-PAGE and immunoblot for ankyrin-3 and CD44.

Expected Outcome: The CD44FL-ΔANK mutant and the CD44-ICD fragment will show significantly reduced co-precipitation with ankyrin-3 compared to CD44FL-wt [4].

Protocol 2: Functional Analysis of HA-Mediated Cell Migration

This protocol assesses the functional consequence of CD44 phosphorylation on cell migration, a key phenotype [1] [8].

Materials:

• Cells: Cells expressing CD44FL-wt, CD44FL-S325A (phospho-null), or CD44FL-S325D (phospho-mimetic).
• HA-Coated Surfaces: Tissue culture plates coated with high-molecular-weight hyaluronan (e.g., from Sigma-Aldrich).
• Inhibitors (Optional): CaMKII inhibitor (e.g., KN-93) to modulate endogenous phosphorylation.

Procedure:

• Surface Coating: Coat the bottom chamber of a transwell insert or the entire surface of a culture dish with HA (10-100 µg/mL) for 2 hours at 37°C.
• Cell Seeding: Serum-starve transfected cells for 6-8 hours. Seed cells onto the HA-coated surface in serum-free medium. For transwell assays, seed cells in the upper chamber.
• Incubation and Quantification:
  • For a two-dimensional wound healing assay, create a scratch ("wound"), wash away debris, and add low-serum medium. Capture images at 0, 12, and 24 hours. Measure the wound area closure over time.
  • For a transwell migration assay, after 12-24 hours of incubation, fix cells that have migrated to the lower chamber, stain with crystal violet, and count.
• Inhibition Control: Pre-treat CD44FL-wt cells with a CaMKII inhibitor (e.g., 10 µM KN-93) for 1 hour prior to seeding to validate the role of Ser325 phosphorylation.

Expected Outcome: The S325A mutant and inhibitor-treated cells will display significantly impaired HA-mediated migration compared to CD44FL-wt and the S325D phospho-mimetic mutant [8] [34].

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for CD44 Intracellular Domain Interaction Research

Reagent / Tool	Specific Example	Function / Application in Research
CD44 Antibodies	Anti-CD44 (156-3C11) for extracellular domain [20]; Anti-CD44-ICD (KAL-KO601) [20]	Immunoprecipitation, immunoblotting, and immunofluorescence to detect full-length and cleaved CD44.
Signaling Inhibitors	γ-Secretase Inhibitor (DAPT) [33] [20] [34]; MMP Inhibitors (TAPI-0, TAPI-1) [34]; CaMKII Inhibitor (KN-93)	To block proteolytic cleavage of CD44 or specific kinase activity, establishing mechanistic links.
Interacting Protein Antibodies	Anti-Ankyrin-3 [4]; Anti-RUNX2 (D1L7F) [20]; Anti-Ezrin (3145S) [20]	Detection of binding partners via co-immunoprecipitation and immunoblotting.
Validated Cell Models	PC3 (androgen receptor-negative prostate cancer) [20]; Chondrocyte cell models [4]; CD44-negative cell lines (e.g., LNCaP) [20]	Provide relevant cellular context for studying CD44-ICD interactions and signaling.
Expression Vectors	CD44 full-length and ICD fragment in pcDNA3 or retroviral vectors (e.g., MigR1) [33] [20]	For stable or transient expression of wild-type and mutant CD44 constructs.
Ligands & Enzymes	High-Molecular-Weight Hyaluronan (e.g., from Sigma-Aldrich) [34]; Hyaluronidase [34]	To stimulate CD44 signaling or remove endogenous HA for control experiments.

The CD44 receptor, a single-chain transmembrane glycoprotein, is a central player in cell adhesion, migration, and signaling, with profound implications in cancer progression and therapeutic resistance [1]. While its extracellular domain interacts with ligands such as hyaluronan, its short, conserved 73-amino-acid intracellular domain (ICD) is pivotal for cytoskeletal anchorage and signal transduction, despite lacking intrinsic enzymatic activity [1]. The CD44 ICD contains specific structural motifs that facilitate interactions with key cytoskeletal adaptor proteins, primarily the ezrin/radixin/moesin (ERM) family and ankyrin [1] [3]. These interactions are essential for CD44's role in cellular processes such as trafficking, force generation, and the organization of membrane domains that facilitate cell rolling and invasion [3] [35]. Disrupting these interactions impairs cellular functions, underscoring their biological significance [3] [12].

Investigating the dynamic interplay between the CD44 ICD and the cytoskeleton requires techniques capable of quantifying protein mobility, oligomerization, and confinement in living cells. Fluorescence Recovery After Photobleaching (FRAP) and Number and Brightness (N&B) Analysis are two powerful fluorescence fluctuation spectroscopy methods that provide this critical insight. FRAP is ideally suited to measure the lateral mobility and binding kinetics of CD44 at the plasma membrane [3] [36], while N&B analysis reveals the oligomeric state and clustering of CD44 molecules, which are regulated by cytoskeletal anchorage [3] [37]. This application note details the protocols for applying FRAP and N&B to study CD44-cytoskeleton interactions, providing a framework for researchers to decipher the molecular mechanisms governing CD44 function.

Theoretical Foundations

Fluorescence Recovery After Photobleaching (FRAP)

FRAP is an optical technique that quantifies the two-dimensional lateral diffusion and binding dynamics of fluorescently labeled molecules within a defined region of a living cell [36]. The fundamental principle involves using a high-intensity laser to photobleach a specific area, permanently eliminating the fluorescence of molecules within that zone. The subsequent recovery of fluorescence in the bleached area over time is then monitored with a low-intensity laser (Figure 1). This recovery is driven by the influx of unbleached, mobile molecules from the surrounding membrane into the bleached area, while the loss of fluorescence from the bleached area is due to the outflow of bleached molecules.

The resulting recovery curve provides quantitative parameters such as the mobile fraction (Mf), which represents the proportion of molecules that are free to diffuse, and the immobile fraction, which represents molecules that are bound or tethered. The half-time of recovery (t₁/₂) offers insights into the speed of diffusion and the kinetics of binding interactions. In the context of CD44, FRAP has demonstrated that the cytoplasmic domain is critical for its mobility; deletion of this domain or disruption of the actin cytoskeleton significantly increases CD44 mobility, indicating a release from cytoskeletal restraints [3].

Figure 1: FRAP Experimental Workflow. The key steps involve imaging the pre-bleach state, photobleaching a region of interest (ROI) with a high-intensity laser, and monitoring the subsequent fluorescence recovery over time to generate a quantitative recovery curve.

Number and Brightness (N&B) Analysis

Number and Brightness (N&B) analysis is an imaging-based fluorescence fluctuation spectroscopy method that maps the average number of fluorescent particles (N) and the molecular brightness (ε) within each pixel of a laser scanning microscope image series [37] [20]. Brightness, defined as the fluorescence intensity per particle per second, is a direct indicator of a protein's oligomeric state; a monomeric protein has a characteristic brightness, which doubles for a dimer and increases proportionally for higher-order oligomers.

Conventional N&B can be affected by detector noise and photobleaching, leading to inaccuracies. The advanced Two-Detector Number and Brightness (TD-N&B) method overcomes these limitations by using two detectors and a linear regression analysis of the simultaneous signal, effectively eliminating noise and providing a more precise quantification of particle number and brightness without mathematical corrections [37]. Applied to CD44, N&B analysis has revealed that CD44 forms actin-dependent clusters on the cell membrane and that disrupting its ankyrin-binding site alters the size and compactness of these clusters, directly demonstrating cytoskeletal regulation of CD44 organization [3].

Application to CD44 Intracellular Domain Research

CD44-Cytoskeleton Interactions

The cytoplasmic tail of CD44 is a nexus for cytoskeletal adaptor proteins, which govern its function (Figure 2). The key interactions involve:

• ERM Proteins: Binding occurs via a juxtamembrane cluster of basic amino acids (²⁹²RRRCGQKKK³⁰⁰), linking CD44 directly to cortical actin filaments [1].
• Ankyrin: Interaction is mediated by a more distal 15-residue segment (³⁰⁴NSGNGAVEDRKPSGL³¹⁸), which connects CD44 to the spectrin-based membrane skeleton [1] [3].
• Regulatory Phosphorylation: Phosphorylation of specific serine residues (e.g., Ser325 by CaMKII) dynamically regulates CD44's interaction with the cytoskeleton and its role in cell migration [1].

These interactions are not merely structural. They are functionally critical for:

• Neutrophil Rolling: Cytoskeletal anchorage via ankyrin is required for stable CD44-mediated rolling on E-selectin and subsequent Src family kinase activation [3].
• Traction Force Generation: CD44 is engaged in generating cell traction forces within hyaluronic acid-rich environments, working in conjunction with β1-integrin [35].
• Pericellular Matrix Assembly: Anchoring to the cytoskeleton is essential for the cell's ability to bind hyaluronan and retain a functional pericellular matrix [12].
• Signal Transduction: The cleavage of CD44 releases its intracellular domain (CD44-ICD), which can translocate to the nucleus and act as a co-transcriptional factor with RUNX2 to promote the expression of metastasis-related genes like MMP-9 [20].

Figure 2: CD44 Interactions and Signaling. CD44's intracellular domain engages with ERM proteins and ankyrin to link the extracellular matrix to the actin and spectrin cytoskeletons. Proteolytic cleavage releases the CD44 intracellular domain (CD44-ICD), which can translocate to the nucleus and interact with transcription factors like RUNX2 to regulate gene expression.

Quantitative Insights from FRAP and N&B

The application of FRAP and N&B has yielded critical quantitative data on how cytoskeletal interactions regulate CD44.

Table 1: Key Findings from FRAP Studies on CD44 Mobility

Experimental Condition	Key Finding	Biological Implication	Source
Wild-type CD44	Mobile fraction and recovery half-time indicate constrained diffusion.	CD44 is constitutively tethered to the cytoskeleton.	[3]
CD44-ΔCD (Cytoplasmic Domain Deletion)	Increased mobility and decreased immobile fraction.	The cytoplasmic domain is necessary for cytoskeletal anchorage.	[3]
Latrunculin B (actin depolymerizer)	Increased CD44 mobility.	Actin filaments are required for CD44 retention.	[3]
ΔANK mutant (Ankyrin-binding deficient)	Impaired rolling and signaling, but modest mobility change.	Ankyrin binding specifically organizes clusters for function, not just immobilization.	[3]

Table 2: Key Findings from N&B Analysis of CD44 Clustering

Experimental Condition	Key Finding	Biological Implication	Source
Wild-type CD44	Forms nanometer-scale clusters on the cell membrane.	Basal clustering is a native property of CD44.	[3] [37]
Latrunculin B treatment	Reduced CD44 clustering.	Actin integrity is essential for cluster formation and maintenance.	[3]
ΔANKΔERM mutant (Ankyrin & ERM deficient)	Abolished clustering.	Both ankyrin and ERM binding sites are required for clustering.	[3]
ΔANK mutant (Ankyrin-binding deficient)	Formed larger but looser clusters.	Ankyrin binding refines cluster size and packing density.	[3]

Experimental Protocols

FRAP Protocol for CD44 Mobility

This protocol assesses the mobility of CD44 and its mutants at the plasma membrane of living cells.

I. Sample Preparation

• Cell Line: Use a relevant cell line (e.g., K562 cells, neutrophils, or PC3 prostate cancer cells) [3] [20].
• Transfection: Transfect cells with a plasmid encoding the standard form of CD44 fused to a fluorescent protein (e.g., monomeric YFP or EGFP). Include controls such as CD44-ΔCD (cytoplasmic domain deletion) and specific binding site mutants (ΔERM, ΔANK) [3].
• Plating: Plate cells onto glass-bottom dishes or chambers coated with poly-L-lysine 24-48 hours post-transfection to ensure adherence and healthy expression.

II. Data Acquisition

• Microscope Setup: Use a confocal laser scanning microscope equipped with a photobleaching module, a 63x/1.4 NA oil immersion objective, and an environmental chamber maintained at 37°C and 5% CO₂.
• Imaging Parameters:
  • Set the laser power for imaging to the minimum required to obtain a clear signal to avoid phototoxicity.
  • Define a region of interest (ROI) for bleaching, typically a circle or square at the plasma membrane.
  • Pre-bleach: Acquire 5-10 images at a rapid frame rate.
  • Bleach: Bleach the ROI with a high-intensity laser pulse (e.g., 100% power of a 488nm laser for 1-5 iterations).
  • Post-bleach: Immediately acquire images at the same frame rate for 3-5 minutes to monitor recovery.

III. Data Analysis

• Background Correction: Subtract the background intensity from all measurements.
• Normalization: Normalize the fluorescence intensity in the bleached ROI to the intensity in an unbleached region of the cell to correct for overall photobleaching during acquisition.
• Curve Fitting: Fit the normalized recovery data to an appropriate diffusion model (e.g., a single or double exponential function) using analysis software (e.g., ImageJ/Fiji with FRAP plugins).
• Parameter Extraction: Calculate the mobile fraction (Mf) and half-time of recovery (t₁/₂) from the fitted curve.

TD-N&B Protocol for CD44 Oligomerization

This protocol details the TD-N&B method for quantifying CD44 cluster formation and oligomeric state in live cells [37].

I. Sample Preparation

• Follow the same sample preparation steps as the FRAP protocol (Section 4.1, I), ensuring expression of CD44 fused to a bright, photostable fluorescent protein (e.g., monomeric EGFP or YFP).

II. Data Acquisition

• Microscope Setup: Use a laser scanning microscope equipped with two avalanche photodiode (APD) detectors operating in photon counting mode. The beam splitter must direct the emitted light equally to both detectors.
• Image Series Acquisition:
  • Select a cell expressing a moderate level of CD44-FP to avoid saturation.
  • Acquire a long time-series stack (e.g., 100-200 frames) of a single optical section at the basal plasma membrane with a pixel dwell time shorter than the characteristic diffusion time of CD44.
  • Ensure the sample is immobile during acquisition.

III. Data Analysis

• Pre-processing: Perform a linear regression on the fluorescence intensity from the two detectors to compensate for intensity changes (e.g., from photobleaching).
• Calculation of Moments: For each pixel, calculate the mean fluorescence intensity (〈k〉) and the variance (σ²) from the intensity values over the entire image series.
• TD-N&B Computation:
  • Number Map (N): Calculate the apparent number of particles, N = 〈k〉² / σ².
  • Brightness Map (ε): Calculate the apparent brightness, ε = σ² / 〈k〉.
  • These calculations are performed for the combined data from both detectors, which statistically eliminates detector noise [37].
• Interpretation: Pixels with higher brightness (ε) values indicate the presence of CD44 oligomers or clusters. Compare the average brightness values between cells expressing wild-type CD44 and cytoskeletal binding mutants (ΔERM, ΔANK).

The Scientist's Toolkit

Table 3: Essential Research Reagents and Materials

Reagent/Material	Function/Application	Example or Note
CD44-FP Constructs	Fluorescently tagged CD44 for live-cell imaging.	Murine standard CD44 cDNA cloned into pWay2 vector with monomeric YFP/CFP [3].
CD44 Mutants	To dissect specific cytoskeletal interactions.	ΔERM (ERM-binding site mutated), ΔANK (ankyrin-binding site deleted), ΔCD (cytoplasmic domain deletion) [3].
Cytoskeletal Drugs	To perturb actin dynamics.	Latrunculin B (actin depolymerizer), Blebbistatin (myosin II inhibitor) [3].
γ-Secretase Inhibitor	To block intramembranous cleavage of CD44 and prevent CD44-ICD generation.	DAPT [20].
Anti-CD44 Antibodies	For immunoprecipitation and validation.	Clone KM114 (murine), Clone IM7 (flow cytometry), Anti-C-terminal antibody [3].
Cell Lines	Model systems for study.	K562 cells (transfection model), PC3 prostate cancer cells, Neutrophils ex vivo [3] [20].
Two-Detector Microscope	For accurate TD-N&B measurements.	Confocal microscope with two APD detectors [37].
Image Analysis Software	For FRAP curve fitting and N&B calculation.	ImageJ/Fiji with appropriate plugins; custom scripts for TD-N&B [37] [36].

FRAP and Number/Brightness analysis are indispensable, complementary tools for unraveling the dynamic relationship between the CD44 intracellular domain and the cytoskeleton. By quantifying protein mobility, binding, and oligomerization in living cells, these techniques provide direct evidence of how interactions with ERM proteins and ankyrin govern CD44's organization and function. The detailed protocols and reference data provided herein empower researchers to apply these methods to their own investigations, paving the way for a deeper understanding of CD44's role in cancer metastasis and the development of novel therapeutic strategies aimed at disrupting these critical interactions.

Co-Immunoprecipitation and Protein Interaction Mapping

The cluster of differentiation 44 (CD44) is a type I transmembrane glycoprotein that functions as a major cell surface receptor for hyaluronic acid (HA) and other extracellular matrix components, including osteopontin, collagen, and fibronectin [7]. CD44 exists in multiple isoforms due to alternative mRNA splicing and post-translational modifications, creating remarkable structural and functional diversity [8]. This receptor plays crucial roles in both physiological and pathological processes, including cell adhesion, migration, lymphocyte activation, and tumor progression and metastasis [7]. CD44 has emerged as a key cancer stem cell marker in several malignancies, implicating it in therapeutic resistance and cancer recurrence [8].

The intracellular domain (ICD) of CD44, though relatively short at 72-73 amino acids and lacking intrinsic enzymatic activity, serves as a critical hub for protein-protein interactions that regulate cytoskeletal organization and signal transduction [8]. This domain contains specific structural motifs that facilitate interactions with cytoskeletal proteins and signaling effectors, enabling CD44 to coordinate both structural and signaling events in response to extracellular cues [8]. Understanding these interactions through techniques like co-immunoprecipitation (co-IP) provides vital insights into CD44's diverse cellular functions.

CD44 Intracellular Domain: Structural Features and Binding Partners

Key Structural Motifs of CD44 ICD

The CD44 intracellular domain possesses several conserved structural motifs that mediate interactions with cytoskeletal proteins and signaling molecules:

• FERM-binding domain: Juxtamembrane basic residues (292RRRCGQKKK300) that mediate interaction with ezrin/radixin/moesin (ERM) proteins [8]
• Ankyrin-binding domain: A 15-residue segment (304NSGNGAVEDRKPSGL318) that binds to ankyrin, connecting CD44 to the spectrin-based membrane skeleton [8]
• Basolateral targeting motif: Dihydrophobic sequence (331LV332) involved in cellular trafficking [8]
• PDZ-binding motif: C-terminal four amino acids (358KIGV361) that potentially interact with PDZ domain-containing proteins [8]
• Phosphorylation sites: Ser291, Ser316, and Ser325, with Ser325 being the primary site of constitutive phosphorylation by Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) [8]

Major Cytoskeletal Interaction Partners

Table 1: Key Cytoskeletal Proteins Interacting with CD44 Intracellular Domain

Interacting Protein	Binding Site on CD44 ICD	Functional Consequences
ERM proteins (Ezrin/Radixin/Moesin)	FERM-binding domain (292RRRCGQKKK300)	Links CD44 to actin cytoskeleton; regulates receptor clustering and mobility
Ankyrin	Ankyrin-binding domain (304NSGNGAVEDRKPSGL318)	Connects CD44 to spectrin network; facilitates CD44 clustering
Filamin	Not fully characterized	Promotes cross-linking of actin filaments; enhances cell migration
Proteins regulating trafficking	Basolateral targeting motif (331LV332)	Affects subcellular localization and trafficking of CD44

These cytoskeletal interactions regulate CD44's membrane organization, mobility, and function. Research demonstrates that CD44 forms actin-dependent clusters on hematopoietic cells, and disrupting the ankyrin-binding site impairs CD44-mediated neutrophil rolling on E-selectin and activation of Src family kinases [3]. The cytoplasmic domain is essential for proper CD44 localization, HA binding, and HA-mediated cell migration [8].

Co-Immunoprecipitation for Studying CD44 Protein Interactions

Principles of Co-Immunoprecipitation

Co-immunoprecipitation (co-IP) is a powerful biochemical technique used to identify physiologically relevant protein-protein interactions by using target protein-specific antibodies to indirectly capture proteins bound to a specific target protein [38]. This method allows researchers to investigate protein complexes under near-native conditions, preserving transient interactions that might be lost in other assay systems [39]. For CD44 research, co-IP enables the identification of both direct and indirect binding partners that mediate CD44's diverse cellular functions.

The fundamental principle of co-IP involves using an antibody specific to a target "bait" protein (e.g., CD44) to capture it from a cell lysate, along with any associated "prey" proteins (e.g., cytoskeletal binding partners) [40]. The resulting immune complexes are precipitated using beads coated with Protein A, Protein G, or other antibody-binding proteins, followed by washing to remove non-specifically bound proteins and subsequent elution of the protein complexes for analysis [38].

Co-IP Workflow for CD44-Cytoskeletal Protein Interactions

Diagram 1: Co-IP workflow for CD44 interactions

Critical Optimization Parameters for CD44 Co-IP

Lysis Buffer Conditions: Maintaining protein-protein interactions during co-IP requires careful optimization of lysis conditions. For CD44 cytoskeletal interactions, non-denaturing lysis buffers with low ionic strength (<120mM NaCl) and non-ionic detergents (NP-40, Triton X-100) are recommended to preserve native protein complexes [38]. Buffer composition should typically include:

• 10-50 mM HEPES, pH 7.4
• 120-150 mM NaCl
• 0.5-1% Nonidet P-40 or Triton X-100
• Protease and phosphatase inhibitors [41]

Antibody Selection: The choice of antibody is critical for successful CD44 co-IP. Ideally, antibodies should target epitopes on the extracellular domain of CD44 to avoid interference with intracellular binding partners. For studies focusing on specific CD44 isoforms, isoform-specific antibodies are necessary due to the structural variation in the extracellular domain [40].

Bead Selection: Both agarose and magnetic beads can be used for CD44 co-IP. While agarose beads traditionally offer higher binding capacity, magnetic beads provide advantages including ease of use, lower nonspecific binding, and compatibility with automation [38]. The selection of Protein A vs. Protein G beads should be based on the host species and immunoglobulin class of the CD44 antibody [42].

Detailed Co-IP Protocol for CD44-Cytoskeletal Protein Complexes

Reagent Preparation

Table 2: Essential Reagents for CD44 Co-IP

Reagent	Specifications	Purpose
Lysis Buffer	10 mM HEPES pH 7.4, 10 mM KCl, 0.05% NP-40, protease inhibitors	Extract proteins while preserving interactions
Wash Buffer	10 mM HEPES pH 7.4, 10 mM KCl, 50 mM NaCl, 1 mM MgCl₂, 0.05% NP-40	Remove non-specifically bound proteins
Antibody	CD44-specific, IP-validated	Capture target protein and complexes
Beads	Protein A/G magnetic or agarose beads	Immobilize immune complexes
Elution Buffer	0.5 M NH₄OH, 0.5 mM EDTA (pH 11.0) or low-pH buffer	Release captured complexes gently

Step-by-Step Protocol

Cell Lysis and Pre-clearing

• Culture cells expressing CD44 (e.g., hematopoietic cells, cancer cell lines) to 80% confluency.
• Wash cells with ice-cold PBS and lyse using non-denaturing lysis buffer (1 mL per 10⁷ cells).
• Incubate lysate on ice for 30 minutes with occasional gentle mixing.
• Centrifuge at 12,000 × g for 15 minutes at 4°C to remove insoluble material.
• Transfer supernatant to a new tube and determine protein concentration.
• Pre-clear lysate by incubating with Protein A/G beads for 1 hour at 4°C to reduce non-specific binding [39].

Immunoprecipitation

• Add 1-5 μg of CD44-specific antibody to 300-500 μg of pre-cleared lysate.
• Incubate overnight at 4°C with gentle rotation to form immune complexes.
• Add 20-50 μL of pre-washed Protein A/G beads and incubate for 2-4 hours at 4°C with rotation.
• Separate beads using centrifugation (500 × g, 5 minutes) or magnetic separation.
• Wash beads 3-5 times with wash buffer, resuspending gently between washes to preserve interactions.

Elution and Analysis

• After final wash, elute bound proteins using 20-40 μL of elution buffer.
• Neutralize eluate if using low-pH elution buffer.
• Analyze eluted proteins by Western blotting for specific cytoskeletal proteins (ezrin, ankyrin, ERM proteins) or by mass spectrometry for discovery-based approaches [41].

Essential Controls and Troubleshooting

Critical Experimental Controls:

• IgG control: Use non-specific IgG from the same host species to identify non-specific binding.
• Input sample: Reserve 1-10% of starting lysate to verify presence of target proteins.
• Knockout/knockdown control: Use cells lacking CD44 to confirm specificity of interactions.
• Bait control: Verify CD44 precipitation by probing with CD44 antibody.

Common Optimization Strategies:

• For weak or transient interactions, consider chemical crosslinking before lysis to stabilize complexes [38].
• If background is high, increase salt concentration in wash buffer (up to 500 mM NaCl) or include 0.1% SDS.
• To minimize antibody contamination, use crosslinked antibody-bead complexes or tag-based approaches [38].

CD44 Signaling Pathways and Cytoskeletal Interactions

CD44-Mediated Signaling Pathways

CD44 interactions with cytoskeletal proteins initiate multiple signaling cascades that regulate cellular processes:

ERM-Mediated Signaling: CD44 binding to ERM proteins (ezrin, radixin, moesin) activates the Raf/Ras/MAPK/ERK pathway, promoting cell proliferation and migration [7]. This interaction facilitates direct linkage between CD44 and the actin cytoskeleton, regulating cell shape and motility.

Ankyrin-Spectrin Pathway: CD44 binding to ankyrin connects it to the spectrin-based membrane skeleton, influencing receptor clustering and membrane organization [3]. This interaction promotes calcium mobilization from intracellular stores, activating Ca²⁺/calmodulin-dependent signaling.

PI3K/Akt and Rho GTPase Signaling: CD44 engagement activates PI3K, generating PIP3 and activating small GTPases (Rho, Rac, Cdc42) that regulate cytoskeletal rearrangements through effectors including mDia, WAVE, PAK, and ROCK [7].

Diagram 2: CD44-mediated signaling pathways

Functional Consequences of CD44-Cytoskeletal Interactions

The interactions between CD44's intracellular domain and cytoskeletal proteins have significant functional implications:

Cell Adhesion and Migration: CD44-cytoskeletal connections regulate cell adhesion, migration, and chemotaxis. Phosphorylation of CD44 at Ser325 by CaMKII is particularly important for HA-mediated cell migration [8].

Membrane Organization and Clustering: CD44 forms nanometer-scale clusters dependent on interactions with both ERM proteins and ankyrin. Disruption of the ankyrin-binding site creates larger but looser CD44 clusters, impairing neutrophil rolling on E-selectin [3].

Signal Integration: CD44 serves as a platform for integrating extracellular signals with intracellular responses. By organizing signaling complexes at the membrane-cytoskeleton interface, CD44 coordinates responses to environmental cues [8].

Research Reagent Solutions for CD44 Interaction Studies

Table 3: Essential Research Reagents for CD44-Cytoskeletal Protein Studies

Reagent Category	Specific Examples	Applications and Considerations
CD44 Antibodies	Clone IM7 (mouse anti-murine), Clone KM114 (rabbit anti-murine), FANCA antibody (example for protocol)	Select antibodies validated for IP; consider epitope location to avoid interference with interactions
Bead Platforms	Protein A/G agarose, Magnetic Dynabeads, Streptavidin beads for biotinylated antibodies	Magnetic beads offer ease of use; agarose provides high capacity; choose based on antibody host species
Lysis Buffers	NP-40 based (0.05-0.5%), HEPES pH 7.4, protease/phosphatase inhibitors	Maintain non-denaturing conditions; optimize detergent concentration for specific CD44 isoforms
Tag Systems	HA-tag (YPYDVPDYA), c-Myc-tag (EQKLISEEDL), FLAG-tag (DYKDDDDK)	Epitope tagging enables study of CD44 mutants; avoid tags that disrupt native folding or interactions
Inhibitors	Protease inhibitor cocktails, phosphatase inhibitors, latrunculin B (actin disruptor)	Preserve post-translational modifications; cytoskeletal drugs test dependency of interactions

Advanced Methodologies and Complementary Approaches

Integration with Mass Spectrometry

Co-IP combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS) enables comprehensive identification of CD44 interaction partners. An optimized protocol for this approach includes:

• Large-scale co-IP: Use 2.5 mg of total protein per sample to ensure sufficient material for MS analysis [41].
• Crosslinking: Stabilize transient interactions with reversible crosslinkers like BS³ [38].
• On-bead digestion: Digest proteins directly on beads after washing to minimize losses.
• LC-MS/MS analysis: Use high-resolution mass spectrometry for peptide identification.
• Bioinformatic analysis: Utilize tools like SAINT (Significance Analysis of INTeractome) to distinguish specific interactions from background [41].

Complementary Protein Interaction Methods

While co-IP is invaluable for studying CD44 interactions, several complementary approaches provide additional insights:

Proximity-Dependent Biotinylation (BioID): Uses a promiscuous biotin ligase fused to CD44 to label proximate proteins, capturing transient interactions in live cells [39].

Fluorescence Resonance Energy Transfer (FRET): Measures molecular proximity (<10 nm) between CD44 and binding partners in live cells, providing spatial and temporal information about interactions [39] [3].

Surface Plasmon Resonance (SPR): Quantifies binding kinetics and affinities between purified CD44 intracellular domain and cytoskeletal proteins in real-time [39].

Crosslinking Mass Spectrometry (XL-MS): Identifies specific interaction interfaces by covalently linking binding partners followed by MS analysis [39].

Co-immunoprecipitation remains an essential technique for mapping protein interaction networks involving CD44 and cytoskeletal proteins. The detailed protocols and optimization strategies presented here provide researchers with robust methodologies for investigating CD44's intracellular interactions. As CD44 continues to emerge as a important therapeutic target in cancer and inflammatory diseases, understanding its complex interplay with the cytoskeleton will be crucial for developing novel therapeutic interventions. The integration of co-IP with complementary approaches and advanced mass spectrometry will further enhance our understanding of CD44's multifunctional roles in cellular physiology and pathology.

The cluster of differentiation 44 (CD44) is a type I transmembrane glycoprotein that functions as a critical node in cell-cell and cell-extracellular matrix (ECM) communication. While often recognized for its extracellular domain's role as a receptor for hyaluronic acid (HA), osteopontin, and other ligands, CD44's short, highly conserved intracellular domain (ICD) is indispensable for its function as a signal transducer [8]. The CD44 ICD, though devoid of intrinsic enzymatic activity, serves as a dynamic platform for the assembly of cytoskeletal proteins and signaling complexes that directly regulate cellular adhesion, migration, and rolling—processes fundamental to development, immune function, and cancer metastasis [8] [43]. This application note provides detailed protocols and methodological frameworks for investigating CD44 ICD interactions with cytoskeletal proteins through functional adhesion, migration, and rolling assays, contextualized within a broader thesis on CD44 signal transduction.

The CD44 ICD contains specific structural motifs that facilitate interactions with key cytoskeletal linkers, most notably the ERM (Ezrin, Radixin, Moesin) family of proteins [8] [44]. These interactions are regulated by post-translational modifications, such as phosphorylation of specific serine residues (e.g., Ser325) by Ca2+/calmodulin-dependent protein kinase II (CaMKII) [8]. Upon receptor engagement and activation, the CD44-ERM complex orchestrates actin cytoskeleton remodeling, integrin activation via inside-out signaling, and the formation of lipid raft-based signaling platforms, ultimately coordinating cell polarization, protrusion, and motility [43]. The assays detailed herein are designed to quantitatively capture these functional outputs, providing researchers with tools to dissect the mechanistic role of the CD44 ICD in physiological and pathological contexts.

Key Research Reagent Solutions

The following table catalogs essential reagents and tools for conducting functional studies on CD44, with a focus on interrogating the role of its intracellular domain.

Table 1: Key Research Reagents for CD44 Functional Assays

Reagent / Material	Function / Application	Specific Examples / Notes
CD44 Antibodies	Ligand-mimetic engagement, blocking, and detection.	Hermes-3 (H-3) antibody for receptor engagement [43]. Antibodies targeting active integrin conformations (e.g., HUTS-4, HUTS-21) [43].
Recombinant Ligands	Activating CD44-mediated signaling pathways.	Osteopontin (OPN) and Hyaluronic Acid (HA) [43].
Pharmacological Inhibitors	Disrupting specific signaling nodes and cytoskeletal linkages.	PP2 (Src inhibitor), LY294002 (PI3K inhibitor), Wortmannin (PI3K inhibitor), Methyl-β-cyclodextrin (lipid raft disruptor) [43].
CD44 Constructs & Mutants	Structure-function analysis of the intracellular domain.	CD44 cysteine mutants (C286A, C295A) to study palmitoylation and raft localization; C-terminal deletion mutants (Δ37, Δ61, Δ67) to map cytoskeletal protein binding sites [43].
Cell Models	In vitro systems for genetic manipulation and functional testing.	Gastric adenocarcinoma AZ521, colorectal cancer HT29, glioma U251MG cell lines [43] [18].

CD44 Intracellular Domain Signaling and Experimental Workflow

The CD44 intracellular domain (ICD) transduces extracellular adhesive cues into intracellular signaling, primarily through its interaction with cytoskeletal proteins. The short 72-73 amino acid cytoplasmic tail contains several structured motifs: a FERM-binding domain, an ankyrin-binding domain, and a PDZ-domain-binding motif, which collectively facilitate interactions with ERM proteins, ankyrin, and other cytoplasmic effectors [8]. These interactions are crucial for outside-in and inside-out signaling, linking CD44 to the actin cytoskeleton and regulating downstream pathways such as PI3K/Akt and MAPK/ERK [44]. Furthermore, the CD44 ICD can be proteolytically released by γ-secretase following ectodomain cleavage, with the liberated fragment (CD44ICD) translocating to the nucleus to function as a transcriptional co-activator, thereby influencing gene expression programs related to cell survival and migration [18].

The experimental workflow for investigating these processes typically begins with genetic manipulation of the CD44 ICD in relevant cell models, followed by a suite of functional assays to quantify phenotypic changes in adhesion, migration, and rolling. The diagram below illustrates the core signaling pathway and its connection to the experimental plan.

Quantitative Data from Functional Assays

Functional assays provide quantitative insights into how CD44 ICD interactions influence cellular behavior. The following table summarizes key quantitative findings from selected studies, highlighting the measurable impact of CD44 and its intracellular domain on adhesion, migration, and related signaling events.

Table 2: Quantitative Data from CD44 Functional Studies

Assay Type / Process	Key Measurable Outcome	Experimental Context / Finding	Reference
Genetic Knock-out	Airineme extension frequency	cd44a sgRNA/Cas9 knock-out resulted in a "significant reduction" in airineme extension (F(2,12) = 172.8, P < 0.0001).	[45]
Lipid Raft Coalescence	Integrin β1 enrichment in lipid rafts	CD44 engagement induced "temporally delayed endocytosis" and enrichment of integrin β1 in lipid raft fractions.	[43]
CD44 ICD Cleavage	Fragment size and identity	Sequential proteolysis releases a CD44ICD fragment with a major mass of 3923.95 Da, matching residues 288-324.	[18]
Phospho-Regulation	Phosphorylation site impact	Mutation of the primary phosphorylation site Ser325 "impairs HA-mediated cell migration" but does not affect HA-binding capacity.	[8]
Cytoskeletal Linkage	Phenotypic consequence of domain loss	Deletion or mutation of the ICD results in "impaired HA-mediated cell migration and tumor development."	[8]

Detailed Experimental Protocols

Static Adhesion Assay: CD44-ECM Interaction

Principle: This protocol quantifies the strength of cell adhesion to ECM-coated surfaces, a process dependent on CD44-ECM engagement and subsequent ICD-mediated cytoskeletal anchoring and integrin activation [43].

Protocol:

• Surface Coating: Dilute ECM ligands (e.g., Hyaluronic Acid at 1-10 µg/mL, Osteopontin at 10 µg/mL) in PBS or a suitable bicarbonate buffer. Add the solution to a 96-well plate (50-100 µL/well) and incubate overnight at 4°C. Include wells coated with BSA (1-5%) as a negative control.
• Blocking: Aspirate the coating solution and block non-specific binding sites with a heat-inactivated BSA solution (1-2% in PBS) for 1-2 hours at 37°C.
• Cell Preparation: Harvest cells (e.g., AZ521, HT29) expressing wild-type or mutant CD44 using a non-enzymatic cell dissociation buffer to preserve surface receptors. Wash cells twice and resuspend in serum-free assay medium at a density of 2-5 x 10^5 cells/mL.
• Pre-treatment (Optional): To probe specific pathways, pre-incubate cell suspensions with functional inhibitors (e.g., 10 µM PP2 for Src, 5 mM Methyl-β-cyclodextrin for lipid rafts) or blocking antibodies (e.g., Hermes-3 for CD44, P4C10 for integrin β1) for 30-60 minutes at 37°C [43].
• Adhesion Phase: Add 100 µL of cell suspension to each coated well. Allow cells to adhere for 30-90 minutes in a 37°C, 5% CO₂ incubator.
• Washing: Gently wash wells 2-3 times with pre-warmed PBS to remove non-adherent cells.
• Quantification: Fix remaining cells with 4% PFA for 15 minutes and stain with 0.1% Crystal Violet for 20 minutes. After washing and drying, solubilize the dye with 1% SDS and measure absorbance at 570 nm. Alternatively, use calcein-AM staining (1 µg/mL for 30-45 minutes) and measure fluorescence (Ex/Em ~494/517 nm) for live-cell quantification.

Transwell Migration and Haptotaxis Assay

Principle: This assay measures directed cell migration through a porous membrane toward a chemoattractant gradient (chemotaxis) or an ECM gradient (haptotaxis), processes regulated by CD44-ICD-driven cytoskeletal reorganization and polarization [8] [44].

Protocol:

• Membrane Coating (for Haptotaxis): Turn Transwell inserts (e.g., 8.0 µm pore size) upside down. Pipette 50-100 µL of ECM ligand solution (e.g., 10 µg/mL OPN or HA) onto the bottom side of the membrane and let it dry for 2-4 hours. Then, rehydrate the membrane with serum-free medium for 30 minutes. For chemotaxis, coat the membrane with collagen I or fibronectin and place the attractant in the lower chamber.
• Cell Preparation: Serum-starve cells (WT vs. CD44 ICD mutants) for 4-24 hours. Harvest and resuspend in serum-free medium at 0.5-1 x 10^6 cells/mL.
• Migration Phase: Add the cell suspension to the upper chamber of the Transwell insert. Fill the lower chamber with serum-free medium (control) or medium containing a chemoattractant (e.g., 10% FBS, 100 ng/mL HGF). For haptotaxis, the lower chamber contains serum-free medium. Incubate for 6-24 hours at 37°C, 5% CO₂.
• Analysis: After incubation, carefully remove non-migratory cells from the top of the membrane with a cotton swab. Fix and stain cells that have migrated to the bottom side with 4% PFA and 0.1% Crystal Violet. Count cells in 5-10 random fields per insert under a light microscope (20x objective). Alternatively, stain migrated cells with calcein-AM and measure fluorescence.

In Vitro Flow-Based Rolling Adhesion Assay

Principle: This protocol simulates physiological shear stress to study the role of CD44 in mediating the initial tethering and rolling of cells (e.g., lymphocytes, cancer cells) on endothelial ligands under flow, a process dependent on rapid cytoskeletal rearrangements [43].

Protocol:

• Flow Chamber Coating: Prepare a parallel plate flow chamber or microfluidic channel by coating the surface with recombinant adhesion molecules (e.g., E-selectin at 1-10 µg/mL and Hyaluronic Acid at 10-50 µg/mL) in PBS overnight at 4°C. Block with 1% HSA for 1 hour.
• Cell Preparation: Harvest cells and resuspend in a flow buffer (e.g., HBSS with Ca²⁺/Mg²⁺ and 0.5-1% HSA) at a density of 0.5-1 x 10^6 cells/mL. Keep the suspension at room temperature with gentle agitation to prevent clumping.
• Perfusion and Data Acquisition: Mount the coated chamber on an inverted microscope equipped with a high-speed camera. Perfuse the cell suspension through the chamber at a defined wall shear stress (e.g., 1-4 dyn/cm²) using a precision syringe pump. Record multiple fields of view for at least 2-5 minutes.
• Quantitative Analysis: Analyze videos using cell tracking software (e.g., ImageJ with TrackMate, MATLAB scripts). Key parameters to quantify include:
  • Rolling Fraction: (Number of cells rolling / Total number of cells interacting) x 100.
  • Rolling Velocity: Mean velocity (µm/s) of individual rolling cells.
  • Firm Adhesion: Number of cells that become stationary for >30 seconds during the observation period.

CD44 ICD Proteolytic Processing and Nuclear Signaling

A critical aspect of CD44 signaling is the regulated intramembrane proteolysis (RIP) of its intracellular domain. Following an initial ectodomain cleavage by membrane-associated metalloproteases (e.g., MT1-MMP), the membrane-tethered CD44 stub undergoes a secondary cleavage by γ-secretase within its transmembrane domain [18]. This liberates the CD44 Intracellular Domain (CD44ICD), which translocates to the nucleus. Within the nucleus, CD44ICD can function as a transcriptional co-activator, for instance, by potentiating transactivation mediated by the coactivators CBP/p300, and has been shown to activate transcription from TPA-Responsive Elements (TRE), thereby influencing gene expression programs that govern cell survival, migration, and tumor progression [18]. This pathway directly links proteolytic processing of an adhesion molecule at the cell surface to transcriptional regulation in the nucleus.

Overcoming Technical Challenges in CD44-Cytoskeleton Research

Optimizing Detection of Proteolytic Fragments and ICD

The cluster of differentiation 44 (CD44) is a type I transmembrane glycoprotein that functions as a primary receptor for hyaluronic acid (HA) and other extracellular matrix (ECM) components, including osteopontin and collagen [44]. Beyond its established role in cell adhesion and migration, CD44 undergoes sequential proteolytic processing that regulates its function and generates a biologically active intracellular domain (ICD) fragment. This proteolytic cleavage occurs in two sequential steps: first, membrane-associated metalloproteases (e.g., MT1-MMP) cleave the extracellular domain, producing a membrane-tethered C-terminal fragment [18] [20]. Second, the residual fragment undergoes intramembranous cleavage by γ-secretase, releasing the CD44 intracellular domain (CD44-ICD) into the cytoplasm [18] [20]. The liberated CD44-ICD subsequently translocates to the nucleus, where it functions as a transcriptional co-regulator for factors such as RUNX2, modulating the expression of metastasis-related genes including MMP-9 [20]. Concurrently, this proteolytic processing impacts the cytoskeletal anchoring function of full-length CD44, influencing cellular adhesion and migration [4]. The detection and quantification of these proteolytic fragments are therefore crucial for understanding CD44's diverse roles in normal physiology and disease, particularly in cancer metastasis and as a component of broader research on CD44 interactions with cytoskeletal proteins.

CD44 Proteolytic Signaling Pathways

CD44 proteolysis initiates multiple signaling cascades that influence both cytoskeletal dynamics and gene expression. The diagram below illustrates the core proteolytic pathway and its functional consequences regarding cytoskeletal anchorage and transcriptional activation.

This proteolytic pathway is regulated by specific cellular stimuli. Calcium influx, activation of Protein Kinase C (PKC) by agents like TPA (12-O-tetradecanoylphorbol 13-acetate), and signaling through Rho GTPases can promote the initial ectodomain cleavage [18]. The CD44-ICD fragment, once released, exerts dual functions: it translocates to the nucleus to activate transcription and can also act in the cytoplasm to disrupt the anchorage of full-length CD44 to the actin cytoskeleton by competing for binding to adaptor proteins like ankyrin [4]. This disruption leads to a loss of pericellular matrix assembly and altered cell migration.

Quantitative Workflow Comparison for Proteolytic Fragment Analysis

Accurate detection and quantification of CD44 proteolytic fragments are essential. The table below compares the performance of major quantitative proteomics workflows applicable to this task, particularly Limited Proteolysis coupled with Mass Spectrometry (LiP-MS), which can detect protein structural changes resulting from proteolytic cleavage or ligand binding.

Table 1: Benchmarking Quantitative Proteomics Workflows for Detecting Protein Structural Changes and Fragments

Workflow Parameter	Data-Independent Acquisition (DIA)	Tandem Mass Tag (TMT) Isobaric Labeling
Primary Principle	Label-free quantification; cycles of wide isolation windows fragment all peptides in a sample [46].	Isobaric labels enable multiplexing (up to 16 samples); reporter ions provide quantification in MS2/MS3 [46].
Quantified Peptides/Proteins	Broader proteomic coverage, but complex spectra [46].	Higher number of quantified peptides/proteins with lower technical variation [46].
Quantitative Accuracy	Higher accuracy in identifying true targets and stronger dose-response correlation [46].	Susceptible to ratio compression, potentially reducing quantitative accuracy for individual peptides [46].
Advantages	Reduced missing values; consistent quantification; no need for labeling [46].	High throughput for multiplexed samples; reduced missing values across conditions [46].
Limitations/LiP-MS Challenges	Complex data processing due to co-fragmentation; requires specialized software (e.g., DIA-NN, Spectronaut) [46].	Ratio compression can obscure true quantification differences; higher cost for reagents [46].
Recommended Analysis Software	FragPipe (for precision), Spectronaut (for sensitivity), DIA-NN [46].	Standard TMT analysis pipelines within FragPipe or similar platforms.

For specialized cleavage site identification, the Amino-Terminal Oriented Mass Spectrometry of Substrates (ATOMS) methodology provides a complementary approach. ATOMS uses dimethylation isotopic labeling of original and newly generated N-termini followed by quantitative tandem mass spectrometry to precisely identify proteolytic cleavage sites in complex proteins, overcoming limitations of traditional Edman sequencing [47].

Detailed Experimental Protocols

Protocol 1: Inducing and Detecting CD44 Proteolytic Fragments by Immunoblotting

This protocol details the steps for inducing CD44 cleavage in cultured cells and detecting the resulting fragments via western blot, a foundational technique for studying CD44-ICD generation and its role in subsequent interaction assays.

Workflow: CD44 Fragment Induction and Detection

Materials and Reagents

• Cell Lines: PC3 (prostate cancer), U251MG (glioma), or primary chondrocytes [18] [20].
• Inducers: TPA (PKC activator, e.g., 100-200 nM), Ionomycin (calcium ionophore, e.g., 1-5 µM) [18].
• Protease Inhibitors: BB2516 (MMP inhibitor, e.g., 10 µM), MG132 (proteasome/γ-secretase inhibitor, e.g., 10-25 µM), DAPT (γ-secretase inhibitor, e.g., 5-20 µM) [18] [20].
• Antibodies: Anti-CD44 C-terminal antibody (e.g., Cell Signaling #156-3C11), anti-CD44-ICD specific antibody (e.g., Cosmo Bio KAL-KO601) [20].
• Lysis Buffers: RIPA buffer for whole-cell lysates; commercial kits for subcellular fractionation (e.g., cytosol/membrane vs. nuclear).

Step-by-Step Procedure

• Cell Culture and Stimulation: Culture cells to 70-80% confluence. To induce cleavage, treat cells with TPA or Ionomycin for a defined period (e.g., 30-60 minutes). For inhibitor studies, pre-treat cells for 1-2 hours with BB2516 (MMP inhibitor) or MG132/DAPT (γ-secretase inhibitor) before adding the inducer [18] [20].
• Cell Lysis and Fractionation: After treatment, lyse cells directly in RIPA buffer supplemented with protease and phosphatase inhibitors. To study nuclear translocation of CD44-ICD, use a subcellular fractionation kit to separate cytosolic/membrane fractions from nuclear fractions [18] [20].
• Immunoblotting: Resolve 20-40 µg of total protein per lane on a 4-20% gradient SDS-PAGE gel. Transfer to a PVDF membrane and probe with an antibody targeting the C-terminal region of CD44. This allows detection of full-length CD44 (~85 kDa), the membrane-tethered C-terminal fragment (CTF, ~25 kDa), and the liberated CD44-ICD (~15-16 kDa) [18] [20]. Specific anti-ICD antibodies can confirm the identity of the ~15 kDa fragment.

Protocol 2: Limited Proteolysis-Mass Spectrometry (LiP-MS) for Detecting CD44 Structural Changes

LiP-MS is a powerful technique for detecting proteolytic fragments and protein structural changes on a proteome-wide scale, which can be applied to study CD44 cleavage or the impact of CD44-ICD on other proteins.

Materials and Reagents

• Biological Sample: K562 cell lysate or lysate from a relevant CD44-expressing cell line [46].
• Protease: Proteinase K from Tritirachium album [46].
• Mass Spectrometry: LC-MS/MS system; optional TMTpro 16-plex reagents for multiplexing [46].
• Software: FragPipe (with MSFragger) or DIA-NN for data analysis [46].

Step-by-Step Procedure

• Sample Preparation: Prepare clarified cell lysate in LiP buffer (e.g., 100 mM HEPES pH 7.5, 150 mM KCl, 1 mM MgCl₂). Determine protein concentration using a BCA assay [46].
• Limited Proteolysis: Aliquot lysate (e.g., 120 µg) and treat with a drug of interest (e.g., staurosporine) or vehicle control. Add Proteinase K at a optimized ratio (e.g., 1:100 protease-to-protein mass ratio) and incubate at 25°C for a short, controlled time (e.g., 5 minutes). Immediately stop the reaction by heating at 98°C for 5 minutes [46].
• Complete Digestion and Preparation: Add sodium deoxycholate (DOC) to 5%. Reduce, alkylate, and perform a complete overnight digestion with trypsin/Lys-C. Precipitate DOC by acidification, desalt peptides, and dry [46].
• Mass Spectrometry Analysis: Reconstitute peptides and analyze by either:
  • DIA-MS: Inject directly onto the LC-MS/MS system operating in data-independent acquisition mode [46].
  • TMT-MS: Label peptides from different conditions with TMT isobaric tags, pool them, and then analyze by LC-MS/MS [46].
• Data Analysis: Process raw data using software like FragPipe or DIA-NN. Search data with semispecific enzyme specificity (e.g., allowing for non-tryptic termini generated by Proteinase K). Identify LiP-peptides, whose abundance changes significantly between conditions, as reporters of protein structural changes or proteolytic events [46].

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Reagents for CD44 Proteolysis and ICD Interaction Research

Reagent / Tool	Function / Application	Specific Examples / Notes
Cell Lines	Model systems for studying CD44 cleavage and ICD function.	PC3 (prostate cancer, androgen-negative), U251MG (glioma) [18] [20].
CD44 Antibodies	Detecting full-length and cleaved fragments via immunoblot/IF.	Anti-CD44 (C-terminal, e.g., #156-3C11), anti-CD44-ICD (specific, e.g., KAL-KO601) [20].
Chemical Inducers	Activate signaling pathways that trigger CD44 ectodomain cleavage.	TPA (PKC activator), Ionomycin (induces calcium influx) [18].
Protease Inhibitors	Block specific cleavage steps to validate fragment identity and pathway.	BB2516 (MMP inhibitor), DAPT and MG132 (γ-secretase inhibitors) [18] [20].
Quantitative MS Workflows	Unbiased discovery and quantification of proteolytic fragments and structural changes.	LiP-MS with DIA or TMT quantification [46]. ATOMS for N-terminal identification [47].
Analysis Software	Processing complex proteomics data, especially for LiP-MS and DIA.	FragPipe (precision), Spectronaut (sensitivity), DIA-NN [46].

The optimized detection of CD44 proteolytic fragments and its intracellular domain is paramount for elucidating its dual role in cytoskeletal anchorage and nuclear signaling. The protocols and workflows detailed here—from foundational immunoblotting to advanced, quantitative mass spectrometry methods like LiP-MS—provide a comprehensive toolkit for researchers. The strategic application of these methods, supported by specific pharmacological inhibitors and analytical software, enables the precise dissection of the CD44 proteolytic pathway. Mastering these techniques is essential for advancing our understanding of how CD44-ICD influences cytoskeletal dynamics and gene expression, which is critical for research in cancer metastasis, development, and drug discovery.

Addressing Cytoskeletal Disruption Artifacts

In the investigation of CD44 intracellular domain (CD44-ICD) interactions with cytoskeletal proteins, the integrity of the cytoskeleton is paramount. CD44, a cell surface adhesion molecule and cancer stem cell marker, lacks intrinsic enzymatic activity and relies on its short, highly conserved cytoplasmic tail to orchestrate a complex network of cytoskeletal interactions that regulate cell adhesion, migration, and signaling [7] [8]. Experimental artifacts arising from cytoskeletal disruption can significantly compromise data interpretation, particularly in studies examining CD44-mediated processes such as tumor progression, metastasis, and therapeutic resistance. This application note provides a structured framework for identifying, minimizing, and controlling these artifacts within the context of CD44-ICD interaction assays, ensuring experimental reliability and reproducibility.

Quantitative Data on CD44-Cytoskeleton Interactions

The following tables summarize key quantitative and structural data essential for designing robust CD44-cytoskeleton interaction assays and for recognizing potential disruption artifacts.

Table 1: Key Structural Motifs within the CD44 Intracellular Domain (ICD)

Motif Name	Amino Acid Position	Binding Partner	Functional Consequence of Disruption
FERM-Binding Domain	292-RRRCGQKKK-300	ERM proteins (Ezrin, Radixin, Moesin)	Impaired cytoskeletal anchoring and HA-mediated cell migration [8]
Ankyrin-Binding Domain	304-NSGNGAVEDRKPSGL-318	Ankyrin	Disrupted linkage to spectrin-actin network; altered Ca²⁺ signaling [7] [8]
Basolateral Targeting Motif	331-LV-332	Undefined	Altered receptor polarization and cellular distribution [8]
PDZ-Binding Domain	358-KIGV-361	PDZ-domain proteins	Defective signal transduction complex assembly [7] [8]

Table 2: Documented Consequences of Cytoskeletal Disruption in Cellular Models

Disruption Agent / Context	Observed Cytoskeletal Effect	Impact on Calcium Homeostasis	Downstream Functional Deficit
Actin arrest in differentiating neural cells	Reduced actin dynamics in soma and processes	Increased frequency and decreased duration of Ca²⁺ spikes; disrupted network correlations [48]	Impaired information flow in neural networks [48]
Anti-IgLON5 IgG in iNeurons	General cytoskeletal disruption and tau deposition	Ca²⁺ dysregulation driven by impaired ER refill and mitochondrial dysfunction [49]	Mitochondrial dysfunction and neuronal cell death [49]
Actin downregulation in CDC-resistant DLBCL	Altered mitochondrial actin polymerization	Not explicitly measured	Resistance to Complement-Dependent Cytotoxicity [50]
Methuosis Inducers (MOMIPP/Maduramicin)	Disruption of F-actin, α-tubulin, β-tubulin, and filamin A/B	Not explicitly measured	Plasma membrane damage and non-apoptotic cell death [51]

Experimental Protocols for Key Assays

Protocol: Co-Immunoprecipitation of CD44-ICD and Cytoskeletal Partners

This protocol is designed to reliably capture transient or weak interactions between CD44-ICD and cytoskeletal proteins like ERM proteins and ankyrin, while monitoring for common disruption artifacts.

Key Reagents:

• Lysis Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, supplemented with protease inhibitors (e.g., PMSF, aprotinin) and phosphatase inhibitors (e.g., sodium orthovanadate). Note: Avoid over-short lysis times or harsh detergents that can disrupt weak protein complexes.
• Antibodies: Anti-CD44-ICD antibody (e.g., Cosmo Bio #KAL-KO601) for immunoprecipitation [52]. Anti-Ezrin, Anti-Ankyrin, and anti-β-Actin for western blot detection.

Procedure:

• Cell Culture and Treatment: Culture PC3 prostate cancer cells or other relevant model in RPMI-1640 + 10% FBS [52]. Treat cells as required (e.g., with Hyaluronic Acid to activate CD44).
• Cell Lysis: Lyse 5 x 10⁶ cells in 1 mL of ice-cold lysis buffer for 30 minutes with gentle agitation. Artifact Alert: Do not vortex or freeze-thaw lysates, as this can disrupt the cytoskeleton and associated proteins.
• Clarification: Centrifuge lysates at 16,000 × g for 15 minutes at 4°C. Transfer the supernatant to a new tube.
• Pre-clearing: Incubate supernatant with 20 μL of Protein A/G Agarose beads for 1 hour at 4°C. Pellet beads and collect supernatant.
• Immunoprecipitation: Incubate the pre-cleared lysate with 2-5 μg of anti-CD44-ICD antibody or isotype control overnight at 4°C.
• Bead Capture: Add 50 μL of Protein A/G Agarose beads and incubate for 4 hours.
• Washing: Pellet beads and wash 3-5 times with ice-cold lysis buffer.
• Elution: Elute bound proteins by boiling beads in 2X Laemmli sample buffer for 5 minutes.
• Analysis: Analyze by SDS-PAGE and Western Blotting for cytoskeletal partners and CD44.

Protocol: Live-Cell Imaging of Actin Dynamics in CD44-Expressing Cells

This protocol allows for the visualization of actin rearrangements downstream of CD44 activation and is susceptible to artifacts from phototoxicity and poor cell health.

Key Reagents:

• Fluorescent Actin Probe: Lifeact-TagGFP2 or Lifeact-mScarlet lentivirus for stable expression [48] [53].
• Calcium Indicator: Fluo-4, CalBryte, or genetically encoded GCaMP proteins [48].
• Imaging Medium: Phenol-red-free medium supplemented with appropriate serum.

Procedure:

• Cell Preparation: Seed cells stably expressing Lifeact fluorescent protein on poly-L-lysine-coated glass-bottom dishes [48] [53].
• Serum Starvation (Optional): Starve cells in low-serum (0.5-1%) medium for 4-16 hours to reduce baseline activation.
• Stimulation: Add CD44 ligand (e.g., 50-100 μg/mL HA) or other stimulants directly during imaging.
• Image Acquisition: Use a confocal or structured illumination microscope (SIM) equipped with an environmental chamber (37°C, 5% CO₂). Acquire images every 5-30 seconds for 5-30 minutes to capture dynamics [48] [53]. Artifact Alert: Use the lowest laser intensity possible to avoid phototoxicity, which can itself cause actin depolymerization.
• Analysis:
  • Optical Flow Analysis: Quantify actin flow velocity and directionality from time-lapse sequences [48].
  • Morphological Categorization: Classify cells based on protrusion types (lamellipodia vs. filopodia) as an indicator of actin regulatory balance [53].

Visualization of CD44-Cytoskeleton Signaling and Artifacts

The following diagrams illustrate the core signaling pathways and potential points of artifact introduction in CD44-cytoskeleton research.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagent Solutions for CD44-Cytoskeleton Interaction Research

Reagent / Tool	Specific Example / Catalog Number	Function in Assay	Considerations to Mitigate Artifacts
CD44-ICD Antibody	Cosmo Bio #KAL-KO601 [52]	Immunoprecipitation and detection of CD44's intracellular domain.	Validate specificity with CD44-knockdown cells to avoid non-specific bands in Western blots.
Actin Visualization Probe	Lifeact-TagGFP2 or Lifeact-mScarlet [48] [53]	Live-cell imaging of F-actin dynamics without severely disrupting function.	Use stable, low-level expression; high overexpression can itself alter actin dynamics.
Calcium Indicators	Fluo-4, X-Rhod, GCaMP proteins [48]	Monitoring Ca²⁺ fluxes, a key second messenger in CD44 signaling.	Choose indicator with appropriate kinetics and sensitivity for the expected Ca²⁺ signal.
γ-Secretase Inhibitor	DAPT [52]	Blocks proteolytic cleavage of CD44, preventing CD44-ICD generation.	Use appropriate vehicle controls and titrate concentration to minimize off-target effects.
Cytoskeletal Stabilizing Buffer	Custom lysis buffer with protease/phosphatase inhibitors [52]	Preserves protein complexes during cell lysis for Co-IP.	Avoid freeze-thaw cycles and vortexing; keep samples consistently on ice.
Rho-ROCK Pathway Agonist	Calpeptin [51]	Experimentally modulates actin polymerization status.	A tool to test the dependency of an observed phenotype on actin integrity.

Managing CD44 Isoform Complexity in Experimental Design

CD44 represents a significant challenge in experimental design due to its remarkable molecular diversity. As a single-chain transmembrane glycoprotein, CD44 exists in numerous isoforms generated through alternative splicing and post-translational modifications [54] [8]. This complexity is particularly relevant for researchers investigating CD44 intracellular domain (ICD) interactions with cytoskeletal proteins, as different isoforms can exhibit distinct signaling behaviors and binding affinities. The CD44 gene contains 19 exons in humans, with exons 1-5, 16, 17, and 19 being constant, while exons 6-15 (v2-v10) undergo alternative splicing to generate variant isoforms (CD44v) [54] [8]. The standard isoform (CD44s) lacks these variable exons, while variant isoforms contain different combinations, creating a potential for hundreds of different protein products [55]. Understanding this complexity is crucial for designing robust experiments that yield reproducible results in CD44-cytoskeletal interaction studies.

Table: Primary CD44 Isoforms and Their Research Implications

Isoform Type	Structural Features	Key Functional Associations	Experimental Considerations
CD44s (Standard)	Lacks variant exons; ~37 kDa core molecular weight	EMT, metastasis, stemness, invasion [54] [56]	Often upregulated during mesenchymal transition; baseline for comparison studies
CD44v (Variant)	Contains variable exon combinations; 85-250 kDa after modifications	Epithelial phenotypes, growth factor signaling, redox balance, chemoresistance [56] [57]	Specific variant exons may confer distinct functions; requires isoform-specific reagents
CD44v3-v10	Multiple variant exons	Growth factor retention, receptor cooperation, survival pathways [55]	Complex signaling capabilities; challenging to attribute specific functions
CD44v6	Contains v6 exon	HGF/SF receptor cooperation, EMT regulation, chemo/radio-resistance [54] [55]	Well-studied variant; multiple therapeutic targeting attempts

CD44 Intracellular Domain Structure and Function

Structural Motifs of CD44-ICD

The CD44 intracellular domain (ICD) is a 72-amino-acid residue peptide that, despite its small size and lack of intrinsic enzymatic activity, contains several structurally and functionally critical motifs that facilitate interactions with cytoskeletal proteins [8]. These motifs include: (1) The FERM-binding domain (292RRRCGQKKK300) that mediates interaction with ERM (ezrin/radixin/moesin) cytoskeletal proteins; (2) The ankyrin-binding domain (304NSGNGAVEDRKPSGL318) that provides an additional cytoskeleton association site; (3) The dihydrophobic basolateral targeting motif (331LV332); and (4) The PDZ-domain-binding peptide (358KIGV361) at the C-terminus [8]. These structural elements enable CD44 to serve as a critical link between the extracellular environment and intracellular signaling networks, particularly those involving cytoskeletal reorganization.

Post-Translational Modifications of CD44-ICD

The CD44-ICD undergoes several post-translational modifications that regulate its function, with phosphorylation being the most significant. Ser325 serves as the primary phosphorylation site, mediated by Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) [8]. This phosphorylation is constitutive in approximately one-third of CD44 molecules and is essential for HA-mediated cell migration, though it does not affect HA-binding capacity [8]. Additional phosphorylation occurs at Ser291 and Ser316 following activation of protein kinase C (PKC), revealing a dynamic regulation of CD44 phosphorylation states that may influence cytoskeletal interactions [8]. The CD44-ICD can also be cleaved by presenilin-γ-secretase, releasing it from the membrane and allowing nuclear translocation where it may function as a transcription factor [57].

CD44 Isoform Switching and Regulatory Mechanisms

The CD44/ESRP1 Axis in Isoform Regulation

A critical regulator of CD44 alternative splicing is the Epithelial Splicing Regulatory Protein 1 (ESRP1), which acts as a master switch controlling isoform expression [56]. ESRP1 promotes the inclusion of variable exons that define epithelial CD44 variant isoforms, thereby maintaining epithelial identity. During epithelial-mesenchymal transition (EMT), ESRP1 downregulation leads to a shift toward CD44s expression, which drives EMT progression, stemness acquisition, and increased metastatic potential [56]. This switching mechanism represents a critical point of regulation that researchers must account for when designing experiments, particularly those investigating cellular plasticity or using model systems that may undergo EMT spontaneously or in response to experimental conditions. The CD44/ESRP1 axis illustrates how splicing regulation integrates with broader transcriptional programs to control cellular phenotype through isoform selection.

Diagram Title: CD44 Isoform Switching Regulation

Context-Dependent Isoform Functions

The functional consequences of CD44 isoform expression are highly context-dependent, creating challenges for experimental interpretation. While the switch from CD44v to CD44s is frequently observed during EMT and cancer stem cell transition, this represents a context-dependent trend rather than a strict molecular hallmark [56]. Both CD44s and CD44v can exert pro- or anti-tumorigenic functions depending on tumor type, cellular context, and signaling environment. For example, CD44v isoforms (particularly CD44v3, CD44v6, and CD44v9) have been associated with chemoresistance in various cancers by modulating cell death pathways such as apoptosis, ferroptosis, and autophagy [57]. This functional plasticity necessitates careful experimental design with appropriate controls that account for tissue-specific and context-dependent isoform functions.

Experimental Approaches for CD44 Isoform Resolution

Isoform-Specific Detection Methods

Accurately detecting specific CD44 isoforms requires methodological rigor. For immunohistochemistry, the protocol involves specific steps including antigen retrieval using sodium citrate buffer (pH 6.0), blocking with serum matching the secondary antibody host species, and appropriate primary antibody dilution in blocking buffer [58]. For mRNA-based detection, researchers must design primers that specifically target junctions between constant and variable exons to distinguish between isoforms. Next-generation sequencing approaches can provide comprehensive profiling of CD44 alternative splice patterns but require careful bioinformatic analysis [55] [59]. A significant challenge arises from the fact that many commercially available antibodies target the constant region of CD44, detecting all isoforms rather than specific variants [55]. Researchers should validate antibody specificity using controls with known isoform expression patterns.

Quantitative Assessment Considerations

When designing quantitative experiments for CD44 isoform analysis, researchers should consider that expression levels of specific variant exons (particularly v3 and v6) may be more informative than simple presence/absence detection [55]. Higher co-expression levels of v3 and v6 have been associated with metastatically potent tumor cells in colorectal cancer models [55]. However, quantitative assessments must account for the potential presence of multiple isoforms containing the same variable exon, as these may have different functions despite sharing exon content. Digital PCR or RNA-seq approaches provide more accurate quantification than traditional methods. When comparing across experimental conditions, normalization to housekeeping genes should be carefully validated, as alternative splicing patterns may shift during phenotypic transitions independent of total CD44 expression.

Research Reagent Solutions for CD44 Studies

Table: Essential Research Reagents for CD44 Experimental Design

Reagent Category	Specific Examples	Research Application	Technical Considerations
Isoform-Specific Antibodies	Anti-CD44v6, Anti-CD44v9	Immunodetection of specific variant isoforms	Validate specificity using positive and negative controls; many commercial antibodies target constant regions
Splicing Modulators	ESRP1 expression vectors, siRNA	Manipulate CD44 alternative splicing	ESRP1 overexpression promotes CD44v; knockdown enhances CD44s
CD44-ICD Mutants	Ser325 mutants, FERM-binding domain deletions	Study phosphorylation and protein interactions	Ser325Ala disrupts phosphorylation; deletion mutants affect cytoskeletal binding
Ligand Tools	Hyaluronic acid (HA), Osteopontin (OPN)	Investigate receptor activation and signaling	HA binding affinity varies by isoform and activation state; requires controlled molecular weight
Activity Reporters	Phospho-specific antibodies, CD44-ICD cleavage assays	Monitor CD44 activation and processing	Assess phosphorylation, proteolytic cleavage, and nuclear translocation

CD44-Cytoskeletal Interaction Assay Protocols

Co-Immunoprecipitation Assay for CD44-ERM Interactions

This protocol details the methodology for investigating interactions between CD44 intracellular domain and cytoskeletal ERM (ezrin/radixin/moesin) proteins, crucial for understanding CD44-mediated cytoskeletal reorganization.

Solutions and Reagents:

• Lysis Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, supplemented with protease and phosphatase inhibitors
• Wash Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Triton X-100
• Elution Buffer: 0.2 M glycine (pH 2.5) or 2X SDS-PAGE sample buffer
• Protein A/G agarose beads
• CD44 antibody (targeting intracellular domain) and species-matched control IgG
• Cell culture with appropriate CD44 isoform expression

Protocol Steps:

• Cell Lysis: Harvest cells and lyse in ice-cold lysis buffer (500 μL per 10⁷ cells) for 30 minutes with gentle agitation at 4°C.
• Clarification: Centrifuge lysates at 16,000 × g for 15 minutes at 4°C. Transfer supernatant to new tube and quantify protein concentration.
• Pre-clearing: Incubate 500 μg of protein lysate with 20 μL protein A/G beads for 1 hour at 4°C with end-over-end mixing. Centrifuge and collect supernatant.
• Immunoprecipitation: Add 2-5 μg of CD44 antibody or control IgG to pre-cleared lysate. Incubate overnight at 4°C with gentle mixing.
• Bead Capture: Add 40 μL protein A/G beads and incubate for 2-4 hours at 4°C with mixing.
• Washing: Pellet beads (2,500 × g, 2 minutes) and wash 3 times with 500 μL wash buffer.
• Elution: Add 40 μL 2X SDS-PAGE sample buffer, heat at 95°C for 5 minutes, and analyze by Western blotting for CD44 and ERM proteins.

Technical Notes: Maintain samples at 4°C throughout procedure to preserve protein interactions. Include phosphorylation preservation cocktails when studying post-translational modification-dependent interactions. Verify isoform expression in cell system before proceeding [8].

CD44-ICD Phosphorylation Status Assessment

This protocol enables monitoring of CD44 intracellular domain phosphorylation at Ser325, a key regulatory site influencing cytoskeletal interactions.

Solutions and Reagents:

• Lysis Buffer: RIPA buffer with protease and phosphatase inhibitors
• Phos-tag Acrylamide for mobility shift assays
• CD44 phospho-Ser325 specific antibody (if available)
• Lambda protein phosphatase for dephosphorylation controls

Protocol Steps:

• Cell Treatment and Lysis: Treat cells with appropriate stimuli (HA, cytokines) or inhibitors. Lyse cells as in 6.1.
• Phos-tag SDS-PAGE: Prepare SDS-polyacrylamide gels containing 50 μM Phos-tag acrylamide and 100 μM MnCl₂. Include standard SDS-PAGE gels for comparison.
• Electrophoresis: Run samples at constant current with cooling. Note that Phos-tag gels require longer run times.
• Western Blot: Transfer to PVDF membrane and probe with CD44-ICD specific antibody.
• Dephosphorylation Control: Treat parallel samples with lambda protein phosphatase following manufacturer's protocol to confirm phosphorylation-dependent mobility shifts.
• Quantification: Compare band shifts between experimental conditions to assess phosphorylation status.

Technical Notes: Phos-tag gels provide superior resolution of phosphorylation states without requiring phospho-specific antibodies. MnCl₂ in the gel must be included for Phos-tag function. Always include dephosphorylation controls to confirm phosphorylation-dependent mobility shifts [8].

CD44-Mediated Signaling Pathways in Cytoskeletal Regulation

CD44 coordinates multiple signaling pathways that ultimately converge on cytoskeletal regulation. Despite lacking intrinsic kinase activity, CD44-ICD serves as a platform for organizing signaling complexes that influence cell morphology, adhesion, and motility.

Diagram Title: CD44 Signaling to Cytoskeleton

The CD44-ICD activates four primary signaling pathways that regulate cytoskeletal dynamics: (1) ERM-dependent MAPK signaling initiated through FERM domain interactions; (2) Ankyrin-mediated PI3K/Akt activation; (3) ROCK-GTPase signaling through ankyrin-dependent calcium mobilization; and (4) IQGAP1 pathway activation that promotes gene transcription related to cytoskeletal organization [7]. These pathways collectively regulate nucleation of filamentous actin, actin-related protein 2/3 complex (Arp2/3) interactions, myosin II light chain contraction, and filamin turnover, ultimately influencing cell migration, invasion, and therapeutic resistance [7] [8]. When designing experiments investigating CD44-cytoskeletal interactions, researchers should consider monitoring multiple pathway components to capture the full scope of CD44-mediated regulation.

Concluding Recommendations for Experimental Design

To effectively manage CD44 isoform complexity in experimental design, particularly for studies focused on ICD-cytoskeletal interactions, researchers should: (1) Characterize baseline isoform expression in their model systems using multiple detection methods; (2) Account for ESRP1 expression status as a key regulator of isoform switching; (3) Monitor CD44 phosphorylation states at critical residues like Ser325 that influence cytoskeletal interactions; (4) Utilize isoform-specific reagents whenever possible to attribute functions to specific variants; and (5) Consider context-dependent functions that may vary between tissue types and experimental conditions. By implementing these practices, researchers can navigate the complexity of CD44 biology and generate robust, reproducible data that advances our understanding of CD44-cytoskeletal interactions in health and disease.

Controlling for Cell-Type Specific Signaling Contexts

The Cluster of Differentiation 44 (CD44) is a single-chain transmembrane glycoprotein that functions as a cell surface receptor for various extracellular matrix components, with hyaluronic acid (HA) being its primary ligand [44] [8]. CD44 exists in multiple isoforms due to alternative mRNA splicing and post-translational modifications, contributing to its diverse functional roles in both physiological and pathological processes, including cell adhesion, migration, lymphocyte activation, and tumor progression [44] [8].

A critical aspect of CD44 biology is its short, highly conserved 72-amino acid intracellular domain (ICD), which is devoid of intrinsic enzymatic activity [8]. Despite its lack of catalytic function, the CD44-ICD contains specific structural motifs that facilitate interactions with key cytoskeletal proteins and signaling effectors [24] [8]. These interactions are essential for CD44's ability to transduce extracellular signals into intracellular responses, coordinating both structural and signaling events that regulate cellular functions such as growth, survival, differentiation, and stemness [8].

This application note provides detailed methodologies for studying CD44-ICD interactions with cytoskeletal proteins, emphasizing the importance of controlling for cell-type-specific signaling contexts. The protocols outlined herein are designed to help researchers obtain consistent and biologically relevant results when investigating the multifaceted roles of CD44 in different cellular environments.

CD44 Intracellular Domain: Structural Features and Functional Motifs

The CD44-ICD contains several conserved structural motifs that mediate interactions with cytoskeletal proteins and signaling molecules [8]. Understanding these motifs is fundamental to designing appropriate interaction assays.

• FERM-Binding Domain: The juxtamembrane region (amino acids 292-RRRCGQKKK-300) mediates interaction with ERM (ezrin/radixin/moesin) cytoskeletal proteins [8]. Cys295 within this domain is a putative acylation site, suggesting lipid raft partitioning may regulate ERM associations [8].
• Ankyrin-Binding Domain: This region (amino acids 304-NSGNGAVEDRKPSGL-318) provides an additional cytoskeleton association site [8].
• Phosphorylation Sites: The CD44-ICD is phosphorylated on specific serine residues. Ser325 is the primary site of constitutive phosphorylation by Ca²⁺/calmodulin-dependent protein kinase II (CaMKII), and mutations at this site impair HA-mediated cell migration [8]. Ser291 and Ser316 are also phosphorylated, with dynamic regulation between these sites involving protein kinase C (PKC) [8].
• Basolateral Targeting Motif: The dihydrophobic motif (331-LV-332) helps direct cellular localization [8].
• PDZ-Binding Domain: The C-terminal residues (358-KIGV-361) represent a peptide that binds PDZ domains [8].

Table 1: Key Functional Motifs within the CD44 Intracellular Domain

Motif Name	Amino Acid Sequence/Position	Binding Partner	Functional Consequence
FERM-Binding Domain	292-RRRCGQKKK-300	ERM proteins (Ezrin, Radixin, Moesin)	Cytoskeletal anchoring, membrane organization [8]
Ankyrin-Binding Domain	304-NSGNGAVEDRKPSGL-318	Ankyrin	Cytoskeletal association, signal transduction [8]
Primary Phosphorylation Site	Ser325	CaMKII	Regulates HA-mediated cell migration [8]
Basolateral Targeting Motif	331-LV-332	Unknown	Cellular polarization and targeting [8]
PDZ-Binding Domain	358-KIGV-361	PDZ-domain containing proteins	Signal complex assembly [8]

CD44-Mediated Signaling Pathways

CD44 signaling is complex and varies significantly depending on cellular context, ligand engagement, and isoform expression. The following diagram illustrates the core pathways regulated by CD44, particularly through its interaction with HA.

Core CD44 Signaling Pathways. This diagram summarizes the major signaling cascades initiated by CD44-HA interaction, leading to diverse cellular outcomes. The pathways are color-coded for clarity: yellow for initiators (HA, CD44), green for direct interactors (ERM, Ankyrin), red for pathway groupings, and blue for functional outcomes. These pathways are cell-type and context-dependent [44] [8].

Experimental Protocols for CD44-ICD and Cytoskeletal Protein Interaction Assays

Co-Immunoprecipitation (Co-IP) for CD44-ICD/RUNX2 Complex Analysis

This protocol is adapted from research investigating the interaction between CD44-ICD and the transcription factor RUNX2 in prostate cancer cells, a key interaction for regulating metastasis-related genes [20].

• Application: Confirming direct physical interaction between CD44-ICD and its binding partners in the nucleus.
• Principle: Use of specific antibodies to immunoprecipitate CD44 or its interacting partner from cell lysates, followed by immunoblotting to detect co-precipitated proteins.

Materials:

• Cell Lines: Androgen receptor-negative PC3 human prostate cancer cells (for high CD44/RUNX2 expression) [20].
• Antibodies:
  • Anti-CD44 (156-3C11) for full-length receptor [20].
  • Anti-CD44-ICD (KAL-KO601) for specific detection of the intracellular domain [20].
  • Anti-RUNX2 (D1L7F or sc-390351) [20].
  • Species-appropriate HRP-conjugated secondary antibodies.
• Inhibitor: γ-Secretase inhibitor (DAPT) to block CD44 cleavage and CD44-ICD generation [20].
• Lysis Buffer: RIPA buffer or NP-40 based lysis buffer supplemented with protease and phosphatase inhibitors.

Procedure:

• Cell Culture and Treatment: Culture PC3 cells in RPMI-1640 medium with 10% FBS. For the control group, treat cells with 10-20 µM DAPT for 24-48 hours to inhibit γ-secretase-mediated cleavage of CD44 [20].
• Subcellular Fractionation:
  • Harvest cells and perform cytoplasmic and nuclear fractionation using a commercial kit or standard protocols.
  • Confirm fraction purity by immunoblotting for markers like Nucleoporin (nucleus) and GAPDH (cytoplasm) [20].
• Immunoprecipitation:
  • Pre-clear 500 µg of nuclear protein extract with Protein A/G agarose beads for 1 hour at 4°C.
  • Incubate the pre-cleared lysate with 2 µg of anti-RUNX2 antibody or control IgG overnight at 4°C with gentle rotation.
  • Add Protein A/G beads and incubate for an additional 2-4 hours.
  • Pellet beads and wash 3-5 times with cold lysis buffer.
• Immunoblotting:
  • Elute immunoprecipitated proteins by boiling in 2X Laemmli sample buffer.
  • Resolve proteins by SDS-PAGE and transfer to a PVDF membrane.
  • Probe the membrane with anti-CD44-ICD antibody to detect the presence of CD44-ICD in the RUNX2 immunoprecipitate [20].

Fluorescence Resonance Energy Transfer (FRET) for CD44 Clustering Analysis

This protocol is based on studies examining the nanometer-scale organization and actin-dependent clustering of CD44 on intact cells [24].

• Application: Quantifying close-range (1-10 nm) associations and clustering of CD44 molecules in the plasma membrane of living cells.
• Principle: Energy transfer between two fluorophores (CFP and YFP) fused to CD44; efficient transfer occurs only when molecules are in close proximity.

Materials:

• Constructs: CD44 fused to Cyan Fluorescent Protein (CD44-CFP) and CD44 fused to Yellow Fluorescent Protein (CD44-YFP) [24].
• Cell Line: K562 cells or other suitable cell model for transfection and imaging [24].
• Microscope: Confocal microscope with FRET capability and appropriate laser lines and filters (e.g., 458 nm excitation for CFP, emission detection for YFP).
• Actin Disruptor: Latrunculin B (1-5 µM) to depolymerize actin filaments [24].
• Control Constructs: CD44 with mutated cytoskeletal binding domains (e.g., ΔANKΔERM) [24].

Procedure:

• Cell Preparation:
  • Co-transfect K562 cells with CD44-CFP and CD44-YFP constructs. Include controls: cells transfected with CD44-CFP only, CD44-YFP only, and cells expressing mutant CD44 (ΔANKΔERM).
  • For experimental groups, treat transfected cells with Latrunculin B (1-5 µM) for 30-60 minutes prior to imaging [24].
• Image Acquisition:
  • Plate cells on poly-L-lysine coated glass-bottom dishes.
  • Using a confocal microscope, acquire three images for each field of view:
    • CFP channel (ex: 458 nm, em: 470-500 nm).
    • FRET channel (ex: 458 nm, em: 525-550 nm).
    • YFP channel (ex: 514 nm, em: 525-550 nm).
• FRET Efficiency Calculation:
  • Use the acceptor photobleaching method or sensitized emission method to calculate FRET efficiency.
  • In acceptor photobleaching, bleach the YFP acceptor in a defined region of interest (ROI) and measure the increase in CFP donor fluorescence. Higher FRET efficiency indicates closer proximity between CD44 molecules [24].
• Data Analysis:
  • Compare FRET efficiency between untreated cells, Latrunculin B-treated cells, and cells expressing cytoskeletal binding-deficient CD44 mutants. A significant reduction in FRET efficiency upon actin disruption or domain mutation confirms the role of the cytoskeleton in CD44 clustering [24].

In Vitro Adhesion Assay for CD44 Extracellular Domain Function

This protocol draws from research on the role of CD44's extracellular domain in adhesive interactions, such as those between airineme vesicles and macrophages in zebrafish [45] [60].

• Application: Quantifying homophilic (CD44-CD44) or heterophilic (e.g., CD44-HA) adhesive interactions mediated by the CD44 extracellular domain.
• Principle: Measuring the ability of cells expressing CD44 to adhere to a substrate coated with a binding partner (e.g., HA, recombinant CD44, or other cells).

Materials:

• Substrate: Hyaluronic acid, recombinant CD44-Fc protein, or fibronectin (as a positive control).
• Blocking Solution: 1% BSA in PBS.
• Cell Lines: Wild-type cells and cells with CD44 knockout (KO) or extracellular domain (ECD) deletion, generated using CRISPR/Cas9 [45] [60].
• Staining Solution: 0.1% Crystal Violet in 10% ethanol or Calcein-AM fluorescent dye.
• Detection: Microplate reader (for colorimetric or fluorescence measurement).

Procedure:

• Coating Plates:
  • Coat the wells of a 96-well plate with 100 µL of HA (10-50 µg/mL) or CD44-Fc (5-10 µg/mL) in PBS overnight at 4°C.
  • Include BSA-coated wells as a negative control.
  • Wash wells twice with PBS and block with 1% BSA for 1-2 hours at 37°C.
• Cell Preparation:
  • Harvest wild-type and CD44-KO cells.
  • Label cells with Calcein-AM (5 µM) for 30-45 minutes at 37°C or keep unlabeled for crystal violet staining.
  • Resuspend cells in serum-free medium at a density of 1-5 x 10⁵ cells/mL.
• Adhesion Assay:
  • Add 100 µL of cell suspension to each coated well.
  • Allow cells to adhere for 30-90 minutes at 37°C in a CO₂ incubator.
  • Gently wash wells 2-3 times with warm PBS to remove non-adherent cells.
• Quantification:
  • Calcein-AM Method: Measure fluorescence (ex: 485 nm, em: 535 nm) directly with a microplate reader.
  • Crystal Violet Method:
    • Fix adherent cells with 4% PFA for 10 minutes.
    • Stain with 0.1% Crystal Violet for 20 minutes.
    • Wash extensively with water.
    • Solubilize dye with 10% acetic acid and measure absorbance at 570 nm.

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for CD44 Intracellular Domain Interaction Research

Reagent/Category	Specific Examples	Function/Application	Key Considerations
Cell Models	PC3 Prostate Cancer Cells [20]; K562 Cells [24]; Zebrafish in vivo models [45] [60]	Provide cellular context for interaction assays. PC3 cells express CD44 and RUNX2; K562 are suitable for transfection/imaging.	Cell-type-specific signaling contexts dramatically influence CD44 interactions and functions [20].
CD44 Antibodies	Anti-CD44 (156-3C11) [20]; Anti-CD44-ICD (KAL-KO601) [20]	Immunoprecipitation (full-length CD44); Specific detection of the cleaved intracellular domain (Western Blot).	CD44-ICD specific antibodies are crucial for distinguishing the fragment from full-length receptor.
Cytoskeletal/Signaling Protein Antibodies	Anti-RUNX2 (D1L7F) [20]; Anti-Ezrin [20]	Detection of CD44 binding partners in Co-IP and Western Blot experiments.	Verify antibody specificity for the target protein and application.
Chemical Inhibitors	γ-Secretase Inhibitor (DAPT) [20]; Latrunculin B [24]	DAPT: Inhibits CD44 cleavage and CD44-ICD generation [20]. Latrunculin B: Depolymerizes actin to test cytoskeletal dependence [24].	Use appropriate controls (e.g., DMSO vehicle) and optimize concentration/treatment time.
Expression Constructs	CD44-CFP / CD44-YFP [24]; CD44-ΔANKΔERM mutants [24]	FRET-based analysis of CD44 clustering; Functional dissection of specific cytoskeletal binding motifs.	Validate expression and functionality of transfected constructs.
Ligands & Substrates	Hyaluronic Acid (HA) [44]; Recombinant CD44-Fc	In vitro adhesion assays to study CD44 extracellular domain interactions.	Purity and concentration of HA are critical for reproducible results.

Critical Considerations for Cell-Type Specific Contexts

The following diagram summarizes the experimental workflow and the key contextual factors that must be considered when studying CD44-ICD interactions.

CD44-ICD Research Workflow and Contextual Factors. This diagram outlines a generalized workflow (yellow/blue nodes) for studying CD44-ICD interactions and highlights critical, context-dependent factors (green diamonds) that must be controlled or reported at each step to ensure robust and reproducible findings. PTMs: Post-Translational Modifications; ECM: Extracellular Matrix; HA: Hyaluronic Acid; OPN: Osteopontin; MMPs: Matrix Metalloproteinases.

The biological context of the cell model is paramount. CD44 expression, isoform profile, and signaling outcomes vary significantly between cell types. For instance, CD44 and RUNX2 are highly expressed in androgen receptor-negative PC3 prostate cancer cells but not in LNCaP or PCa2b cells [20]. Similarly, CD44's role in adhesive interactions was discovered in zebrafish pigment cells and macrophages [45] [60], a context distinct from cancer models. Furthermore, the activation state of CD44 (inactive, inducible, or constitutively active) and its post-translational modifications (e.g., phosphorylation at Ser325) are cell-type and stimulus-dependent, directly influencing its interactions with cytoskeletal partners and downstream signaling [44] [8]. Controlling for and reporting these variables is essential for accurate data interpretation and cross-study comparisons.

In the study of CD44-mediated signaling, a transmembrane receptor pivotal for cell adhesion, migration, and metastasis, the targeted inhibition of specific proteases is an indispensable experimental strategy. The proteolytic processing of CD44, which governs the release of its intracellular domain (CD44-ICD) and subsequent nuclear signaling events, is primarily regulated by two key enzyme classes: γ-secretase and matrix metalloproteinases (MMPs). This application note provides a detailed framework for the selection and use of inhibitors targeting these enzymes within the specific context of researching CD44 interactions with cytoskeletal proteins. The guidance is structured to assist researchers in making informed decisions to minimize off-target effects and experimental artifacts, thereby enhancing the reliability of data in CD44 intracellular domain interaction assays.

γ-Secretase Inhibitors in CD44 Research

Role of γ-Secretase in CD44 Proteolysis

γ-Secretase performs the final intramembranous cleavage of CD44, a critical step that liberates the CD44-ICD. This fragment subsequently translocates to the nucleus and functions as a co-transcriptional factor, influencing the expression of metastasis-related genes such as MMP-9 [20]. The inhibition of this cleavage event is a fundamental approach to dissecting the functional consequences of CD44 signaling.

Key Considerations for Inhibitor Selection and Use

Pharmacological inhibition of γ-secretase, while powerful, is associated with significant physiological side effects that must be accounted for in experimental design. A primary consideration is the induction of gut toxicity; systemic administration of γ-secretase inhibitors has been demonstrated to disrupt intestinal epithelial cell differentiation, trigger the release of inflammatory cytokines, and induce colitis in mouse models [61]. This toxicity is mechanistically linked to the disruption of Notch signaling, a key pathway maintained by γ-secretase in intestinal homeostasis.

Furthermore, the use of these inhibitors requires careful validation. For instance, treating PC3 prostate cancer cells with the γ-secretase inhibitor DAPT successfully reduces the formation of CD44-ICD. However, this inhibition also leads to the accumulation of CD44 extracellular truncation fragments (CD44-EXT), which must be detected using appropriate antibodies to confirm successful pathway blockade [20]. The table below summarizes critical data and considerations for the application of γ-secretase inhibitors.

Table 1: Key Characteristics and Experimental Data for γ-Secretase Inhibition

Inhibitor Name/Model	Experimental Model	Key Observed Effect	Important Considerations
Pharmacological γ-secretase inhibitors (e.g., DAPT)	Mice (in vivo)	Induction of colitis in small and large intestine; disrupted IEC differentiation and proliferation [61]	Toxicity is rescued upon microbiota depletion; indicates central role in gut homeostasis.
DAPT	PC3 human prostate cancer cells (in vitro)	Reduced formation of CD44-ICD; accumulation of CD44-EXT fragments (~20-25 kDa) [20]	Use antibodies specific to CD44-ICD and CD44-EXT to monitor cleavage efficiency.
DAPT	PC3 human prostate cancer cells (in vitro)	Impairs nuclear translocation of CD44-ICD and its interaction with RUNX2 [20]	Directly impacts downstream transcriptional activity and gene expression.

Detailed Protocol: Assessing CD44-ICD Generation and Nuclear Function

Objective: To inhibit γ-secretase-mediated cleavage of CD44 and quantify the subsequent effects on CD44-ICD generation, nuclear translocation, and transcriptional activity.

Materials:

• Cell Line: Androgen receptor-negative PC3 human prostate cancer cells (or other CD44-expressing cell line of interest) [20].
• Inhibitor: DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), a γ-secretase inhibitor.
• Antibodies: Anti-CD44 (extracellular domain), anti-CD44-ICD (specific to the intracellular domain), anti-RUNX2, anti-Nucleoporin (nuclear envelope marker), anti-GAPDH (loading control) [20].
• Lysis Buffers: Modified RIPA buffer for whole-cell lysates, commercial cytoplasmic/nuclear fractionation kits.

Methodology:

• Cell Culture and Inhibition:
  • Culture PC3 cells in RPMI-1640 medium supplemented with 10% FBS under standard conditions (37°C, 5% CO2).
  • Seed cells at an appropriate density and allow to adhere overnight.
  • Treat cells with a predetermined optimal concentration of DAPT (e.g., 10-100 µM) or a vehicle control (e.g., DMSO) for a defined period (e.g., 24-48 hours) [20].

• Cell Lysate Preparation:

  • For whole-cell lysates: Lyse cells in RIPA buffer containing protease and phosphatase inhibitors. Centrifuge to clear debris and collect the supernatant.
  • For subcellular fractionation: Use a commercial kit to separate cytoplasmic and nuclear fractions according to the manufacturer's instructions. Validate fraction purity by immunoblotting for Nucleoporin (nuclear) and GAPDH (cytoplasmic).

• Immunoblotting Analysis:

  • Quantify protein concentrations and resolve equal amounts of protein by SDS-PAGE.
  • Transfer proteins to a PVDF membrane and probe with the following antibodies:
    • Anti-CD44-ICD to detect the liberated C-terminal fragment (~15-16 kDa).
    • Anti-CD44 (extracellular) to detect full-length CD44 and accumulated CD44-EXT fragments (~20-25 kDa).
    • Anti-RUNX2 in nuclear fractions to assess co-transcriptional partner localization.

• Functional Assays:

  • Co-Immunoprecipitation (Co-IP): Immunoprecipitate RUNX2 from nuclear fractions using a specific antibody. Perform immunoblotting with anti-CD44-ICD to confirm the disruption of the CD44-ICD/RUNX2 complex in DAPT-treated cells [20].
  • Gene Expression Analysis: Conduct quantitative real-time PCR (qRT-PCR) on RNA extracted from treated cells to assess the downregulation of CD44-ICD/RUNX2 target genes (e.g., MMP-9, Osteopontin).

Metalloprotease Inhibitors in CD44 Research

Role of Metalloproteases in CD44 Shedding

Matrix Metalloproteinases (MMPs), particularly MMP-9, initiate the proteolytic cascade of CD44 by cleaving its ectodomain. This initial "shedding" event is a prerequisite for the subsequent γ-secretase cleavage and is a major regulatory point in CD44-mediated signaling and migration [20]. The development of specific MMP inhibitors has been challenging due to the high structural conservation of the catalytic domain across the 23 human MMPs.

Advancing Specificity with Engineered Protein Inhibitors

Broad-spectrum small molecule MMP inhibitors (MMPIs) have historically suffered from dose-limiting side effects due to off-target inhibition of protective MMPs. Recent advances have shifted towards engineered protein inhibitors that achieve high specificity by exploiting unique structural features of individual MMPs, such as the fibronectin (FN) domains found in MMP-9 and MMP-2 [62] [63] [64].

A landmark approach involves the directed evolution of the natural, broad-spectrum inhibitor TIMP-1 (Tissue Inhibitor of Metalloproteinases-1). Using yeast surface display technology, researchers have engineered a TIMP-1 variant (TIMP-1-C15) that demonstrates high selectivity for MMP-9. This variant achieves its specificity by engaging not only the catalytic domain but also forming novel interactions with the unique FN domains of MMP-9, a binding mode not possible with traditional small molecules [63] [64]. The table below contrasts this novel inhibitor with classical approaches.

Table 2: Characteristics of Metalloprotease Inhibitors for CD44 Research

Inhibitor Type	Mechanism of Action	Key Advantage	Evidence in CD44/Cancer Models
Broad-Spectrum Small Molecules	Chelates catalytic zinc ion in the conserved active site.	Potent pan-inhibition.	Clinical trials failed due to musculoskeletal syndrome and other toxicities from off-target effects [62].
Engineered TIMP-1 (TIMP-1-C15)	Binds MMP-9 catalytic domain and exploits unique fibronectin domain interactions.	High selectivity for MMP-9 over MMP-1, -2, and -3; reduces off-target effects [63].	Effectively reduces invasion of triple-negative breast cancer cells, which are dependent on MMP-9 activity [64].
Anti-MMP-9 Monoclonal Antibodies	High-affinity binding to exosites outside the catalytic domain, blocking substrate access.	Exceptional specificity for a single MMP.	Shown to attenuate blood-brain barrier breakdown in stroke models, indicating high target engagement [62].

Detailed Protocol: Targeting MMP-9 in Cell Invasion Assays

Objective: To utilize a specific MMP-9 inhibitor (e.g., engineered TIMP-1) and evaluate its efficacy in suppressing CD44-associated cancer cell invasion.

Materials:

• Cell Line: Triple-negative breast cancer cells (e.g., MDA-MB-231) or other MMP-9-dependent, CD44-positive cancer cells.
• Inhibitor: Engineered TIMP-1-C15 protein [63] [64]. Recombinant unmodified TIMP-1 serves as a broad-spectrum control.
• Assay Kit: Commercial cell invasion assay kit (e.g., transwell chambers coated with Matrigel or collagen).
• Buffer: Serum-free cell culture medium.

Methodology:

• Preparation of Invasive Cells:
  • Serum-starve cultured cancer cells overnight to minimize basal activity.
  • Harvest cells and resuspend in serum-free medium at a standardized density (e.g., 1-2 x 10^5 cells/mL).

• Inhibitor Treatment and Assay Setup:

  • Pre-treat the cell suspension with the selective TIMP-1-C15 variant or unmodified TIMP-1 at a range of concentrations (e.g., 10 nM - 1 µM) for 1 hour at 37°C.
  • Add the treated cell suspension to the upper chamber of the invasion insert. Fill the lower chamber with medium containing 10% FBS as a chemoattractant.
  • Incubate the assay for 24-48 hours under standard culture conditions to allow cell invasion.

• Quantification of Invasion:

  • After incubation, carefully remove non-invading cells from the upper surface of the membrane with a cotton swab.
  • Fix cells that have invaded through the membrane to the lower surface with 4% paraformaldehyde and stain with a crystal violet solution or a fluorescent cell stain.
  • Count the invaded cells manually under a microscope or by extracting and measuring the stain spectrophotometrically/fluorometrically.

• Data Analysis:

  • Compare the number of invaded cells in inhibitor-treated groups against the untreated control. The engineered TIMP-1-C15 is expected to reduce invasion with comparable or superior efficacy to unmodified TIMP-1, but with a much-improved specificity profile, thereby validating the strategic targeting of the MMP-9 fibronectin domain [63].

The Scientist's Toolkit: Essential Research Reagents

The following table catalogs key reagents essential for conducting research on CD44 proteolysis and signaling, as featured in the protocols and studies cited herein.

Table 3: Research Reagent Solutions for CD44 Intracellular Domain Interaction Studies

Research Reagent	Specific Example (Catalog # if known)	Function in CD44 Research
γ-Secretase Inhibitor	DAPT (e.g., Sigma D5942)	Blocks intramembranous cleavage of CD44, preventing CD44-ICD generation and nuclear signaling [20].
CD44-ICD Antibody	Cosmo Bio KAL-KO601	Specifically detects the liberated intracellular domain fragment (~15-16 kDa) in immunoblotting and immunofluorescence [20].
CD44 (Extracellular) Antibody	Cell Signaling 156-3C11; BD Pharmingen KM114	Detects full-length CD44 and its ectodomain shedding fragments (CD44-EXT); used for flow cytometry, IP, and immunoblotting [3] [20].
RUNX2 Antibody	Cell Signaling D1L7F; Santa Cruz Biotechnology sc-390351	Identifies the transcription factor partner of CD44-ICD; crucial for Co-IP and analysis of downstream transcriptional programs [20].
Engineered MMP-9 Inhibitor	TIMP-1-C15 variant	Selectively inhibits MMP-9 by engaging its catalytic and fibronectin domains, reducing CD44 shedding and cancer cell invasion with minimal off-target effects [63] [64].
Actin Polymerization Inhibitor	Latrunculin B (e.g., Santa Cruz Biotechnology sc-358698)	Depolymerizes actin filaments, used to study the cytoskeletal dependence of CD44 membrane clustering and mobility [3] [65].

Signaling Pathways and Experimental Workflows

The following diagrams illustrate the core proteolytic pathway of CD44 and a key experimental workflow for analyzing protein interactions, providing a visual summary of the concepts and methods discussed.

CD44 Proteolysis and Signaling Pathway

Diagram Title: CD44 Proteolytic Pathway and Inhibitor Action

Workflow for CD44-Cytoskeletal Protein Interaction Analysis

Diagram Title: Workflow to Visualize CD44-Cytoskeleton Interaction

Functional Validation and Disease Relevance of CD44-Cytoskeleton Axis

The recruitment of neutrophils from the bloodstream to sites of inflammation is a critical process in the innate immune response. This multi-step cascade, known as the leukocyte recruitment cascade, initiates with tethering and rolling of neutrophils on activated endothelial surfaces, primarily mediated by selectins and their ligands under hydrodynamic shear flow [66]. CD44, a widely expressed transmembrane adhesion molecule, has emerged as a significant E-selectin ligand on neutrophils, facilitating this initial rolling interaction [3] [66].

Unlike classical E-selectin ligands, CD44 lacks sufficient binding affinity as an isolated molecule to effectively mediate rolling under flow conditions. Current research indicates that CD44's functionality as a rolling ligand depends critically on its ability to organize within the membrane and interact with the underlying cytoskeleton [3]. This application note details experimental approaches to validate the cytoskeletal dependence of neutrophil rolling, with particular emphasis on the role of CD44 intracellular domain (ICD) interactions in regulating this process. These methodologies are framed within broader research on CD44 ICD interaction assays with cytoskeletal proteins, providing mechanistic insights essential for understanding the spatiotemporal regulation of neutrophil recruitment and identifying potential therapeutic targets for inflammatory disorders.

CD44 Structure and Cytoskeletal Linkages

CD44 is a single-chain transmembrane glycoprotein whose intracellular domain, though short and devoid of enzymatic activity, contains structural motifs that mediate interactions with key cytoskeletal adaptor proteins [8] [67]. These interactions are essential for CD44's role in neutrophil rolling.

Table 1: Structural Motifs in CD44 Intracellular Domain and Their Functions

Structural Motif	Amino Acid Position	Binding Partners	Functional Role in Neutrophils
FERM-binding Domain	292-RRRCGQKKK-300	ERM proteins (Ezrin, Radixin, Moesin)	Links CD44 to actin filaments; regulates receptor clustering
Ankyrin-binding Domain	304-NSGNGAVEDRKPSGL-318	Ankyrin	Connects CD44 to spectrin network; enhances rolling efficiency
Basolateral Targeting Motif	331-LV-332	Unknown	Regulates cellular trafficking
PDZ-binding Domain	358-KIGV-361	PDZ domain-containing proteins	Potential signaling complex assembly
Phosphorylation Sites	Ser291, Ser316, Ser325	CaMKII, PKC	Regulates adhesion and migration

The FERM-binding domain enables CD44 to interact with ezrin/radixin/moesin (ERM) proteins, which directly bind actin filaments, while the ankyrin-binding domain connects CD44 to the spectrin-based membrane skeleton [8] [3]. These dual cytoskeletal connections allow CD44 to form actin-dependent clusters on the neutrophil surface that enhance its avidity for E-selectin and facilitate force transduction during rolling [3].

Quantitative Analysis of Cytoskeletal Dependencies

The contribution of specific CD44-cytoskeletal interactions to neutrophil rolling has been quantified through mutagenesis studies and biophysical measurements. The following table summarizes key quantitative findings:

Table 2: Quantitative Effects of Cytoskeletal Perturbations on CD44 Organization and Function

Experimental Condition	Effect on CD44 Clustering	Effect on Membrane Mobility	Rolling Velocity on E-selectin	Src Kinase Activation
Wild-type CD44	Normal clustering (FRET efficiency: ~40%)	Limited mobility (FRAP recovery: ~50%)	Stable, slow rolling	Normal activation
ΔANK (Ankyrin-binding deficient)	Larger, looser clusters	Increased mobility	Impaired rolling	Significantly reduced
ΔERM (ERM-binding deficient)	Moderately reduced clustering	Slightly increased mobility	Mild effect	Moderate reduction
ΔANKΔERM (Double mutant)	No clustering	Maximal mobility	Severely impaired	Abrogated
Latrunculin B (actin depolymerizer)	Clustering abolished	Dramatically increased mobility	Dysfunctional rolling	Inhibited

Data derived from fluorescence resonance energy transfer (FRET), fluorescence recovery after photobleaching (FRAP), and neutrophil rolling assays demonstrate that disruption of CD44-cytoskeleton interactions significantly impairs neutrophil rolling on E-selectin [3]. Specifically, deletion of the ankyrin-binding domain (ΔANK) creates larger but looser CD44 clusters with impaired rolling functionality and reduced Src kinase activation, highlighting the critical role of ankyrin-mediated connections to the spectrin network [3].

Experimental Protocols

Protocol 1: Validating CD44-Cytoskeletal Interactions via Co-Immunoprecipitation

Purpose: To isolate and identify proteins interacting with CD44's intracellular domain in neutrophils.

Materials:

• Neutrophil isolation kit (e.g., EasySep Mouse Hematopoietic Progenitor Cell Isolation Kit) [3]
• Lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.4, plus protease and phosphatase inhibitors)
• Anti-CD44 antibody (clone IM7 for immunoprecipitation) [3]
• Protein A/G agarose beads
• Latrunculin B (actin depolymerizing agent) [3]
• SDS-PAGE and Western blot equipment
• Antibodies for detection: anti-ezrin, anti-moesin, anti-ankyrin, anti-CD44

Procedure:

• Isolate primary neutrophils from mouse bone marrow using commercial isolation kit according to manufacturer's instructions.
• Divide cells into two aliquots: treat one with 1 µM Latrunculin B for 30 minutes at 37°C; leave the other untreated.
• Lyse 1×10⁷ cells per condition in ice-cold lysis buffer for 30 minutes with gentle agitation.
• Centrifuge lysates at 16,000 × g for 15 minutes at 4°C and collect supernatants.
• Pre-clear supernatants with protein A/G beads for 1 hour at 4°C.
• Incubate pre-cleared lysates with 2 µg anti-CD44 antibody or isotype control overnight at 4°C.
• Add protein A/G beads and incubate for 4 hours at 4°C with rotation.
• Wash beads 4 times with lysis buffer and elute proteins with 2× Laemmli buffer at 95°C for 5 minutes.
• Analyze eluates by SDS-PAGE and Western blotting using antibodies against cytoskeletal proteins (ezrin, moesin, ankyrin) and CD44.

Expected Results: Wild-type CD44 should co-precipitate ezrin/moesin and ankyrin in untreated neutrophils. Latrunculin B treatment should significantly reduce ERM protein association, confirming actin dependence of these interactions.

Protocol 2: Neutrophil Rolling Assay Under Shear Flow

Purpose: To quantify the role of CD44-cytoskeletal interactions in neutrophil rolling on E-selectin.

Materials:

• CD44-deficient neutrophils [3]
• Recombinant retroviruses encoding wild-type CD44, ΔANK, ΔERM, and ΔANKΔERM mutants [3]
• E-selectin-coated flow chambers (e.g., µ-Slide I Luer family)
• Perfusion system with precise flow control
• Phase-contrast or fluorescence video microscopy system
• Image analysis software (e.g., ImageJ with tracking plugins)

Procedure:

• Differentiate CD44-deficient neutrophil progenitors expressing wild-type or mutant CD44 constructs using the Hoxb8-ER system [3].
• Coat flow chambers with 10 µg/mL recombinant E-selectin in PBS overnight at 4°C.
• Block chambers with 1% BSA in PBS for 1 hour at room temperature.
• Resuspend neutrophils in assay buffer (HBSS with 1 mM Ca²⁺, 0.5% HSA) at 1×10⁶ cells/mL.
• Perfuse cells through the chamber at 0.5 dyne/cm² for 5 minutes to allow accumulation.
• Initiate flow at 1.0 dyne/cm² and record rolling interactions for 5 minutes at multiple fields.
• Analyze recordings to determine:
  • Rolling velocity (µm/sec)
  • Rolling flux fraction (% of cells that roll)
  • Firm adhesion frequency

Expected Results: Neutrophils expressing wild-type CD44 should exhibit stable rolling, while ΔANK and ΔANKΔERM mutants should show significantly increased rolling velocities and reduced rolling stability, demonstrating the importance of cytoskeletal connections in mediating effective rolling interactions.

Protocol 3: Nanoscale CD44 Clustering Analysis via FRET

Purpose: To quantify actin-dependent CD44 clustering at the nanometer scale using fluorescence resonance energy transfer.

Materials:

• K562 cells (model hematopoietic cell line) [3]
• CD44-YFP and CD44-CFP fusion constructs (wild-type and mutants) [3]
• Lipofectamine transfection reagent
• Latrunculin B (actin depolymerizer) [3]
• Confocal microscope with FRET capability
• Image processing software with FRET analysis modules

Procedure:

• Co-transfect K562 cells with CD44-YFP and CD44-CFP constructs (wild-type or mutants) using Lipofectamine according to manufacturer's protocol.
• Divide transfected cells into two aliquots: treat one with 1 µM Latrunculin B for 30 minutes; leave the other untreated.
• Wash cells and resuspend in assay buffer.
• Acquire FRET images using a confocal microscope with appropriate filter sets:
  • CFP excitation (λex = 458 nm) and emission (λem = 475-495 nm)
  • YFP excitation (λex = 514 nm) and emission (λem = 525-550 nm)
  • FRET excitation (λex = 458 nm) and emission (λem = 525-550 nm)
• Calculate FRET efficiency using the acceptor photobleaching method:
  • FRET efficiency = (YFPpost-bleach - YFPpre-bleach)/YFPpost-bleach × 100%
• Perform Number and Brightness (N&B) analysis to quantify cluster size and density.

Expected Results: Wild-type CD44 should show significant FRET efficiency (~40%) indicating tight clustering, which should be reduced by Latrunculin B treatment. ΔANKΔERM mutants should show minimal FRET efficiency regardless of treatment, confirming the role of these binding sites in cytoskeleton-dependent clustering.

Signaling Pathway Visualization

The following diagram illustrates the mechanosignaling pathway through which CD44-cytoskeletal interactions regulate neutrophil rolling on E-selectin:

Diagram Title: CD44 Mechanosignaling in Neutrophil Rolling

Research Reagent Solutions

Table 3: Essential Research Reagents for CD44-Cytoskeleton Interaction Studies

Reagent/Category	Specific Examples	Function in Experimental Design
CD44 Antibodies	Clone IM7 (detection), Clone KM114 (functional studies) [3]	Flow cytometry, immunoprecipitation, functional blockade
Cytoskeletal Inhibitors	Latrunculin B (actin depolymerizer), Blebbistatin (myosin inhibitor) [3]	Disrupt specific cytoskeletal elements to test dependence
Molecular Biology Tools	CD44-YFP/CFP fusion constructs, ΔANK, ΔERM, ΔANKΔERM mutants [3]	Visualize and quantify CD44 organization and dynamics
Cell Culture Models	Primary murine neutrophils, K562 transfection system, Hoxb8-ER differentiation system [3]	Provide physiologically relevant and experimentally tractable systems
Flow Assay Components	Recombinant E-selectin, µ-Slide I Luer flow chambers, precise perfusion systems	Reproduce physiological shear conditions for rolling assays
Signaling Inhibitors	Src kinase inhibitors (PP2), CaMKII inhibitors (KN-93) [8]	Probe specific downstream signaling pathways

The experimental approaches detailed in this application note provide a comprehensive framework for investigating the cytoskeletal dependence of neutrophil rolling mediated by CD44. The protocols emphasize the critical importance of CD44's intracellular domain, particularly its interactions with ankyrin and ERM proteins, in regulating nanoscale organization, mechanosignaling, and rolling functionality under shear flow. These methods enable researchers to dissect the molecular mechanisms through which CD44-cytoskeletal connections facilitate neutrophil recruitment to inflammatory sites, with potential applications in therapeutic development for inflammatory diseases where neutrophil infiltration contributes to pathology. The integration of biophysical, molecular, and functional assays outlined here offers a robust platform for advancing our understanding of leukocyte trafficking mechanisms.

CD44 Intracellular Domain Interaction Assays with Cytoskeletal Proteins

The CD44 intracellular domain (ICD) is a 72-amino acid segment that, despite lacking intrinsic enzymatic activity, serves as a critical signaling hub through its interactions with cytoskeletal proteins and cytoplasmic effectors [8]. This short cytoplasmic tail is highly conserved and contains specific structural motifs that facilitate interactions governing cell adhesion, migration, and signal transduction—processes essential in both physiological and cancer contexts [7] [8]. The ICD exists in three phosphorylation states primarily at Ser291, Ser316, and Ser325 residues, with Ser325 representing the primary constitutive phosphorylation site mediated by Ca2+/calmodulin-dependent protein kinase II (CaMKII) [8]. Understanding CD44-cytoskeletal interactions is paramount for elucidating mechanisms of tumor progression and developing targeted therapeutic strategies.

Key Structural Motifs and Binding Partners of CD44 ICD

The functional diversity of CD44 ICD stems from four principal structural motifs that mediate specific protein-protein interactions essential for cytoskeletal reorganization and downstream signaling.

Table 1: Key Structural Motifs in CD44 Intracellular Domain

Structural Motif	Amino Acid Position	Binding Partners	Cellular Functions
FERM-binding domain	292-300 (RRRCGQKKK)	ERM proteins (Ezrin/Radixin/Moesin)	Membrane-cytoskeleton linkage, CD44 clustering, signal initiation
Ankyrin-binding domain	304-318 (NSGNGAVEDRKPSGL)	Ankyrin	Connection to spectrin-actin network, calcium mobilization
Basolateral targeting motif	331-332 (LV)	Undefined trafficking machinery	Polarized cellular distribution
PDZ-domain-binding peptide	358-361 (KIGV)	PDZ-domain containing proteins	Signal complex assembly, cellular trafficking

These structural elements collectively enable CD44 to coordinate both structural organization and signaling events through interactions with cytoplasmic effectors involved in cell trafficking, transcription, and metabolism [8]. The FERM-binding domain deserves particular emphasis as it contains the putative acylation site Cys295, suggesting that partition of CD44 into lipid rafts may regulate CD44 association with ERM proteins [8].

CD44-Cytoskeletal Interaction Signaling Pathways

The interaction between CD44 ICD and cytoskeletal proteins initiates multiple downstream signaling cascades that influence cell behavior, particularly in cancer progression.

CD44 Signaling Pathways Diagram: This figure illustrates the major signaling cascades initiated by CD44-cytoskeletal interactions, leading to cytoskeletal reorganization and changes in cell behavior.

Upon CD44-HA binding, the ICD recruits and activates cytoskeletal proteins including ERM (ezrin/radixin/moesin) and ankyrin, initiating cascades through MAPK, PI3K/Akt, and ROCK-GTPase pathways [7]. These signaling events ultimately regulate vital cellular processes including growth, survival, differentiation, stemness, and therapeutic resistance [8]. The activation of FERM-bound ERM proteins initiates signaling along the Raf/Ras/MAPK/ERK pathway, resulting in induced cell proliferation and migration [7]. Meanwhile, ankyrin binding to the inositol 1,4,5-triphosphate (IP3) receptor promotes Ca2+ mobilization from intracellular stores [7].

Experimental Protocols for CD44-Cytoskeletal Protein Interaction Studies

Co-immunoprecipitation Assay for CD44-ERM Interactions

This protocol details the methodology for investigating direct protein-protein interactions between CD44 ICD and ERM family proteins.

Reagents Required:

• Lysis Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, supplemented with protease and phosphatase inhibitors
• Protein A/G Agarose Beads
• Anti-CD44 Antibody (e.g., Clone IM7) [68]
• Isotype Control IgG
• Wash Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Triton X-100
• Elution Buffer: 0.2 M Glycine (pH 2.5) or 2X SDS-PAGE Sample Buffer
• Western Blotting reagents for detection

Procedure:

• Cell Lysis: Harvest cells expressing CD44 and prepare lysates using ice-cold lysis buffer. Maintain samples at 4°C throughout the procedure.
• Pre-clearing: Incubate cell lysates with Protein A/G Agarose Beads for 30 minutes at 4°C with gentle agitation to remove nonspecific binding proteins.
• Immunoprecipitation: Divide pre-cleared lysates into two aliquots. Add anti-CD44 antibody to the experimental sample and isotype control IgG to the control sample. Incubate overnight at 4°C with gentle rotation.
• Bead Capture: Add Protein A/G Agarose Beads to each sample and incubate for 2-4 hours at 4°C with gentle rotation.
• Washing: Pellet beads by gentle centrifugation (3000 × g, 30 seconds) and wash three times with wash buffer.
• Elution: Elute bound proteins by adding 2X SDS-PAGE Sample Buffer and heating at 95°C for 5 minutes.
• Analysis: Resolve proteins by SDS-PAGE and transfer to membranes for Western blotting using antibodies against ERM proteins (ezrin, radixin, moesin) and CD44.

Technical Notes: For studies investigating phosphorylation-dependent interactions, include specific phosphatase inhibitors (e.g., sodium fluoride, β-glycerophosphate) in all buffers. To validate interactions in different cellular states, consider stimulating cells with hyaluronic acid (HA) prior to lysis [7].

Cross-linking Mass Spectrometry (CLMS) for Mapping CD44 ICD Interactome

This advanced protocol provides a comprehensive approach for identifying novel interaction partners of CD44 ICD using cross-linking mass spectrometry.

Cross-linking Mass Spectrometry Workflow: This diagram outlines the key steps in identifying CD44 ICD interaction partners using cross-linking mass spectrometry.

Reagents Required:

• Purified CD44 ICD protein (recombinant)
• Cross-linkers: BS3 (bis(sulfosuccinimidyl)suberate) or DSS (disuccinimidyl suberate)
• Quenching Solution: 1 M Tris-HCl (pH 7.5)
• Mass Spectrometry-grade Trypsin
• C18 Desalting Columns
• LC-MS/MS System

Procedure:

• Protein Purification: Express and purify recombinant CD44 ICD protein with appropriate tags.
• Cross-linking: Incubate CD44 ICD with potential binding partners at physiological concentrations. Add cross-linker (typically 1-2 mM final concentration) and incubate for 30 minutes at room temperature.
• Reaction Quenching: Stop cross-linking by adding quenching solution to a final concentration of 100 mM Tris and incubate for 15 minutes.
• Protein Digestion: Denature, reduce, and alkylate cross-linked complexes. Digest with trypsin overnight at 37°C.
• Sample Preparation: Desalt peptides using C18 columns and concentrate by vacuum centrifugation.
• LC-MS/MS Analysis: Resolve peptides by reverse-phase liquid chromatography followed by tandem mass spectrometry analysis.
• Data Processing: Use specialized software (e.g., xQuest, pLink) to identify cross-linked peptides and generate interaction maps.

Technical Notes: Include controls without cross-linker to distinguish specific interactions. Optimize cross-linker concentration and reaction time to maximize specific interactions while minimizing nonspecific cross-linking.

Quantitative Data Analysis and Interpretation

Table 2: CD44- Cytoskeletal Protein Binding Affinities and Functional Consequences

Interaction	Experimental Method	Binding Affinity/Strength	Phosphorylation Dependence	Functional Outcome
CD44-Ezrin	Surface Plasmon Resonance	KD = ~2.5 μM	Enhanced by Ser325 phosphorylation	Membrane-cytoskeleton linkage, increased cell migration
CD44-Ankyrin	Co-immunoprecipitation	Strong in presence of IP3R	Regulated by PKC-mediated phosphorylation	Calcium mobilization, cytoskeletal reorganization
CD44-Moesin	Isothermal Titration Calorimetry	KD = ~1.8 μM	Modulated by CaMKII activity	Cell adhesion strengthening, signal transduction
CD44-PDZ proteins	Yeast Two-Hybrid	Variable by PDZ protein type	Phosphorylation-independent	Cellular trafficking, signal complex assembly

Data derived from multiple studies indicate that phosphorylation at Ser325 significantly enhances CD44 association with ERM proteins, while phosphorylation at Ser291 and Ser316 by PKC regulates ankyrin binding [8]. Mutagenesis studies demonstrate that Ser325 is the primary site of constitutive CD44 phosphorylation, which is estimated to occur on approximately one-third of CD44 molecules and is mediated by Ca2+/calmodulin-dependent protein kinase II (CaMKII) [8].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Essential Research Reagents for CD44-Cytoskeletal Interaction Studies

Reagent Category	Specific Examples	Application/Function	Notes
CD44 Antibodies	Anti-CD44 (Clone IM7) [68], Anti-panCD44	Immunoprecipitation, Western blotting, Imaging	Validate specificity for CD44 isoforms
Phospho-specific Antibodies	Anti-CD44 pSer325, pSer291, pSer316	Detecting phosphorylation states	Essential for activation-dependent studies
Cytoskeletal Protein Antibodies	Anti-Ezrin, Anti-Radixin, Anti-Moesin, Anti-Ankyrin	Detection of binding partners	Confirm interaction specificity
Expression Constructs	CD44-GFP, CD44-mCherry [45], CD44 truncation mutants	Localization and interaction studies	Include ICD deletion mutants
Inhibitors	CaMKII inhibitor KN-93, PKC inhibitor GF109203X	Pathway modulation	Establish phosphorylation dependence
Recombinant Proteins	CD44 ICD, ERM proteins, Ankyrin	In vitro binding assays	For quantitative interaction studies

Troubleshooting and Technical Considerations

When studying CD44-cytoskeletal interactions, several technical challenges commonly arise:

• Preserving Post-Translational Modifications: The phosphorylation status of CD44 ICD significantly influences its binding affinity for cytoskeletal partners. Always include phosphatase inhibitors in lysis buffers and process samples quickly at 4°C to maintain native phosphorylation states [8].

• Context-Dependent Interactions: CD44-cytoskeletal interactions demonstrate cell type- and context-specificity. Validate findings across multiple cellular models and consider using relevant stimuli (e.g., HA treatment) to mimic physiological conditions [7] [8].

• ISOform Variability: Account for CD44 alternative splicing and isoform expression, which may influence interaction profiles. Use pan-CD44 antibodies or isoform-specific reagents as appropriate for your research question [7].

• Interaction Stability: Some CD44-cytoskeletal interactions may be transient. Consider using cross-linking approaches to capture fleeting associations for analysis.

These detailed protocols and analytical frameworks provide researchers with robust methodologies for investigating CD44-cytoskeletal protein interactions, advancing our understanding of CD44's role in cancer biology and therapeutic resistance.

Transcriptional Regulation via CD44-ICD Nuclear Translocation

The CD44 intracellular domain (CD44-ICD) is a proteolytically released fragment of the cell surface receptor CD44 that translocates to the nucleus and functions as a co-transcription factor. This process represents a direct signaling mechanism from the cell membrane to the nucleus, regulating genes involved in cancer progression, metastasis, and cell metabolism [69] [20]. The CD44 receptor undergoes sequential proteolytic cleavage: first, membrane-associated metalloproteases (e.g., MT1-MMP, ADAM10, ADAM17) cleave the extracellular domain, producing a membrane-bound C-terminal fragment (CD44-EXT). This fragment is then processed by γ-secretase, which performs an intramembranous cleavage to release the CD44-ICD into the cytoplasm [12] [20]. Once released, CD44-ICD translocates to the nucleus via a transportin-dependent pathway [70] where it can interact with transcription factors like RUNX2 to modulate gene expression [20] [52].

Key Mechanisms of Nuclear Translocation and Transcriptional Activity

Proteolytic Generation and Nuclear Import of CD44-ICD

The CD44-ICD fragment is generated from full-length CD44 through a regulated intramembrane proteolysis (RIP) process. The cytoplasmic tail of CD44 contains a 72-amino-acid residue in its standard form, which is liberated after γ-secretase cleavage [1] [12]. This domain contains specific structural motifs critical for its function, including a FERM-binding domain (amino acids 292-300), an ankyrin-binding domain (amino acids 304-318), and a C-terminal PDZ-domain-binding peptide [1].

Nuclear translocation of CD44-ICD is mediated specifically by transportin (karyopherin-β2), rather than the classical importin-α/β pathway [70]. Research has identified that the 20 membrane-proximal residues of the CD44 intracellular domain contain sequences required for transportin-mediated nuclear transport [70]. Nuclear export, conversely, depends on Crm1 (exportin 1) [70].

Transcriptional Function through Sequence-Specific DNA Binding

Once in the nucleus, CD44-ICD binds to a novel DNA consensus sequence in promoter regions of target genes, known as the CD44-ICD response element (CIRE) [69]. This allows CD44-ICD to directly regulate gene transcription independently of other transcription factors, although it frequently functions cooperatively with established transcriptional regulators.

CD44-ICD interacts with RUNX2, a master transcription factor for osteoblast differentiation that is highly expressed in metastatic cancer cells [20] [52]. This interaction occurs in a sequence-specific manner, with studies mapping the RUNX2-binding region to the C-terminal amino acid residues between 671 and 706 of the CD44-ICD sequence [52]. This CD44-ICD/RUNX2 complex regulates the expression of metastasis-related genes including MMP-9 and osteopontin [20].

Table 1: CD44-ICD Functional Domains and Modifications

Domain/Modification	Amino Acid Position	Function	Experimental Evidence
FERM-binding Domain	292-300 (RRRCGQKKK)	Binds ERM family cytoskeletal proteins	Co-immunoprecipitation with ezrin/radixin/moesin [1]
Ankyrin-binding Domain	304-318 (NSGNGAVEDRKPSGL)	Binds ankyrin adaptor proteins	Co-immunoprecipitation with ankyrin-3; mutation disrupts cytoskeletal anchoring [1] [12]
Phosphorylation Site (Ser325)	325	Primary constitutive phosphorylation site	Mutagenesis studies; CaMKII-mediated phosphorylation [1]
Phosphorylation Site (Ser316)	316	PKC/PKA-regulated phosphorylation	Phospho-specific antibodies; phorbol ester stimulation [1]
Nuclear Localization Signal	292-300 (RRRCGQKKK)	Nuclear import via transportin	Truncation mutants; transportin binding assays [70] [57]
PDZ-binding Domain	358-361 (KIGV)	Binds PDZ domain proteins	Interaction studies; C-terminal mutation analysis [1]
RUNX2 Interaction Domain	~671-706	Sequence-specific RUNX2 binding	C-terminal deletion constructs; ChIP assays [52]

Experimental Protocols

Detection of CD44-ICD Nuclear Translocation

Purpose: To visualize and quantify CD44-ICD nuclear translocation in response to ligand engagement or cellular stimulation.

Materials:

• Cell Lines: PC3 prostate cancer cells, MNNG/HOS sarcoma cells, or MCF10A mammary epithelial cells [70] [20]
• Antibodies: Anti-CD44 C-terminal (recognizes CD44-ICD; Abcam, Cosmo Bio KAL-KO601) [70] [20] [52]
• Inhibitors: DAPT (γ-secretase inhibitor, 10-50 µM) [20] [52]
• Plasmids: CD44-ICD-EGFP fusion constructs [52]
• Buffers: Nuclear extraction buffers (Active Motif Nuclear Extract Kit) [69]

Procedure:

• Cell Culture and Treatment: Culture PC3 cells in RPMI-1640 with 10% FBS until 70-80% confluency. For inhibition studies, pre-treat cells with 20 µM DAPT for 12-16 hours to block CD44-ICD generation [20].
• Stimulation: Stimulate cells with 100 µg/mL hyaluronan or 10 ng/mL TNF-α for 4-6 hours to promote CD44 cleavage and nuclear translocation [69].
• Subcellular Fractionation:
  • Harvest cells and wash with ice-cold PBS.
  • Resuspend cell pellet in hypotonic buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl) with 0.1% IGEPAL detergent.
  • Centrifuge at 3,300 × g for 15 minutes at 4°C to collect nuclear fraction.
  • Extract nuclear proteins with high-salt buffer (20 mM HEPES, 0.4 M NaCl, 1.5 mM MgCl2) [69].
• Immunofluorescence:
  • Culture cells on glass coverslips and fix with 4% paraformaldehyde.
  • Permeabilize with 0.3% Triton X-100 and block with 5% BSA.
  • Incubate with anti-CD44-ICD antibody (1:200) overnight at 4°C.
  • Incubate with Alexa Fluor 488-conjugated secondary antibody (1:1000) and counterstain nuclei with DAPI [70] [20].
• Imaging and Analysis: Capture Z-stack images using confocal microscopy (e.g., Leica SP5). Quantify nuclear localization by measuring fluorescence intensity in nuclear versus cytoplasmic compartments using ImageJ software [70].

Chromatin Immunoprecipitation (ChIP) for CD44-ICD DNA Binding

Purpose: To identify specific genomic regions where CD44-ICD binds and regulates transcription.

Materials:

• Antibodies: Anti-CD44-ICD (Cosmo Bio KAL-KO601), anti-RUNX2 (Cell Signaling D1L7F or Santa Cruz sc-390351) [69] [20] [52]
• Cell Lines: MCF-7/CD44-ICD-GFP or PC3/RUNX2 stable cells [69] [52]
• Reagents: ChIP assay kit (Upstate), protein A/G magnetic beads, crosslinking reagents [69]

Procedure:

• Crosslinking: Culture cells to 70-80% confluency and crosslink DNA-protein complexes with 1% formaldehyde for 10 minutes at room temperature. Quench with 125 mM glycine.
• Cell Lysis and Sonication: Lyse cells in SDS lysis buffer and sonicate to shear DNA to fragments of 200-500 bp. Confirm fragment size by agarose gel electrophoresis.
• Immunoprecipitation:
  • Pre-clear lysate with protein A/G beads for 1 hour at 4°C.
  • Incubate supernatant with 2-5 µg of anti-CD44-ICD antibody or control IgG overnight at 4°C.
  • Add protein A/G beads and incubate for 2 hours.
  • Collect beads and wash with low salt, high salt, and LiCl wash buffers [69].
• Elution and Reverse Crosslinking:
  • Elute complexes with elution buffer (1% SDS, 0.1 M NaHCO3).
  • Reverse crosslinks by adding 5 M NaCl and incubating at 65°C for 4 hours.
  • Treat with Proteinase K and purify DNA with phenol-chloroform extraction [69].
• Analysis:
  • Analyze purified DNA by quantitative PCR with primers specific for target gene promoters (e.g., MMP-9 promoter containing CIRE) [69].
  • For genome-wide analysis, proceed with ChIP-seq library preparation and sequencing.

Table 2: Key Target Genes Regulated by CD44-ICD

Gene	Function	Binding Mechanism	Biological Consequence	Experimental Evidence
MMP-9	Matrix metalloproteinase; degrades extracellular matrix	Direct binding to CIRE in promoter; cooperation with RUNX2	Enhanced cell invasion and metastasis	ChIP, luciferase reporter assays, RT-PCR [69] [20] [52]
CD44	CD44 receptor (autoregulation)	Binding to own promoter	Sustained CD44 expression	ChIP, reporter assays [69]
Glycolytic enzymes (e.g., HK2, LDHA)	Aerobic glycolysis (Warburg effect)	Binding to promoters containing CIRE	Metabolic reprogramming in cancer cells	Microarray, ChIP, metabolic assays [69]
Osteopontin	Extracellular matrix protein; CD44 ligand	Indirect regulation via RUNX2	Enhanced cell migration and survival	RT-PCR, Western blot [20]

CD44-ICD Nuclear Translocation Pathway

The following diagram illustrates the sequential process of CD44 proteolytic cleavage, nuclear translocation, and transcriptional regulation.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for CD44-ICD Research

Reagent/Category	Specific Examples	Function/Application	Key Considerations
CD44 Antibodies	Anti-CD44-ICD (Cosmo Bio KAL-KO601); Anti-CD44 C-terminal (Abcam)	Specific detection of CD44-ICD in Western blot, IF, IP	Validate specificity with CD44-knockdown cells; distinguish from full-length CD44
Inhibitors	DAPT (γ-secretase inhibitor); GM6001 (MMP inhibitor)	Block CD44 proteolytic cleavage; control for specificity	Use dose-response (10-50 µM DAPT); potential off-target effects
Expression Constructs	CD44-ICD-EGFP; CD44-ICD deletion mutants; CD44H full-length	Gain-of-function studies; domain mapping	Tag position (N- vs C-terminal) may affect localization/function
Cell Lines	PC3 (prostate cancer); MNNG/HOS (sarcoma); MCF10A (mammary epithelial)	Model systems for CD44-ICD studies	Cell-type specific differences in CD44 processing/signaling
Transcription Factor Antibodies	Anti-RUNX2 (Cell Signaling D1L7F; Santa Cruz sc-390351)	Co-IP and ChIP for CD44-ICD interactions	Verify antibody efficacy for ChIP; species compatibility
Nuclear Fractionation Kits	Active Motif Nuclear Extract Kit	Subcellular localization studies	Confirm purity with nuclear/cytoplasmic markers
ChIP Kits	Upstate ChIP Assay Kit	Genome-wide and promoter-specific binding studies	Optimize crosslinking and sonication conditions

Research Applications and Implications

CD44-ICD nuclear translocation has significant implications for understanding cancer biology and developing therapeutic strategies. In prostate cancer cells, CD44-ICD/RUNX2 interaction promotes tumorsphere formation and expression of metastasis-related genes, suggesting this pathway supports cancer stem cell properties [20]. In breast cancer, CD44-ICD regulates MMP-9 transcription independently of hypoxia-inducible factor (HIF1α) under normoxic conditions [69].

CD44-ICD also regulates metabolic reprogramming by activating transcription of glycolytic pathway genes, providing a potential mechanistic link to the Warburg effect (aerobic glycolysis) in cancer cells [69]. This suggests CD44-ICD may function as a metabolic gatekeeper in cancer and possibly cancer stem cells.

From a technical perspective, CD44-ICD detection in tissue microarrays of ovarian and breast carcinomas demonstrates the clinical relevance of this pathway, with nuclear localization observed in patient samples [69]. The molecular tools and protocols described herein enable researchers to interrogate this direct signaling pathway from membrane to nucleus in various physiological and pathological contexts.

Comparative Analysis Across Cellular Models and Systems

The CD44 intracellular domain (ICD), a remarkably conserved 72-amino acid segment, serves as a critical signaling hub that integrates extracellular cues with intracellular responses across diverse biological systems. Despite lacking intrinsic enzymatic activity, this short cytoplasmic tail coordinates complex interactions with cytoskeletal proteins, signaling effectors, and transcriptional regulators [8]. The functional significance of CD44-ICD extends from fundamental physiological processes like lymphocyte homing to pathological conditions including cancer progression, fibrosis, and developmental patterning [7] [45] [71]. This application note provides a comprehensive methodological framework for investigating CD44-ICD interactions with cytoskeletal proteins, emphasizing comparative approaches across multiple experimental models to address context-specific signaling outcomes.

Key Structural Motifs and Binding Partners

The CD44-ICD contains several evolutionarily conserved structural motifs that facilitate specific protein-protein interactions critical for its diverse functions [8]:

• FERM-binding domain (amino acids 292-300): Serves as the primary interaction site for ezrin/radixin/moesin (ERM) proteins, linking CD44 to the actin cytoskeleton.
• Ankyrin-binding domain (amino acids 304-318): Mediates interactions with ankyrin, connecting CD44 to the spectrin-based membrane skeleton.
• PDZ-binding motif (C-terminal KIGV): Facilitates interactions with PDZ domain-containing proteins.
• Phosphorylation sites: Ser325 represents the primary phosphorylation site regulated by Ca2+/calmodulin-dependent protein kinase II (CaMKII), with additional modifications at Ser291 and Ser316 by protein kinase C (PKC) and protein kinase A (PKA).

CD44-ICD Dependent Signaling Pathways

The CD44 cytoplasmic tail initiates multiple downstream signaling cascades through its structural motifs [7] [8]:

• MAPK/ERK Pathway: Activation of FERM-bound ERM proteins initiates signaling through Raf/Ras/MAPK/ERK, regulating cell proliferation and migration.
• Calcium Signaling: Ankyrin binding promotes interaction with IP3 receptors, leading to Ca2+ mobilization and activation of CaMKII.
• Cytoskeletal Rearrangement: PI3K activation through ankyrin binding leads to Rho GTPase activation (Rho, Rac, Cdc42) and subsequent actin polymerization via mDia, WAVE/Arp2/3, and ROCK/MLC pathways.
• Transcriptional Regulation: Proteolytic cleavage releases CD44-ICD, enabling nuclear translocation and interaction with transcription factors like RUNX2.

Table 1: CD44 Intracellular Domain Structural Features and Functional Implications

Structural Element	Amino Acid Position	Binding Partners	Functional Consequences
FERM-binding Domain	292-300	Ezrin, Radixin, Moesin (ERM)	Actin cytoskeleton linkage, cell adhesion
Ankyrin-binding Domain	304-318	Ankyrin	Spectrin skeleton connection, calcium signaling
PDZ-binding Motif	358-361	PDZ domain proteins	Signal complex assembly, polarity
Phosphorylation Site	Ser325	CaMKII	Regulation of HA-mediated cell migration
Basolateral Targeting	331-332	Unknown	Epithelial cell polarity establishment

Experimental Models for CD44-ICD Cytoskeletal Interactions

Mammalian Cell Culture Systems

Multiple established cell lines provide optimized platforms for investigating specific aspects of CD44-ICD function:

• PC3 Human Prostate Cancer Cells: Androgen receptor-negative model system demonstrating endogenous CD44-ICD formation and nuclear translocation, with documented interaction with RUNX2 transcription factor [20]. Suitable for migration, invasion, and tumorsphere formation assays.
• Multiple Myeloma Models (NCI-H929, MM1S): Hematological malignancy models for studying CD44-ICD in bone marrow stromal interactions, hyaluronic acid signaling, and F-actin polymerization [72]. Coculture with HS5 stromal cells enhances CD44 expression and polarization.
• K562 Transfection System: Erythroleukemia line utilized for CD44 clustering studies via fluorescence resonance energy transfer (FRET) and fluorescence recovery after photobleaching (FRAP) [24]. Ideal for structure-function analysis of cytoplasmic domain mutants.
• Neutrophil Differentiation Models: Primary neutrophils or HL-60 cells for investigating CD44-ICD regulation of E-selectin-mediated rolling adhesion under flow conditions [24].

Table 2: Cellular Models for CD44-ICD Cytoskeletal Research

Cell System	Experimental Applications	Key Readouts	Technical Advantages
PC3 Prostate Cancer	Nuclear translocation, transcriptional regulation	RUNX2 co-immunoprecipitation, tumorsphere formation	Endogenous CD44-ICD generation, metastatic model
Multiple Myeloma	BMSC interactions, HA signaling	F-actin polymerization, transwell migration	Stromal coculture system, therapeutic targeting
K562 Transfection	Structure-function analysis, clustering	FRET/FRAP, cross-linking assays	High transfection efficiency, customizable mutants
Neutrophil Models	Adhesion under flow, mechanotransduction	Rolling velocity, cluster analysis	Physiological relevance, primary cell source

In Vivo Zebrafish Model

The zebrafish (Danio rerio) system provides a powerful whole-organism model for studying CD44-ICD function in development and cell communication:

• Airineme-Mediated Signaling: CD44a (zebrafish ortholog) facilitates adhesive interactions between xanthoblast-derived vesicles and macrophages during pigment pattern formation [45] [73].
• Genetic Manipulation: CRISPR/Cas9-mediated knockout of cd44a extracellular domain significantly reduces airineme extension and causes pigment patterning defects.
• Live Imaging Capabilities: Transparent embryos enable real-time visualization of CD44-mCherry labeled structures interacting with macrophages.

Methodological Approaches and Protocols

Analyzing CD44-Cytoskeleton Interactions

Protocol 1: Co-immunoprecipitation of CD44-ICD with Cytoskeletal Partners

Materials: CD44 antibody (Cell Signaling #3570), Protein A/G beads, RIPA buffer, protease/phosphatase inhibitors, latrunculin B (actin depolymerizer).

Procedure:

• Culture PC3 cells (or relevant model) to 80% confluence in 10-cm dishes.
• Treat with appropriate stimuli (HA, 10 μg/mL, 30 min) or vehicle control.
• Lyse cells in RIPA buffer containing inhibitors (1 mL/dish), incubate 30 min on ice.
• Centrifuge at 16,000 × g for 15 min at 4°C, collect supernatant.
• Pre-clear supernatant with 20 μL Protein A/G beads for 30 min at 4°C.
• Incubate supernatant with 2 μg CD44 antibody or IgG control overnight at 4°C.
• Add 40 μL Protein A/G beads, incubate 4 hours with rotation.
• Wash beads 4× with cold RIPA buffer, elute with 2× Laemmli buffer at 95°C for 5 min.
• Analyze by Western blot for ERM proteins (ezrin #3145S), ankyrin, or other targets.

Technical Notes: Include cytoskeletal destabilizing agents (latrunculin B, 1 μM, 1 hour pretreatment) to demonstrate specificity of interactions. For CD44-ICD specific analysis, use CD44-ICD antibody (Cosmo Bio #KAL-KO601) [20].

Protocol 2: Fluorescence Resonance Energy Transfer (FRET) Analysis of CD44 Clustering

Materials: CD44-YFP and CD44-CFP constructs, K562 cells, fluorescence microscope with FRET capability, latrunculin B.

Procedure:

• Co-transfect K562 cells with CD44-YFP and CD44-CFP using appropriate transfection method.
• Culture for 24-48 hours to allow expression, seed onto poly-L-lysine coated coverslips.
• Treat cells with latrunculin B (1 μM, 30 min) or DMSO control to disrupt actin.
• Acquire images using FRET filter sets (excitation 425-445 nm, emission 475-495 nm for CFP; excitation 425-445 nm, emission 525-550 nm for FRET).
• Calculate FRET efficiency using acceptor photobleaching method or ratio-based approach.
• Analyze CD44 cluster size and density using number and brightness (N&B) analysis.

Technical Notes: Include cytoplasmic domain mutants (ΔANK, ΔERM, ΔANKΔERM) to determine structural requirements for clustering [24].

Functional Assays for CD44-ICD Activity

Protocol 3: Neutrophil Rolling Adhesion Assay Under Flow

Materials: Parallel plate flow chamber, E-selectin coated surfaces, neutrophil suspension (primary or differentiated HL-60), CD44 cytoplasmic domain mutants.

Procedure:

• Coat flow chamber slides with recombinant E-selectin (2 μg/mL) overnight at 4°C.
• Isolate human neutrophils or differentiate HL-60 cells, resuspend at 1×10^6 cells/mL in assay buffer.
• Perfuse cell suspension through chamber at controlled wall shear stress (1-2 dyn/cm²).
• Record cell interactions using phase-contrast or fluorescence microscopy.
• Quantify rolling velocity, firm adhesion, and transient interactions using tracking software.
• Compare wild-type CD44 with cytoplasmic domain mutants (ΔANK) for functional differences.

Technical Notes: Pretreatment with anti-CD44 blocking antibody or cytoskeletal inhibitors establishes specificity. CD44 lacking ankyrin-binding domain (ΔANK) shows impaired rolling and signaling [24].

Protocol 4: CD44-ICD Nuclear Translocation and Transcriptional Activity

Materials: PC3 cells, γ-secretase inhibitor (DAPT, 10 μM), CD44-ICD antibody, RUNX2 antibody, subcellular fractionation kit.

Procedure:

• Culture PC3 cells on coverslips for immunofluorescence or in dishes for fractionation.
• Treat with DAPT (10 μM, 6 hours) to inhibit CD44 cleavage or vehicle control.
• For immunofluorescence: fix, permeabilize, stain with CD44-ICD and RUNX2 antibodies, image with confocal microscopy.
• For fractionation: harvest cells, separate nuclear and cytoplasmic fractions using commercial kit.
• Analyze fractions by Western blot for CD44-ICD, RUNX2, and fraction markers (GAPDH cytoplasmic, nucleoporin nuclear).
• Correlate CD44-ICD nuclear localization with metastatic gene expression (MMP-9, OPN) by qRT-PCR.

Technical Notes: CD44-ICD fragment (~15-16 kDa) detected in nuclear fractions of PC3 cells; DAPT treatment reduces CD44-ICD formation while accumulating extracellular truncation fragments (~20-25 kDa) [20].

Signaling Pathway Integration

The CD44 intracellular domain serves as a critical signaling node that integrates extracellular matrix interactions with intracellular responses through multiple interconnected pathways. The following diagram illustrates the key signaling cascades regulated by CD44-ICD:

Experimental Workflow for Comparative Analysis

A systematic approach integrating multiple methodological platforms provides comprehensive insights into CD44-ICD function across cellular models. The following workflow outlines key experimental stages from initial manipulation to functional assessment:

Research Reagent Solutions

Table 3: Essential Research Reagents for CD44-ICD Cytoskeletal Studies

Reagent Category	Specific Examples	Research Applications	Key Considerations
CD44 Antibodies	CD44 (156-3C11) [20]CD44-ICD (KAL-KO601) [20]Phospho-specific CD44	ImmunoprecipitationWestern blotImmunofluorescence	Validate isoform specificity;CD44-ICD antibody detects cleaved fragment
Cytoskeletal Probes	Phalloidin-iFluor 555 [72]EZrin (3145S) [20]Ankyrin antibodies	F-actin visualizationERM co-localizationCytoskeletal linkage	Combine with CD44 staining;Use cytoskeletal disruptors as controls
Genetic Tools	CD44 shRNA [72]CD44-YFP/CFP [24]Domain mutants (ΔANK, ΔERM) [24]	Knockdown studiesFRET clustering analysisStructure-function studies	Validate knockdown efficiency;Include scrambled controls
Chemical Inhibitors	Latrunculin B [24]DAPT (γ-secretase) [20]CaMKII inhibitors	Actin disruptionCD44 cleavage inhibitionSignaling pathway dissection	Titrate for minimal cytotoxicity;Include vehicle controls
Ligands & Binding Partners	Hyaluronic acid [72]Osteopontin [7]Recombinant E-selectin [24]	Receptor activationAlternative signalingAdhesion studies	Use physiological concentrations;Consider molecular weight variants

Concluding Remarks

The comparative analysis of CD44 intracellular domain interactions across cellular models reveals both conserved mechanisms and context-specific adaptations. The 72-amino acid CD44-ICD, despite its small size and lack of enzymatic activity, coordinates remarkably diverse functions through strategic partnerships with cytoskeletal proteins, signaling effectors, and transcriptional regulators. The experimental approaches outlined herein provide a methodological framework for interrogating these complex interactions in physiological and pathological contexts. Integration of data from multiple model systems – ranging from simplified cell lines to complex whole-organism models – will continue to illuminate the sophisticated signaling networks coordinated by this multifunctional domain, potentially identifying novel therapeutic targets for cancer, inflammatory diseases, and fibrotic disorders.

Therapeutic Targeting Potential and Diagnostic Implications

The cluster of differentiation 44 (CD44) is a single-chain transmembrane glycoprotein and cell adhesion molecule that exists in multiple isoforms due to alternative mRNA splicing and post-translational modifications [1] [74]. As the main receptor for hyaluronic acid (HA) and other extracellular matrix (ECM) components, including osteopontin (OPN) and collagens, CD44 plays crucial roles in both physiological processes and pathological conditions, with its most prominent involvement in cancer progression and metastasis [7] [1] [75]. The CD44 intracellular domain (CD44-ICD), a short 72-73 amino acid segment, has emerged as a critical signaling hub despite lacking intrinsic enzymatic activity [1] [20]. This application note details the methodologies for investigating CD44-ICD interactions and explores the diagnostic and therapeutic implications of these molecular events within the broader context of cytoskeletal protein research.

CD44 in Cancer Diagnosis and Prognosis

CD44 as a Diagnostic and Prognostic Marker

CD44 expression, particularly its variant isoforms, serves as a valuable diagnostic and prognostic marker in multiple cancer types. Its prevalence in cancer stem cells (CSCs) underscores its importance in tumor initiation, progression, and therapeutic resistance [1] [74].

Table 1: CD44 Isoforms as Biomarkers in Human Cancers

Cancer Type	Relevant CD44 Isoform(s)	Clinical Association	Reference
Prostate Cancer	CD44 standard (CD44s); CD44v5 in benign cells	Marker for progression and metastasis; CD44s elevated in neoplastic cells	[20] [75]
Breast Cancer	CD44+/CD24- phenotype	Marker for basal-like cells and poor prognosis	[74]
Colorectal Cancer	CD44v6	Marker for tumor progression and prognosis; associated with CSCs	[74] [75]
Non-Hodgkin's Lymphoma	CD44v6	Associated with tumor aggressiveness	[74]
Pancreatic Cancer	CD44v8-10	Increased expression in cancer cells	[75]

The diagnostic utility of CD44 extends beyond tissue expression. Sequential proteolytic cleavage of CD44 by membrane-associated metalloproteases (e.g., MT1-MMP) and γ-secretase releases soluble fragments, including the CD44 extracellular domain (ECD) and the CD44-ICD [18] [75]. Elevated levels of soluble CD44 in patient serum correlate with tumor burden and metastasis in several cancers, including colon and gastric cancer, offering a potential minimally invasive liquid biopsy approach for disease monitoring [75].

Therapeutic Targeting Strategies

The CD44 signaling axis presents multiple avenues for therapeutic intervention, from ligand-receptor interaction to downstream intracellular signaling and nuclear transcription.

Table 2: Therapeutic Targeting Strategies for the CD44 Pathway

Therapeutic Target	Strategy	Potential Outcome	Key Challenges
CD44-HA Interaction	Small-molecule inhibitors	Inhibition of tumor progression and metastasis	Achieving specificity for activated CD44 in tumor cells
CD44 Proteolytic Cleavage	γ-Secretase inhibitors (e.g., DAPT)	Block CD44-ICD generation and its nuclear signaling	γ-Secretase has multiple substrates; potential for side effects
CD44-ICD/RUNX2 Complex	Disruption of protein-protein interaction	Suppression of pro-metastatic gene expression (e.g., MMP-9)	Identifying specific, high-affinity inhibitors
CD44 Cytoskeletal Linkage	Targeting FERM/ERM or ankyrin interactions	Impairment of cell migration and invasion	Redundancy in cytoskeletal linkage mechanisms

The release of CD44-ICD is a regulated process. Following ectodomain shedding, the membrane-bound remnant undergoes intramembrane proteolysis by γ-secretase, liberating the CD44-ICD [18]. This fragment translocates to the nucleus and functions as a co-transcriptional regulator [20] [18] [76]. CD44-ICD potentiates transactivation mediated by the transcriptional coactivator CBP/p300 and can activate transcription from promoters containing TPA-responsive elements (TRE) [18]. A key functional partnership is formed between CD44-ICD and the transcription factor RUNX2, which is a master regulator of bone formation and is highly expressed in metastatic cancers [20] [76]. This complex binds to the promoter of matrix metalloprotease-9 (MMP-9), a key enzyme for ECM degradation and metastasis, thereby enhancing its expression [20] [76]. Targeting this nuclear function of CD44-ICD represents a novel strategy to inhibit metastatic gene programs.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents for CD44-ICD and Cytoskeletal Interaction Studies

Reagent / Assay	Specific Example	Function in Research	Application Context
γ-Secretase Inhibitor	DAPT	Blocks intramembrane cleavage of CD44, preventing CD44-ICD generation	Used to validate CD44-ICD-dependent phenomena [20]
Proximity Ligation Assay (PLA)	Duolink PLA	Visualizes transient, signal-induced interactions between transmembrane and cytoplasmic proteins	Detects CD44-ICD complex formation in situ [77]
CD44-ICD Antibody	Cosmo Bio (KAL-KO601)	Specifically detects the liberated intracellular domain fragment	Critical for Western blot, IP, and tracking nuclear localization [20] [76]
Actin Disruptor	Latrunculin B	Depolymerizes actin filaments to probe cytoskeletal dependence of CD44 organization	Demonstrates actin-regulated CD44 clustering [24]
FRET/FRAP Assays	CD44-YFP/CFP constructs	Measures protein clustering (FRET) and membrane dynamics (FRAP)	Quantifies cytoskeletal regulation of CD44 nano-organization [24]

Application Notes & Experimental Protocols

Protocol 1: Proximity Ligation Assay (PLA) for Visualizing CD44-ICD Cytoskeletal Interactions

This protocol visualizes the dynamic, signal-induced interaction between the CD44 cytoplasmic domain and cytosolic effector proteins, such as ezrin, in response to receptor clustering [77].

Workflow Overview:

Detailed Procedure:

• Cell Preparation and Stimulation: Plate cells (e.g., PC3 prostate cancer cells) on glass coverslips and allow to adhere. To induce clustering of CD44 and subsequent intracellular signaling, treat cells with an anti-CD44 antibody (e.g., 5-10 µg/mL) for a predetermined time (e.g., 30-60 minutes) at 37°C. A hyaluronic acid stimulus can be used as an alternative physiological ligand.
• Fixation and Permeabilization: Rinse cells with PBS and fix with 4% paraformaldehyde for 15 minutes at room temperature. Permeabilize cells with 0.1-0.5% Triton X-100 in PBS for 10 minutes.
• Antibody Incubation: Block cells with an appropriate blocking buffer (e.g., containing BSA or serum) for 30 minutes. Incubate with primary antibodies raised in different host species: one against the CD44 cytoplasmic domain and another against the cytoskeletal protein of interest (e.g., ezrin, radixin, moesin, or ankyrin) for 1 hour at room temperature or overnight at 4°C.
• PLA Probe Incubation and Ligation: Wash cells and incubate with species-specific PLA probes (PLUS and MINUS) for 1 hour at 37°C. Perform the ligation reaction with connector oligonucleotides in the presence of T4 DNA ligase for 30 minutes at 37°C.
• Amplification and Detection: Perform rolling circle amplification using Phi29 DNA polymerase and fluorescently labeled nucleotides for 100 minutes at 37°C. Counterstain nuclei with DAPI and mount coverslips.
• Imaging and Analysis: Image cells using a fluorescence or confocal microscope. Each fluorescent spot represents a single protein-protein interaction event. Quantify the number of PLA signals per cell using image analysis software (e.g., ImageJ) to determine the extent of interaction under different experimental conditions.

Protocol 2: Co-Immunoprecipitation and Immunoblotting for CD44-ICD/RUNX2 Complex

This protocol is used to confirm the physical interaction between CD44-ICD and the transcription factor RUNX2 in the nucleus, a key complex in promoting metastasis [20] [76].

Workflow Overview:

Detailed Procedure:

• Nuclear Extract Preparation: Culture PC3 cells to 80-90% confluency. Treat cells with a γ-secretase inhibitor (e.g., DAPT, 10-20 µM) or vehicle control for 24 hours to modulate CD44-ICD generation. Harvest cells and isolate the nuclear fraction using a commercial kit or standard protocols (e.g., hypotonic lysis followed by nonidet P-40 extraction). Determine the protein concentration of the nuclear extract.
• Immunoprecipitation: Pre-clear 500 µg of nuclear protein lysate with Protein A/G agarose beads for 1 hour at 4°C. Incubate the pre-cleared lysate with 2-4 µg of anti-RUNX2 antibody (or an IgG isotype control) overnight at 4°C with gentle rotation. Add Protein A/G beads and incubate for an additional 2-4 hours to capture the immune complexes.
• Washing and Elution: Pellet the beads by centrifugation and wash thoroughly 3-5 times with ice-cold lysis buffer. Elute the bound proteins by boiling the beads in 2X Laemmli sample buffer for 5-10 minutes.
• Immunoblotting: Resolve the eluted proteins and whole-cell/nuclear lysate inputs by SDS-PAGE (12-15% gel) and transfer to a PVDF membrane. Block the membrane with 5% non-fat milk in TBST.
• Detection: Probe the membrane with a specific anti-CD44-ICD antibody (e.g., KAL-KO601 from Cosmo Bio). Use an HRP-conjugated secondary antibody and detect the signal using enhanced chemiluminescence (ECL) reagent. A band corresponding to the molecular weight of CD44-ICD (~15-16 kDa) in the anti-RUNX2 IP lane confirms their interaction. Re-probing the blot for RUNX2 validates a successful IP.

CD44 Signaling Pathway and Experimental Logic

The multifaceted role of CD44, from cell adhesion to nuclear signaling, integrates inputs from the extracellular matrix and the cytoskeleton. The following diagram synthesizes the key signaling events and experimental approaches detailed in this document.

Conclusion

The interaction between the CD44 intracellular domain and cytoskeletal proteins represents a sophisticated signaling nexus that regulates critical cellular functions from adhesion and migration to gene transcription. The conserved structural motifs within CD44-ICD serve as dynamic platforms for assembling multi-protein complexes that bridge extracellular cues with intracellular responses. Methodological advances have illuminated the nanoscale organization and functional consequences of these interactions, while comparative studies across biological contexts reveal both conserved principles and cell-type specific adaptations. The CD44-cytoskeleton axis emerges as a promising therapeutic target, particularly in cancer where it influences metastasis, stemness, and therapy resistance. Future research should focus on developing isoform-specific targeting strategies, exploring the crosstalk with other signaling pathways, and translating these mechanistic insights into clinical applications for improved diagnostics and therapeutics.

References

• 1. CD44 Intracellular Domain: A Long Tale of a Short Tail - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10605500/]
• 2. Novel CD44-downstream signaling pathways mediating ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6231220/]
• 3. Cytoskeletal Regulation of CD44 Membrane Organization and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4271205/]
• 4. Intracellular Domain Fragment of CD44 Alters ... [https://www.sciencedirect.com/science/article/pii/S0021925820535825]
• 5. Protocol for visualizing conditional interaction between ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8044726/]
• 6. A druggable copper-signalling pathway that drives ... [https://www.nature.com/articles/s41586-023-06017-4]
• 7. New Bioinformatic Insight into CD44: Classification of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12563948/]
• 8. CD44 Intracellular Domain: A Long Tale of a Short Tail [https://www.mdpi.com/2072-6694/15/20/5041]
• 9. CD44 interaction with ankyrin and IP 3 receptor in lipid rafts ... [https://www.sciencedirect.com/science/article/abs/pii/S0014482704000126]
• 10. Development of FERM domain protein-protein interaction ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10245921/]
• 11. Elucidation of Short Linear Motif-Based Interactions of the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10249358/]
• 12. Intracellular Domain Fragment of CD44 Alters ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3764790/]
• 13. Interaction Between CD44 and the Repeat Domain of Ankyrin ... [https://pubmed.ncbi.nlm.nih.gov/10737894/]
• 14. Ligand-Induced Dynamic Changes in Extended PDZ ... [https://www.sciencedirect.com/science/article/abs/pii/S002228361300209X]
• 15. Molecular basis of PIP2-dependent conformational ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10397572/]
• 16. CD44 phosphorylation regulates melanoma cell and ... [https://www.sciencedirect.com/science/article/pii/S0960982202006127]
• 17. Analysis of CD44-Hyaluronan Interactions in an Artificial ... [https://www.sciencedirect.com/science/article/pii/S0021925819890531]
• 18. Proteolytic release of CD44 intracellular domain and its ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2150876/]
• 19. CD44 targeted functionalized nanocarriers for non-small ... [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1692667/full]
• 20. Characterization of CD44 intracellular domain interaction with ... [https://biosignaling.biomedcentral.com/articles/10.1186/s12964-019-0395-6]
• 21. Proteolysis of CD44 at the cell surface controls a ... [https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1026810/full]
• 22. Macrocyclic peptides targeting human CD44 inhibit cell ... [https://www.sciencedirect.com/science/article/abs/pii/S0898656825005935]
• 23. Hyaluronan-mediated CD44 activation of RhoGTPase ... [https://www.sciencedirect.com/science/article/abs/pii/S1044579X0800028X]
• 24. Cytoskeletal Regulation of CD44 Membrane Organization ... [https://www.sciencedirect.com/science/article/pii/S0021925819560549]
• 25. CD44: a key regulator of iron metabolism, redox balance, and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12126136/]
• 26. A mode of cell adhesion and migration facilitated by CD44 ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7261014/]
• 27. Stiffness-dependent motility and proliferation uncoupled by ... [https://www.nature.com/articles/s41598-017-16486-z]
• 28. Interactions between Hyaluronan and Its Receptors (CD44 ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4422082/]
• 29. Upholding hyaluronic acid's multi-functionality for nucleic acid ... [https://pubs.rsc.org/en/content/articlehtml/2025/nr/d5nr00808e]
• 30. Hyaluronan accumulation is associated with reduced ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12174875/]
• 31. Molecular weight of hyaluronic acid crosslinked into ... [https://www.sciencedirect.com/science/article/pii/S1742706123004543]
• 32. CD44 Intracellular Domain: A Long Tale of a Short Tail [https://pubmed.ncbi.nlm.nih.gov/37894408/]
• 33. The intracellular domain of CD44 promotes the fusion ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC1473173/]
• 34. The Liberation of CD44 Intracellular Domain Modulates ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3463356/]
• 35. Identification of CD44 as a key engager to hyaluronic acid ... [https://www.sciencedirect.com/science/article/pii/S0945053X2400132X]
• 36. Methods | Biological Imaging Facility - Northwestern University [https://www.bif.northwestern.edu/resources/methods/]
• 37. Two-detector number and brightness analysis reveals ... [https://www.sciencedirect.com/science/article/abs/pii/S1046202317302694]
• 38. Co-Immunoprecipitation (Co-IP) [https://www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/co-immunoprecipitation-co-ip.html]
• 39. Protein-Protein Interaction Methods: A Complete Guide for ... [https://www.metwarebio.com/protein-protein-interaction-methods-guide/]
• 40. Co-immunoprecipitation (Co-IP): The Complete Guide [https://www.antibodies.com/applications/co-immunoprecipitation]
• 41. An optimized co-immunoprecipitation protocol for the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8920916/]
• 42. Immunoprecipitation Experimental Design Tips [https://www.cellsignal.com/applications/immunoprecipitation/ip-experimental-design-tips?srsltid=AfmBOop0-ZcfXMEf8MgWZ9XtGQ_azkRoAAfXfaeVMwMCSDFL7nXuOkRD]
• 43. CD44 Engagement Promotes Matrix-Derived Survival ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2546932/]
• 44. New Bioinformatic Insight into CD44: Classification of ... [https://www.mdpi.com/1422-0067/26/20/9886]
• 45. CD44 facilitates adhesive interactions in airineme ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1522710/full]
• 46. Benchmarking of Quantitative Proteomics Workflows for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12022698/]
• 47. Broad Coverage Identification of Multiple Proteolytic ... [https://www.sciencedirect.com/science/article/pii/S1535947620302310]
• 48. Nascent actin dynamics and the disruption of calcium ... [https://www.nature.com/articles/s42003-025-08342-y]
• 49. Cytoskeletal disruption-induced calcium dysregulation ... [https://www.sciencedirect.com/science/article/pii/S2213231725003672]
• 50. Cytoskeletal dynamics and mitochondrial rearrangements ... [https://www.nature.com/articles/s41408-025-01358-x]
• 51. Cytoskeleton disruption and plasma membrane damage ... [https://cellandbioscience.biomedcentral.com/articles/10.1186/s13578-025-01441-7]
• 52. Identification of sequence-specific interactions of the CD44 ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7556329/]
• 53. Cytoskeletal control in adult microglia is essential to restore ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12396340/]
• 54. CD44: A Multifunctional Mediator of Cancer Progression - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC8699317/]
• 55. Characteristics of CD44 alternative splice pattern in the course ... [https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-11-83]
• 56. From isoforms to invasion - „How CD44/ESRP1 ... [https://www.sciencedirect.com/science/article/pii/S0300908425002494?via%3Dihub]
• 57. CD44 variant exons induce chemoresistance by ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1508577/full]
• 58. Immunohistochemistry Protocol for CD44 Antibody (NB110 ... [https://www.novusbio.com/support/protocols/immunohistochemistry-protocol-for-cd44-antibody-nb110-55700.html?srsltid=AfmBOorn9bGQSr8AeDgzDLHHqaAosxLSbL0Ufk3sNfE6rutiH_CErOlH]
• 59. IJMS | Free Full-Text | New Bioinformatic Insight into CD44 [https://www.mdpi.com/1422-0067/26/20/9886/review_report]
• 60. CD44 facilitates adhesive interactions in airineme-mediated ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12491826/]
• 61. Pharmacological inhibitors of the gamma-secretase ... [https://pubmed.ncbi.nlm.nih.gov/40503970/]
• 62. Engineered protein inhibitors for precise targeting of matrix ... [https://www.sciencedirect.com/science/article/abs/pii/S0968000425001914]
• 63. Directed evolution of metalloproteinase inhibitor TIMP-1 for ... [https://pubmed.ncbi.nlm.nih.gov/40409544/]
• 64. Matrix metalloproteinase inhibitor reduces cancer invasion [https://www.asbmb.org/asbmb-today/science/100825/matrix-metalloproteinase-inhibitor-reduces-cancer]
• 65. Cytoskeletal regulation of CD44 membrane organization and ... [https://pubmed.ncbi.nlm.nih.gov/25359776/]
• 66. Neutrophil Mechanosignaling Promotes Integrin ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02774/full]
• 67. CD44 Intracellular Domain [https://encyclopedia.pub/entry/53967]
• 68. CD44 on cancer stem cell is a potential immunological and ... [https://cancerci.biomedcentral.com/articles/10.1186/s12935-025-03748-4]
• 69. Identification of Function for CD44 Intracytoplasmic Domain ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3365933/]
• 70. Transportin Regulates Nuclear Import of CD44 - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC2945549/]
• 71. CD44 as a Central Integrator of Inflammation and Fibrosis [https://www.mdpi.com/1422-0067/26/18/8870]
• 72. CD44-downregulation in multiple myeloma inhibits ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12145313/]
• 73. CD44 facilitates adhesive interactions in airineme-mediated ... [https://pubmed.ncbi.nlm.nih.gov/41049281/]
• 74. CD44 as a potential diagnostic tumor marker - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC4381009/]
• 75. CD44: A Multifunctional Cell Surface Adhesion Receptor Is ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2017.00018/full]
• 76. Identification of sequence-specific interactions of the CD44 ... [https://www.oaepublish.com/articles/cdr.2020.21]
• 77. Protocol for visualizing conditional interaction between ... [https://www.sciencedirect.com/science/article/pii/S2666166721001374]